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Welcome to Helsinki 
Sitting on the edge of the Baltic, the modern, cosmopolitan city of Helsinki was the World 
Design Capital for 2012. The beauty of the surrounding nature blends seamlessly with high-
tech achievements and contemporary trends. Walking tours of the city center show layers 
of history, while modern architecture and cutting-edge style stake the city's claim to the 
future. Helsinki during its endless summer days is a refreshing experience. 
June is a splendid time of the year to visit Helsinki. The midnight sun allows us to continue 
discussions outdoors until dawn and over - be ready for an intensive 60 hour package. In 
the Helsinki city you can find places to listen the sound of silence, for example in the fortress 
of Suomenlinna - not typical for all capitals in Europe. Helsinki offers a wide variety of 
attractions to explore: the Market Square with its seagulls, the Esplanade Park with the 
beautiful Kappeli restaurant building and the option for a lawn picnic, wonderful well-
preserved architecture and historic monuments, design, delicious traditional food, and great 
natural sightseeing opportunities in the Finnish archipelago. 
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From the Organizing Committee  
It is our great pleasure and honor to welcome you to the 3rd Conference of the International 
Society of Plant Molecular Farming. The 3rd ISPMF Conference will take place in the 
amazing city of Helsinki, from the 11th to the 13th of June, 2018. We have selected the 
Helsinki Congress Paasitorni, established already in 1908, as the meeting venue. Paasitorni 
is located by the sea in the city center in close vicinity of the Hakaniemi market place and 
Hakaniemi metro station. The meeting itself takes place in the Congress Hall of Paasitorni, 
the pearl of Paasitorni with its tall ceilings, splendid chandeliers and impressive balconies. 
The topics addressed by the Conference will cover the whole palette of interests for the 
Plant Molecular Farming community, presenting all possible aspects of recombinant proteins 
and bioactive small molecules. Besides nine keynote speakers, we have selected over 30 
oral presentations and 70 poster presentations. The Conference will provide a delightful 
forum for 150 attendees to improve their scientific knowledge and explore the latest 
outcomes and trends in the field. It will offer plenty of networking opportunities, interaction 
with leading scientists, and stimulating creative exchange among researches and people 
working in the respective industries. 
We hope you will join us for this outstanding scientific event, the 3rd ISPMF, and take a little 
extra time to enjoy the remarkable and exceptional beauty of Helsinki! 
  
With best wishes, 
On behalf of the whole Organizing Committee 
  
Kirsi-Marja Oksman Anneli Ritala 
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Keynote Speakers 
 
 
Dr Jennifer Bromley  
Group Leader at British American Tobacco Plant Biotechnology, 
Cambridge UK. 
Jennifer Bromley studied for her Ph.D in Plant Molecular Development at 
the University of Cambridge. She then held postdoctoral research 
positions at the University of Cambridge, University of Copenhagen and 
Lawrence Berkeley National Laboratory in California. She moved to BAT 
in 2014. She leads a Computational Biology & Gene Discovery group of 7 
scientists who have built a number of computational biology resources 
including the public release of a high-quality tobacco genome sequence. 
 
  
 
 
Professor Paul Christou 
ICREA Professor, Universitat de Lleida-Agrotecio Center, Lleida, Spain 
Paul Christou has held at least 170 invited lectures; he is named in almost 
250 publications in peer-reviewed journals and over 50 chapters in books. 
He is co-inventor in more than 20 patents and patent applications. His 
main research interests are in transgene structure and function in 
genetically engineered crops; metabolic engineering and synthetic 
biology, production of pharmaceutical macromolecules in crop plants; 
engineering of multiple novel agronomic traits in crop plants. He is also 
interested in training and technology transfer for developing country 
biotechnology, intellectual property issues and regulatory and bio-safety 
issues of transgenic crops, focusing on developing countries. 
Furthermore, Paul Christou is also interested in science policy issues and 
strategic planning covering the interphase between fundamental and 
applied research. 
 
Prof. Christou holds a bachelor’s degree in Organic and Natural Products 
Chemistry, and a PhD in Plant Biochemistry. 
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Dr Marc-André D’Aoust 
Vice-President Research & Innovation at Medicago Inc., Canada 
Dr D’Aoust joined Medicago in July 1999 as Team Leader, Research and 
Development. He was successively Project Leader, Product 
Development, and Director, Research and Innovation, prior to his 
appointment as Vice-President, Research and Innovation. He was closely 
involved in development of the Medicago technological platform as well 
as the capacity to produce virus-like particles and biotherapeutics in alfalfa 
and Nicotiana benthamiana. He is co-inventor on more than 330 patents 
or patent applications related to the technological platform or the 
company’s products.  
Dr D’Aoust holds a bachelor’s degree in biology and a PhD in plant 
biochemistry and molecular biology. 
 
 
 
 
Dr Dominik Mojzita 
Principal Scientist at VTT Technical Research Centre of Finland Ltd., 
Finland 
Dominik Mojzita received his PhD in Microbiology in 2007 from the 
Göteborg University in Sweden and his MSc in Cell Biology in 2001 from 
Charles University in Czech Republic. 
Dr Mojzita has a background in molecular biology and genetic engineering 
of yeast and filamentous fungi. He worked on the identification and 
characterization of novel genes and metabolic pathways, transcriptional 
and metabolic regulation, genome-wide and gene-specific expression 
analysis, and the production of organic compounds in fungal hosts. 
Currently, his focus is on the development of synthetic expression tools 
and the establishment of synthetic control circuits in eukaryotic hosts, 
especially fungi and plants.  
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Dr Kirsi-Marja Oksman-Caldentey 
Research Manager at VTT Technical Research Centre of Finland Ltd., 
Finland 
Kirsi-Marja Oksman received her PhD in pharmacognosy. She has a long 
experience in plant biotechnology from both academia and 
pharmaceutical industry. Currently she is a research manager at VTT’s 
Industrial Biotechnology and Food Solutions research area comprising 
about 130 scientists and research assistants. The focus is to develop 
technologies using living cells as bioreactors, and plants as raw materials 
for the production of fuels, chemicals and industrial ingredients. Her own 
research interest focuses on understanding the complexity of biosynthetic 
pathways of plant secondary metabolism at systems level. Her newest 
research path is related to the concept of “Food without fields” evaluating 
the potential of plant cells as food.  
Dr Oksman holds an adjunct professorship at the University of Helsinki, 
Faculty of Pharmacy since 1994. She is named in over 100 publications 
in peer-reviewed journals, books chapters and 8 patents or patent 
applications. 
 
 
 
 
Dr Frank Petersen 
Executive Director Natural Product Unit, Novartis Ltd, Switzerland 
Frank Petersen studied microbiology at the universities of Hohenheim and 
Tübingen, Germany. After receiving his PhD at the Institute of 
Microbiology/Antibiotics with Hans Zähner, he joined the natural products 
research group at CIBA-Geigy in 1991. As laboratory head in 
microbiology, he introduced new strategies in the detection of new natural 
products scaffolds from microorganisms. Since 2001, he heads the 
natural products research unit at Novartis Pharma. He established 
microbial sourcing collaborations with various institutes in Africa and Asia. 
Dr Pettersen received visiting professorships at the Shanghai Institute of 
Materia Medica/ Chinese Academy of Sciences and at the SKKU 
University, Seoul, Korea. Since 2004 he advises governmental 
committees and scientific organizations on Convention of Biological 
Diversity and Nagoya Protocol related matters, e.g. at the European 
Commission, Government of the Federal Republic of Germany, Swiss 
Government, United Nations, WIPO, or at the NIH. 
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Professor Kazuki Saito 
Dean, Chiba University and RIKEN, Yokohama, Japan 
Kazuki Saito obtained his PhD from the University of Tokyo in 1982. He 
has served as the Dean and a professor of Graduate School of 
Pharmaceutical Sciences, Chiba University, and a deputy center director 
and a group director of RIKEN Center for Sustainable Resource Science. 
He also served as a scientific advisor of several international research 
activities, such as a European Project ‘SmartCell’, VIB-Plant Systems 
Biology, Belgium, and CEPLAS Project, Germany. He was awarded the 
Prize for Science and Technology by the Minister of Education, Culture, 
Sports, Science and Technology, Japan, JSPP Award 2016 by the 
Japanese Society of Plant Physiologists, and the Pharmaceutical Society 
of Japan Award 2017. He was also selected one of Thomson Reuters 
Highly Cited Researchers in the 'Plant & Animal Science' field, and an 
ASPB Top Author. Professor Saito’s research is focused on 
metabolomics, functional genomics and biotechnology of plant natural 
products.  
 
 
 
 
 
Professor Jochen Schiemann  
Director at Julius Kühn Institute, Quedlinburg, Germany 
Jochen Schiemann has been director of the Institute for Biosafety in Plant 
Biotechnology at Julius Kuehn Institute (JKI), Federal Research Centre 
for Cultivated Plants, until his retirement in September 2016. Since 2006 
he is Honorary Professor at University of Lüneburg. He has been 
coordinating several national and EU-funded cluster projects on biosafety 
research. From 2003 to 2009 he was member of the Panel on Genetically 
Modified Organisms of the European Food Safety Authority (EFSA). From 
2002 to 2012 he was member of the Executive Committee of the 
International Society for Biosafety Research (ISBR), from 2004 to 2008 
President of ISBR. From 2004 to 2017 he has been member of the 
Steering Council of the European Technology Platform “Plants for the 
Future”. In 2016 he has been nominated as plant expert for the 
Explanatory Note “New techniques in Agricultural Biotechnology” 
published by the Group of Chief Scientific Advisors. Jochen Schiemann is 
co-founder of the ISPMF. 
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Professor Dr Stefan Schillberg 
Fraunhofer Institute for Molecular Biology and Applied Ecology IME, 
Germany 
Stefan Schillberg is member of the management team (provisional) of the 
Fraunhofer Institute for Molecular Biology and Applied Ecology IME as 
well as head of the Department Plant Biotechnology in Aachen. He 
received his PhD in Molecular Biology from the RWTH Aachen University 
in 1994. Current activities in his laboratory focus on recombinant protein 
production in various hosts including whole plants and plant suspension 
cells as well as cell-free expression systems, metabolic pathway 
engineering, genome editing, strategies to scale-up processes and to 
improve product levels in plants as well as engineering novel traits in 
crops. 
He holds an honorary professorship at the Justus-Liebig-University in 
Giessen, Germany. 
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Social Events 
Pre-conference excursion to Suomenlinna  
There will be a possibility for an excursion to Suomenlinna (www.suomenlinna.fi) on Monday 
morning on June 11th, 2018 prior to the conference. This will be on your own costs.  
Suomenlinna is a sea fortress 
that was built on the coast of 
Helsinki in 1748. Here you can 
get a real feeling for Finland’s 
position between East and West; 
Suomenlinna was shaped by the 
distinct historic eras when helped 
defend first Sweden, then Russia 
and ultimately Finland. In 1991 
Suomenlinna was listed as a 
UNESCO World Heritage Site to 
be preserved for future 
generations as an example of the European military architecture of its time. Today about 
850 people live permanently in Suomenlinna.  
You can get to Suomenlinna by a ferryboat 
leaving from the market place every 20 
minutes. The boat drive lasts 15 minutes.  
There are several restaurants in 
Suomenlinna where you can have lunch. 
The islands themselves are very interesting 
to explore but you can also visit several 
small museums and a submarine there. 
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Get-together party  
The City of Helsinki is kindly inviting all the participants of the 
conference to a reception in the beautiful Empire Hall of the 
neoclassical style Old Town Hall building, Aleksanterinkatu 
20, on Monday 11th June, 2018 at 19 o’clock. The building is 
located in the heart of Helsinki close to the Senate square, 
only a 15-20 minutes walk from the conference site. This 
event is included to the registration fee.  
 
 
Conference dinner 
 
Conference dinner is included in the registration fee. We invite warmly all the attendees to 
participate this closing event of our conference. The dinner will take place at the opposite 
side of our conference venue Paasitorni in the beautiful restaurant Meripaviljonki just over 
the sea (www.ravintolameripaviljonki.fi) on Wednesday June 13th, 2018 at 19.30. 
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Useful Information of Helsinki 
Here we collected some practical information that maybe useful during your visit.  
Finland is a country of forests and lakes. Inland 
lakes and rivers make up 10% of the country. The 
large areas of forest cover almost two thirds of the 
land mass. Only 6% of Finland is arable. It is one of 
the Nordic countries and bordering Sweden, Norway 
and Russia. Area wise the country is the fifth largest 
in Europe (338,424 km²) with only 5.5 million 
inhabitants. It is the most sparsely populated country 
in the European Union, with only 16 inhabitants per 
km². There are four seasons in Finland winters being cold and summers warm.  
Finland is a republic and is an independent country since 1917. It became a member 
of the European Union in 1995 and part of the European Monetary Union in 2002 and the 
only Nordic country using the Euro as currency. Finland was the third country in the world 
and the first one in Europe allowing women to vote. This happened as early as 1906. The 
electronics, machinery, forestry, high-tech and design industries are Finland's most 
important revenue sources. Finland is the world's biggest producer of mobile phones.  
Finnish language is a noN-Indo-European language belonging to the Uralic family, along 
with Estonian and Hungarian. However, language is not a problem. As most Finns take it for 
granted that you do not speak their language, they are glad to make use of their English or 
other European languages they master. Finland is in fact a bilingual country, the second 
official language being Swedish. 
Climate and weather 
Helsinki’s climate combines characteristics of both a 
maritime and a continental climate. The proximity of the 
Arctic Ocean and the North Atlantic creates cold weather, 
while the Gulf Stream brings in warmer air.  
Spring arrives in Helsinki usually sometime in April. The 
days grow rapidly longer and warmer, attracting people to 
the city while the nature blossoms all around.  
Summer in Helsinki is bright. Days are at their longest in 
the second half of June, when the sun stays above the 
horizon for 19 hours.  
Average temperatures in Helsinki  
Entire year: +5.9°C  
Warmest month: July +17,8°C  
Coldest month: February -4,7°C  
For the latest weather forecast, see website (en.ilmatieteenlaitos.fi) by the Finnish 
Meteorological Institute.   
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City bikes  
The City of Helsinki is attempting to increase levels of cycling in city traffic. The city bike 
system supports this goal. During 2018 city bike season there will be 1,500 bikes and 150 
bike stations in Helsinki.  
 
City sightseeings in Helsinki  
Boat tour in Helsinki archipelago. Enjoy a guided 
sightseeing tour by boat and experience the 
beautiful archipelago and canals of Helsinki. The 
tour passes the maritime highlights of the capital.  
Guided tours & Hop On Hop Off in Helsinki. Explore 
the city on a guided sightseeing tour by bus and 
see all the top sights of Helsinki! Take a tour with 
Hop On Hop Off or enjoy a city tour with Helsinki 
Panorama.  
Sightseeing by bus and boat in Helsinki: Enjoy 
Helsinki by bus and boat with our combination 
tickets. Two guided sightseeing tours that let you 
discover the main sights in the capital both from 
land and sea.  
More information: www.stromma.fi/en/helsinki/ 
 
Currency and payments  
The local currency in Finland is Euro (EUR). All major credit cards are widely accepted in 
Finland. For an ATM machine, look for the sign “OTTO”. These 24-hour cashpoint machines 
are widely available and accept the following international ATM and credit cards: Visa, Visa 
Electron, EuroCard, MasterCard, Maestro, Cirrus and EC.  
Banks are usually open on weekdays 10am–4:30pm.  
In addition to banks, there are several foreign currency exchange points available around 
the city center. See for example: Forex at Stockmann Department Store or Central Railway 
Station and Tavex on Fabianinkatu 12  
Electricity  
Voltage: 220–240 Volts. Electrical sockets (outlets) in Finland are one of the two European 
standard electrical socket types: ”Type C” Europlug and ”Type E/F” Schuko.  
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Emergency number  
General Emergency number for police, ambulance and fire department is 112.  
Postal services  
Post offices are open 9am–6pm (some offices even until 8pm) from Monday to Friday. 
Yellow mailboxes are available for collections on weekdays.  
Stamps can be purchased at post offices, bookstores, newsagents, kiosks and hotels.  
Helsinki General Post Office is located at the center of Helsinki, Elielinaukio 2 F. 
Esplanade Park 
Situated in the heart of Helsinki, the 
Esplanade Park serves as a promenade 
for visitors and a place to relax for the 
locals. The park and the Espa Stage 
host many popular events, including the 
Marimekko Fashion Show in June and 
the Jazz-Espa concert series 
throughout July. 
 
Tax free shopping  
Citizens of noN-European countries are eligible for tax-free returns upon leaving EU territory. 
Purchases must be made in shops displaying the Tax Free Shopping sign. The minimum 
total sum of purchased goods must be €40.  
Time zone  
The time zone in Helsinki is Eastern European Time (EET), 2 hours ahead of Greenwich 
Mean Time (GMT+2).  
Tourist information  
Helsinki Tourist Information (www.myhelsinki.fi) offers free information about the city, sights, 
events and services including a wide range of brochures and maps all year round. 
WiFi  
You can connect your laptop or mobile phone to a wireless network in many places 
throughout the city center e.g. in several cafes, restaurants and libraries.  
For free WiFi, connect to “Helsinki City Open Wlan”. There are plenty of hotspots available 
in the city center and at harbors. In addition, most hotels offer their guests a free internet 
connection. For the international research and education community, it is also possible to 
use Eduroam service while in Helsinki.  
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Scientific Programme 
Monday 11.6.2018  
09:30 – 14:00 Optional pre-conference excursion to Suomenlinna (trip and lunch)  
12:00 Registration opens 
 
Opening session 
14.30 – 15:00 Anneli Ritala-Nurmi (VTT, Espoo, Finland) and  
George Lomonossoff (John Innes Centre, Norwich, UK) 
Welcome and Opening the 3rd ISPMF Congress 
15:00 – 15:10 Kirsi-Marja Oksman-Caldentey (VTT, Espoo, Finland) 
Launching a Research Topic article collection for Frontiers in Plant 
Science 
15:10 – 15:30 Eija Lehmuskallio (NatureGate, Helsinki, Finland) 
Video presenting the biodiversity of Finnish nature 
 
 
Session 1  
 
 
 
Chairs 
George Lomonossoff and Anneli Ritala 
15:30 – 16:10 Keynote  
Kirsi-Marja Oksman-Caldentey (VTT, Espoo, Finland)  
Plant biotechnology beyond genome era in the dawn of synthetic 
biology 
16:10 – 16:40 Refreshments 
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16:40 – 17:00 
 
 
Franziska Kellner (Leaf Expression Systems, Norwich, UK)  
Rift Valley Fever Virus – A case study 
17:00 – 17:20 Teresa Capell Capell (University of Lleida, Spain) 
A tríple combination microbiside against HIV-1 expressed in rice 
17:20 – 17:40 Efraim Lewinsohn (The Volkani Centre, Ramat Yishay, Israel) 
Modulation of sesquiterpene biosynthesis in Khat (Catha edulis) 
leaves upon harvesting 
17:40 – 18:00 Lauri Reuter (VTT, Espoo, Finland) 
Future of disruptive technologies and plant molecular farming 
19:00 – 21:00 Get-together in Old Town Hall, Empire Room                       
(Addess: Aleksanterinkatu 20, Helsinki) 
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Tuesday 12.6.2018  
Session 2   
Chairs 
Stefan Schillberg and Suvi Häkkinen 
09:00 – 09:40 Keynote 
Stefan Schillberg (Fraunhofer IME, Aachen, Germany) 
A critical view on the business potential of recombinant protein 
production in plants  
09:40 – 10:00 Andreas Schaaf (Greenovation Biotech GmbH, Freiburg, Germany) 
Pharmacokinetics, pharmacodynamics, and safety of moss-
aGalactosidase A in patients with Fabry disease 
10:00 – 10:20 Cornelius Gunter (University of Cape Town, Rodenbosch, South 
Africa) 
Immunogenicity of plant-produced porcine circovirus-like particles 
10:20 – 10:45 Five elevator talks for selected posters 
10:45 – 11:15 Posters with refreshments 
11:15 – 11.55 Keynote 
Kazuki Saito (Chiba University and RIKEN, Yokohama, Japan) 
Phytochemical genomics: from Arabidopsis to medicinal plants 
11:55 – 12.15 Hadrien Peyret (John Innes Centre, Norwich, UK) 
Using a synthetic biology approach to develop a novel, easy to use, 
and open access transient expression system 
12:15 – 12:35 Christina Dickmeis (RWTH Aachen University, Germany) 
Small, smaller, nano: New applications for Potato Virus X in 
bionanotechnology 
12:35 – 12:55 Katja Härtl (Technical University of Munich, Freising, Germany) 
Tailoring bioactive natural products with glycosyltransferases 
13:00 – 14:00 Lunch 
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Session 3 
 
 
 
Chairs 
Paul Christou and Dominik Mojzita 
14:00 – 14:40 Keynote 
Paul Christou (University of Lleida, Spain) 
From genes to products: A plant biotechnology product portfolio for 
human and animal health and nutrition  
14:40 – 15:00 Heribert Warzecha (Technische Universität Darmstadt, Germany) 
Toward engineering of cannabinoid biosynthesis: In-planta 
characterization of enzymes involved in the synthesis of THCA and 
derivatives 
15:00 – 15:20 Somen Nandi (University of California, Davis, USA)  
Supporting explorers on Mars: A biomanufacturing solution for 
producing biologics during deep space exploration  
15:20 – 16:00 Keynote 
Dominik Mojzita (VTT, Espoo, Finland)  
On-demand gene expression in plants: New frontiers set by the new 
synthetic expression system  
16:00 – 16:30 Posters with refreshments 
16:30 – 16:50 Kaewta Rattanapisit (Chulalongkorn University, Bangkok, Thailand) 
Recombinant human osteopontin expressed in Nicotiana benthamiana 
stimulates osteogenesis related genes in human periodontal ligament 
cells 
16:50 – 17:10 Ani Barbulova (Arterra Bioscience srl, Naples, Italy) 
Plant somatic embryo cultures are a profitable source of compounds 
with skin rejuvenating activity  
17:10 – 17:30 Sara Selma García (IBMCP, CSIC-UPV, Valencia, Spain) 
Combinatorial design of modular and programmable transcriptional 
regulators in plants 
17:30 – 17:45 Julia Jansing (RWTH Aachen University, Germany) 
Molecular Farming 6.0: Hexa-mutant Nicotiana benthamiana plants 
lacking plant-specific N-glycans for transient expression 
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17:45 - 18:15 
 
 
Keynote 
Jochen Schiemann (Julius Kühn Institute, Quedlinburg, Germany) 
Genome Editing: challenging our views and interpretation of the 
current regulatory systems 
18:15 – 18:45 Introduction of new H2020 plant molecular farming projects 
Diego Orzaez: Newcotiana 
Dirk Bosch: CHIC 
Julian Ma: PharmaFactory 
 
19:00 - 20:00 
 
ISPMF General assembly (members only) 
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Wednesday 13.6.2018  
Session 4   
Chairs: Marc-André D’Aoust and Jussi Joensuu 
09:00 – 09:45 Keynote  
Marc-André D’Aoust (Medicago Inc., Quebec, Canada)  
Development of the next generation influenza vaccine 
09:45 - 10:05 Sebastian Mercx (Université catholique de Louvain, Louvain-la-
Neuve, Belgium) 
Genome editing of Nicotiona tabacum suspension cells by a multiplex 
CRISPR/Cas9 strategy results in humanized pharmaceutical 
glycoproteins without plant specific glycans 
10:05 – 10:25 Ingo Appelhagen (John Innes Centre, Norwich, UK) 
Colour bio-factories: Scale-up production of anthocyanins in plant cell 
culture 
10:25 –10:45 Philippe Varennes-Jutras (University of Oxford, UK) 
pH gradient mitigation in the leaf cell secretory pathway – One goal, 
several effects 
10:45 – 11:20 Posters with refreshments 
11:20 – 12.00 Keynote 
Frank Petersen (Novartis Pharma AG, Basel, Switzerland) 
Natural products based molecules for target and drug discovery in 
pharmaceutical research 
12:00 – 12:20 Audrey Teh (St. George´s University of London, UK) 
Prolonging serum half-life of plant-made anti-HIV broadly neutralising 
antibodies (bNAbs) by improving binding to human neonatal Fc 
receptor (hFcRn) and reducing binding to human macrophage 
receptor (hMR) 
12:20 – 12:40 David Ullisch (Phyton Biotech GmbH, Ahrensburg, Germany) 
Green chemistry? Environmental performance evaluation of 
commercial plant cell culture-derived paclitaxel production 
12:40 – 13:00 Rima Menassa (Agriculture and AgriFood Canada, London, Canada) 
Developing an IgA biobetter antibody against E. coli O157:H7 with 
enhanced stability by rational design of a bovine Fc chain 
13:00 – 14:00 Lunch 
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Session 5  
 
 
Chairs: Julian Ma and Heiko Rischer 
14:00 – 14:40 Keynote 
Jennifer Bromley (Bristish American Tobacco, Cambridge, UK) 
A multi-omics approach to harness tobacco biochemistry 
14:40 – 15:00 Benjamin Gengenbach (Fraunhofer IME, Aachen, Germany) 
Recombinant production of the toxic anti-cancer lectin viscumin in 
tobacco plants and microbial cells. A comparative analysis of yield, 
process costs and toxicity 
15:00 – 15:20 Anatoli Giritch (Nomad Bioscience GmbH, Halle, Germany) 
Plant-made antimicrobial proteins for food safety 
15:20 – 15:40 Mark A Jackson (University of Queensland, Brisbane, Australia) 
Co-expression of a cyclizing asparaginyl endopeptidase enables 
efficient production of cyclic peptides in planta 
15:40 – 16:10 Posters with refreshments 
16:10 – 16:30 Muriel Bardor (University of Rouen, France) 
Understanding the regulation of the N-glycosylation pathway is a 
prerequisite to optimize microalgae as a cell factory for the production 
of biopharmaceuticals 
16:30 – 16:50 George Lomonossoff (John Innes Centre, Norwich, UK) 
Global food security – Plant-made Virus-Like Particles as a candidate 
vaccine against Nervous Necrosis Virus 
16:50 – 17:10 Ann Meyers (University of Cape Town, Rondebosch, South Africa) 
Immunogenicity of a virus-like particle (VLP) vaccine against African 
horse sickness 
17:10 – 17:30 Luis Matias Hernández (Sequentia Biotech, Barcelona, Spain) 
From TricoPharming to Artennua: From medicinal trichomes research 
to business 
Closing  
17:30 – 18:00 Kirsi-Marja Oksman-Caldentey (VTT, Espoo, Finland) and George 
Lomonossoff (John Innes Centre, Norwich, UK) Closing remarks and 
announcing the 4th ISPMF 
 
19:30 - 22:00 Conference Dinner at Meripaviljonki, Helsinki 
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Video presenting the biodiversity of Finnish nature 
Eija Lehmuskallio 
NatureGate, Helsinki, Finland 
Corresponding author: Eija Lehmuskallio <eija@naturegate.net> 
 
NatureGate (NG) is a comprehensive but easy knowledge website and identification tool. It 
enables fast species identification and nature observations. As an awareness building 
nature web service, NatureGate offers solutions for joyful learning of scientific knowledge as 
well as practical skills. 
Current human behavior and ignorance cause dramatic stress to the nature. Climate 
changes now faster than ever. People's contacts with nature have declined dramatically. We 
cannot read nature's signs anymore. NG helps create new links between people and the 
nature. Our solution enables people again to understand nature’s signs as well as the 
relationships between their actions and the environment. Our solution popularizes 
scientifically accurate natural science, spreading understanding of species as well as the 
effects of accelerating climate change. We help people read the nature and become 
conscious of the relationship between our actions and the environment 
Global warming alters habitats, species' native ranges and their behavior. A growing number 
of species will not adapt to the faster-than-ever climate change. When is our time? Experts 
predict that 25% of Earth’s species will be heading for extinction by 2050. Only a fraction of 
our global population understands the basics of biodiversity and the strong dependency 
between species. Only people who can read nature are conscious of the relation between 
their actions and the environment.  
NatureGate offers a comprehensive, practical and inspiring way to observe and identify 
species, and spot the signals of change. It enables you to read nature anywhere on our 
globe. Learning can replace out-of-date books in nature and species teaching at schools. 
We provide a field-tested, shared research platform with a vast constantly expanding online 
database. NatureGate data and information reflect proven changes in our nature. Even small 
childrens' observations may help scientific research by producing real time nature 
information. e.g. new species. NatureGate's species identification method helps users find 
species by sorting the database according to the features, location etc. of the observation. 
NatureGate is designed to be easy, fast and suitable also for amateurs as well as to 
professional researchers.
Opening 
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Session 1 
Keynote  
Plant biotechnology beyond genome era in the dawn 
of synthetic biology 
Kirsi-Marja Oksman-Caldentey  
VTT Technical Research Centre of Finland, Ltd., Espoo, Finland 
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Keynote  
Plant biotechnology beyond genome era in the dawn 
of synthetic biology 
Kirsi-Marja Oksman-Caldentey 
VTT Technical Research Centre of Finland Ltd., Espoo, Finland 
Corresponding author: Kirsi-Marja Oksman-Caldentey <kirsi-marja.oksman@vtt.fi> 
 
Plant biotechnology is considered to have started from the discovery of the principles of 
cellular totipotency in the late 19th century, followed by Agrobacterium-mediated genetic 
transformation about 45 years ago. Today, the two main pilars of plant biotechnology are 
the possibilities to utilize efficiently living plant cells as green factories to produce highly 
complex small molecules (secondary metabolities), and recombinant proteins. On the other 
hand, plant biotechnology offers also valuable tools for plant breeding, e.g. introducing novel 
traits to crop or ornamental plants, nowadays also through new plant breeding techniques 
with unprecedented efficiency.  
The main bottleneck in producing efficiently plant seconday metabolites has been the lack 
of understanding of how these complex molecules are synthetized and regulated in plant 
cells. The tissue-specific and subcellular localization adds an extra challenge to this picture.  
Moreover, only recently the rapid and more economic genome sequencing tools have 
allowed to obtain genome data, also from non-model plants, thus permitting the modelling 
of biosynthetic pathways. We are now able to utilize synthetic biology tools to readily map 
the key genes playing the major roles in pathway engineering, as well as producing entirely 
new-to-nature molecules with novel acivities through combinatorial biochemistry. 
Examples of metabolic engineering of pharmaceutically important plant metabolites in plants 
and plant cells as well as possibilities to transfer entire pathways to simpler organisms such 
as yeast will be given. Plant cells can also be used for biotransformation as will be illustrated 
with the example of a raspberry ketone flavour coumpound. To overcome the additional 
bottleneck related to the instability of the undifferentiated cell cultures, we have shown the 
metabolic stability of hairy root cultures for more than 15 years of cultivation. 
Recombinant protein production in plants and plant cell cultures has resulted in excellent 
outcomes, especially for pharmaceutical applications. These discoveries will also be 
highlighted.    
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Manufacturing plant based vaccines “Rift Valley Fever 
Virus – A case study” 
Kellner F¹, Holton N¹, Cater P¹, Charlton S², Dowall S² 
¹Leaf Expression Systems, Norwich, United Kingdom  
²Public Health England, Porton Down, United Kingdom 
Corresponding author: Franziska Kellner <kellnerf@leafexpressionsystems.com> 
 
New and emerging viral diseases pose a growing threat of a global epidemic. Rift Valley 
Fever (RVF) is an acute viral disease caused by RVF virus (RVFV) transmitted to animals 
through bites from infected mosquitoes. First reported in cattle in Kenya’s Rift Valley in the 
early 1910, subsequent outbreaks have been reported throughout sub-Saharan Africa. In 
livestock, the RVFV causes disease and a high abortion rate, leading to significant societal 
and economic impacts. Worryingly, the virus can be transmitted to humans through contact 
with blood and tissues of infected animals. At present no vaccination strategy is approved 
for human use and veterinary vaccines are not effective or have unwanted side effects.  
Within this project we aimed to develop new virus-like particle(VLP) based vaccine against 
Rift Valley Fever virus (RVFV) using plant transient expression (Sainsbury and 
Lomonossoff, 2008). In order to produce this vaccine we employed two strategies: (1) 
Production of a native RVFV VLP, composed of the structural proteins of the virus; (2) 
Incorporation of RVFV epitopes into the coat protein of Cowpea Mosaic virus to provide a 
stable vehicle for epitope delivery (Porta el al., 2003). Initial preclinical evaluation indicates 
the potential effectiveness of this vaccine against RVFV. Further work is however required 
to develop this product and evaluate its effectiveness in a clinical setting.  
References 
Porta, C., Spall, V.E., Findlay, K.C., Gergerich, R.C., Farrance, C.E., Lomonossoff, G.P. 2003. Cowpea mosaic 
virus-based chimaeras: effects of inserted peptides on the phenotype, host range, and transmissibility of the 
modified viruses. Virology, 310: 50-63. 
Sainsbury, F., Lomonossoff, G.P. 2008. Extremely high-level and rapid transient protein production in plants 
without the use of viral replication. Plant Physiology, 148: 1212-1218. 
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A triple combination microbicide against HIV-1 
expressed in rice 
Capell  T1, Vamvaka E1, Farré G1, Molinos-Albert LM2, Evans A3, Canela-
Xandri A1, Twyman RM4, Carrillo J2, Ordóñez RA1, Shattock R3, O’Keefe BR5, 
Clotet B2,6, Blanco J2,6, Christou P1,7 
1University of Lleida-Agrotecnio Center, Lleida, Spain 
2IrsiCaixa AIDS Research Institute, Badalona, Barcelona 
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The transmission of Human immunodeficiency virus (HIV) can be prevented by the 
prophylactic application of broadly-neutralizing monoclonal antibodies and lectins. Plants 
offer an alternative platform for the production of protein microbicides benefiting from 
inexpensive and highly scalable upstream production and the ability to produce multiple 
components in a single plant line. The latter is important because multiple components are 
required to avoid the rapid emergence of HIV-1 strains resistant to single microbicides. 
Furthermore, crude extracts from plants expressing multiple microbicides can be used 
directly for prophylaxis to avoid the massive costs associated with downstream processing 
and purification. Having previously established that rice (Oryza sativa) plants can individually 
express the monoclonal antibody 2G12 and the lectins cyanoviriN-N (CV-N) and griffithsin 
(GRFT) as functional proteins in the endosperm, we wished to investigate the potential of 
rice to produce all three functional proteins simultaneously. Transgenic plants were 
generated expressing all three proteins and the crude extracts showed in vitro binding to 
gp120 and HIV-1 neutralization. Therefore, the production of HIV-1 combination 
microbicides in rice may not only reduce costs compared to traditional platforms but also 
provide strategies for long term durability by making it difficult for the virus to mutate 
simultaneously against multiple components in the combination microbicide. 
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Khat (Catha edulis) leaves are common in East Africa and the Middle East and traditionally 
chewed for their psycho-stimulating amphetamine-like properties. In addition to S-cathinone 
and other pharmacoactive phenylpropylamino alkaloids, leaves also accumulate various 
terpenoids including volatile mono- and sesquiterpenes and noN-volatile quinone methide 
triterpenes and cathedulin alkaloids exhibiting substantial pharmacological interest. 
Sesquiterpenes are accumulated in many plant species in response to mechanical injury or 
biotic challenges.  
In this work we characterized the sesquiterpenes present in khat leaves in response to 
harvesting. Leaf volatiles were sampled using solid-phase microextraction (SPME) coupled 
to GC-MS. Harvesting the leaves resulted in marked increases in the total sesquiterpene 
content, and especially in the levels of (E)-caryophyllene and α-copaene. (E)-Caryophyllene 
is a modulator of cannabinoid action influencing the therapeutic properties of cannabis by 
binding to and activating the human CB2 receptor. To test for the potential sesquiterpene 
biosynthetic capacity of khat leaves, crude protein extracts were incubated with farnesyl 
diphosphate as a substrate and the sesquiterpenes produced in vitro were identified using 
GC-MS. Increased biosynthetic potential for sesquiterpenes, including (E)-caryophyllene, 
elemol, and α-eudesmol were detected in extracts from harvested leaves as compared to 
controls. To get a broader view of genes that are up or down regulated in harvested leaves, 
we performed deep RNA sequencing.  
The analysis resulted in the identification of novel putative terpene synthase genes 
transcriptionally upregulated upon harvesting. Functional expression of three of these genes 
indicated that they encoded proteins catalyzing the formation of sesquiterpenes from 
farnesyl diphosphate. CeTps17580 produced mainly α-copaene and α-elemene, 
CeTps13580 generated mainly elemol and α-eudesmol, while CeTps6019 produced a 
mixture of α-copaene, α-cubebene, γ-cadinene and δ-cadinene as main components. The 
identification and characterization of these genes together with the study of their expression 
levels as a result of harvesting will help us to better understand the mechanism that brings 
about phytochemical changes in khat leaves upon harvesting. 
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The speed of technological development accelerates. Changes are coming faster and from 
ever more unexpected directions. Fast sequencing technologies and cost effective gene 
editing have already changed the field. That is obvious. What are the developments we are 
not expecting? What is it that will surprise us all? Where is the next disruption coming? 
Unprecedented data processing capabilities of neural networks, machine intelligence, 
changes massive industries. Image recognition has already transformed radiology and AI 
keeps newborn children safe in hospitals. Generative design has changed the ways cars 
and aircrafts will be built. In the digital world, the learning cycle has suddenly shortened. 
What happens when all the tools are applied to molecular farming? The only way to keep 
up is to run. Are you running?  
Technology has come on and under your skin. Mobile devices and wearable sensors collect 
data. Social media collects meta-data. Biobanks collect data. Everything collects data and 
that data will change everything. What are the implications for clinical trials? What happens 
when n=5 billion, everyone becomes her own control group and cost drops to a fraction? 
What are the questions you want to ask when all answers exist?   
This is a provocation to set the tone for discussions going beyond the obvious.  
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A critical view on the business potential of 
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The global protein expression market size was estimated at USD 1,654 million in 2017 and 
is expected to reach USD 2,850 million in 2022. The market is dominated by prokaryotic and 
mammalian expression systems, whereby prokaryotic platforms provide high production 
capacities and inexpensive production, and mammalian cells are the favoured system for 
the production of biopharmaceutical products. Although plants are now gaining widespread 
acceptance as a general platform for the large-scale production of recombinant proteins, 
their market share is rather small. This is partly because of low yields, poor and inconsistent 
product quality and difficulties with downstream processing at larger scale. In addition, 
examples demonstrating the capacity of plants to provide proteins at lower costs and 
improved quality are still relatively scarce, and therefore industry is reluctant to switch from 
their established and approved processes to plant-based production. Nevertheless, plant-
produced proteins for application in medicine, research and cosmetics have reached the 
market demonstrating that production in plants can be competitive and sustainable. The talk 
will present the strengths of plant expression systems for specific uses, but will also address 
bottlenecks requiring expedient solutions to expand the implementation of plant systems.  
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Moss-aGal is a plant-made version of human alpha-galactosidase developed for enzyme 
replacement therapy (ERT) in Fabry patients. Manufactured in a moss (Physcomitrella 
patens), the enzyme exhibits an extraordinary homogenous N-glycosylation profile with 
more than 90% mannose-terminated glycans. In contrast to mammalian cell produced Fabry 
ERTs, moss-aGal does not rely on Mannose-6-phosphate receptor (M6PR) mediated 
endocytosis but targets the mannose receptor (MR) for tissue uptake. Extensive quality 
testing revealed outstanding and reproducible biochemical product purity and definition. 
Between January and October 2017, we conducted a Phase 1 clinical trial evaluating 
pharmacokinetics, pharmacodynamics, and safety of Moss-aGal in patients with Fabry 
disease. Recruiting took place in Mainz (Germany) and Budapest (Hungary). In total, 6 
patients with confirmed diagnosis of Fabry disease, elevated lyso-Gb3 concentrations and 
seronegative for antibodies against agalsidase participated in this trial and received a single 
dose of Moss-aGal with 0.2 mg/kg body weight by intravenous infusion. Following injection, 
tolerability of the drug, patient’s safety and quality of life as well as initial explorative efficacy 
parameters were assessed during a 28-day clinical schedule. For all six patients, the drug 
was well tolerated and no safety issues were observed. 
The presentation will introduce and discuss the outcome of this first-iN-human study 1of the 
first moss-made enzyme replacement therapy. 
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Porcine circovirus type 2 (PCV-2) is the main causative agent associated with diseases now 
collectively known as porcine circovirus-associated disease. Costs associated with 
commercial PCV-2 vaccines currently used to protect pigs have placed a significant 
economic strain on the global swine industry. Plant-made pharmaceuticals are rapidly 
becoming a viable alternative to established production systems. Plant-made viral proteins 
have been demonstrated to self-assemble into virus-like particles (VLPs) eliciting more 
potent antibody and cellular immune responses. Our objective in this study was the 
expression of PCV-2 capsid protein (CP) in Nicotiana benthamiana, the detection of 
assembled VLPs, and assessment of their immunogenicity in mice. 
The PCV-2 CP was transiently expressed in N. benthamiana using the pEAQ-HT 
Agrobacterium-delivered expression vector. Plant-made CP was confirmed using 
immunoblotting and expression was optimised for the OD600 of infiltrated recombinant A. 
tumefaciens and day of harvest. VLPs were isolated using CsCl density purification, 
visualised by transmission electron microscopy, and used in immunogenicity studies in mice. 
The 27-kDa PCV-2 CP was successfully expressing in N. benthamiana and the optimum 
expression conditions were determined to be four days post infiltration at an A. tumefaciens 
optical density of one. The particles of between 17-20 nm diameter were detected that were 
absent in the control indicating that the CP had assembled into VLPs. The plant-made PCV-
2 VLPs elicited an immune response in mice with high antibody titres.  
This is the first report describing the assembly of plant-made PCV-2 CP into VLPs and their 
immunogenicity in mice. These results contribute to our understanding of foreign protein 
production in plants and may well serve as viable alternative for commercial vaccine 
development. 
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The recent advances of genomics and metabolomics in plants accelerate our understanding 
about the mechanism, regulation and evolution of biosynthesis and function of plant 
specialized products. The questions now can be addressed how the metabolomic diversity 
of plants is originated at the levels of genome and how we should apply this knowledge to 
medicine and industry. Such study called as ‘Phytochemical Genomics’ is regarded as the 
new sector in plant science and natural products chemistry, which elucidates the genomic 
basis of the biosynthesis and the function of plant metabolites (Saito, 2013; Sumner et al., 
2015; Rai et al., 2017; Yamazaki et al., 2018). In this presentation, I will report an overview 
of our recent studies on the phytochemical genomics in a model plant, Arabidopsis thaliana, 
and medicinal plants. The topics include: 1) Strategy of phytochemical genomics for 
understanding the origins of the chemical diversity of plants as A. thaliana as the model, and 
2) A couple of examples for identification of genes involved in the biosynthesis of specialized 
products in medicinal plants. 
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Expression systems for the transient overproduction of proteins in plants have come a long 
way in the past 10-15 years. The development of a range of different expression systems 
from numerous different research groups and private companies all allow plant 
biotechnologists to obtain high yields of their proteins of interest. The most successful of 
these expression systems are deconstructed viral vectors, which include different genetic 
components from different (usually) viral sources in order to maximise protein yield. We have 
taken the pre-existing pEAQ-HT expression vector (Sainsbury et al., 2009) as a starting 
point for rationally-designed improvements based on first principles and the current state of 
knowledge about plant viral gene regulation and recombinant protein expression. In an 
iterative process, improvements were made to the untranslated regions (UTRs) and to the 
vector backbone in order to improve ease of use as well as recombinant protein yield. The 
main result of this is the development of a novel expression system which allows for two-
fold higher recombinant protein yield than the original pEAQ-HT. Moreover, a suite of novel, 
synthetic, rationally-designed 5’- and 3’-UTRs have been developed which allow tailoring of 
expression to suit desired yields. As a side effect of this work, valuable insight has been 
gained into the relative roles of the pEAQ-HT UTRs, and more generally what is required for 
a transient expression system to be successful. Another aspect of the work has been to 
focus on the development of free-to-use components that can be used throughout the plant 
molecular farming community by rethinking the traditional approach to intellectual property 
and material transfer. Another expression vector has therefore been created which is free 
of patented components and can be used by anyone in the plant molecular farming 
community. 
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Nanotechnology is an emerging interdisciplinary field of interest. Nanostructured materials 
originate from inorganic or organic compounds such as polymers and peptides. Plant virus 
nanoparticles became a key instrument for the introduction of tailored functionalities by 
genetic engineering and conjugation chemistry. The most popular plant viruses include 
tobacco mosaic virus (TMV) and cowpea mosaic virus (CPMV) and have shown to be 
applicable for instance in bioimaging, vaccination and electronics. However, little attention 
was paid to potato virus X (PVX), although exhibiting great potential in diverse application 
areas in which multi-functional flexible scaffolds with a high aspect ratio are desired. Here 
we present new applications for PVX and new functionalization methods. By peptide 
presentation, we could modify PVX for improved cell attachment with the integriN-binding 
domain RGD and improved mineralization with different mineralizatioN-inducing peptides. 
The PVX nanoparticles (NP) support hydroxyapatite nucleation for improved bone tissue 
replacement in hydrogel applications. By this means, PVX comprises a genetically 
programmable control of its surface, while showing excellent biocompatibility and 
biodegradability, which makes it particularly attractive for medical applications.  
PVX can further be genetically modified for silicification. We have shown that filamentous, 
anisotropic, flexible plant viruses offer a versatile platform for the formation of complex 
hybrid materials including isolated coated virus particles and complex microstructures. 
These structures formed under mild conditions making them suitable for more delicate viral 
particles. By silicification the PVX NPs are further suited for chemical modifications for 
applications as semiconductors, imaging dyes and drug carrier.  
Additionally, we developed more diverse fusions strategies for larger protein attachments to 
the surface of PVX. As an alternative strategy, we utilized a broad variety of 2A sequences 
for different fusion efficiencies and tested different proteiN-protein interaction partners. The 
most promising interacting pair on PVX NPs was the SpyTag-SpyCatcher system from 
Staphylococcus pyogenes. The fusion of the SpyTag to the PVX NP allows a covalent 
linkage of any desired protein fused to the SpyCatcher expressed separately in its most 
appropriate expression system.  
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The bioactivity of plant natural products depends on more than just their scaffolds. Tailoring 
them by addition or removal of functional groups can decisively alter their physicochemical 
properties. In Nature, the addition of sugar residues to small lipophilic molecules is one of 
those mechanisms being particularly frequent. In plants, the sugar transfer is mostly 
conveyed by nucleoside diphosphate (NDP)-sugar dependent glycosyltransferases (GTs). 
The glucosylated products show increased solubility and stability, and reduced toxicity. 
Conveniently, the glycosidic bond can later be cleaved on demand by heat or enzymes. As 
a result, the bioactivity and bioavailability can be manipulated offering numerous 
opportunities for industrial application. 
The interest of the food, pharma and cosmetics industry for new and applicable natural 
products has increased tremendously. Therefore, we have built a library of plant GTs to 
glucosylate commercially important small molecules such as the flavour compounds 
geraniol and vanillin. Furthermore, we employ whole cell biocatalysis to produce the 
glucosides on large scale and test the purified products in food and cosmetic applications. 
We have established the first economically viable process for the production of small 
molecule glucosides. 
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We recreated the carotenoid and ketocarotenoid pathways in elite South African white maize 
inbred lines. One of the resulting high carotenoid transgenic lines was registered in Spain 
under the name of Carolight. We describe the process used to generate Carolight and 
also a breeding program and experimental field trials to assess the performance of elite 
transgenic hybrids using locally adapted commercial inbred lines. We present data on the 
interactions of Carolight with pests and diseases in the field. The use of Carolight in poultry 
and swine production in a commercial setting will be discussed. Experiments demonstrating 
the beneficial effects of a high carotenoid corn diet specifically delivered through Carolight 
in human health, using an experimental animal model will be described. The performance 
of a high ketocarotenoid line in fish production will be used as a case study to illustrate 
transition from the laboratory to a commercial setting. IP and FTO analysis as well as 
regulatory aspects will also be discussed to address remaining barriers to 
commercialization. 
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Cannabis sativa L. or hemp has been a crop plant for centuries, providing fibers and oil but 
is most prominent for its content of pharmacologically highly active compounds, with THC 
being the main psychotropic ingredient and the reason for the plants treatment as an illicit 
drug in many countries. However, numerous of the cannabinoids have been shown to be 
effective in the treatment of various diseases, making them interesting drug targets or lead 
compounds for the development of semisynthetic derivatives. To uncouple targeted 
cannabinoid production from a THC-producing plant, a biotechnological production system 
with defined products would be advantageous (Schachtsiek et al., 2018). 
Here we describe the engineering of late biosynthetic genes into Nicotiana benthamiana to 
evaluate biosynthetic capacity in a transient expression system. With THCA synthase, we 
were able to show that active enzyme can be obtained after ER/apoplast-targeting (Geissler 
et al., 2018). Moreover, THCAS seems to be glycosylated in N. benthamiana, suggesting 
that this modification has an influence on the stability of the protein. Activity assays with 
cannabigerolic acid as substrate showed that the recombinant enzyme not only produces 
THCA (123 ± 12 fkat g
-  1
FW activity towards THCA production) but also cannabichromenic 
acid (CBCA; 31 ± 2.6 fkat g
-  1
FW activity towards CBCA production). This preliminary work 
shows that N. benthamiana could be a suitable host for cannabinoid production, but towards 
whole pathway integration careful analysis of subcellular localization is necessary.   
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The Center for the Utilization of Biological Engineering in Space (CUBES), one of two 
inaugural National Aeronautics and Space Administration (NASA) Space Technology 
Research Institutes (STRIs), recently formed to pioneer research in biomanufacturing to 
produce fuel, materials, pharmaceuticals, and food. These biotic solutions aspire to realize 
inherent advantages of in situ resource utilization in space biotechnology over traditional 
abiotic approaches. 
Deep space exploration mission environments pose a variety of obstacles for sustained 
human life support systems. Continuous exposure to lower gravity reduces bone mass, 
muscle mass, and alters cardiac performance. Increased levels of cosmic radiation outside 
of Earth’s protective atmosphere result in high risks of cancer and accelerated degradation 
of many human organs. Physical isolation from earth-reliant supply chains introduce noN-
negligible complications in nutritional provisions and access to therapeutics. The primary 
tasks of our team are to develop platform technologies that could be practiced to provide 
necessary nutritional and medical support to overcome these human life support system 
challenges. 
Plants are well-studied as a food source for astronauts. More than a dozen plant cultivation 
experiments have been performed on space missions since the 1970’s. Plants harness the 
abundance of solar energy and close the human waste loop with complementary 
metabolism. Our overarching research goal is to demonstrate the multi-functional utility of 
plants not only as a source of food but also for human pharmaceuticals that address unmet 
needs in deep space exploration. Our primary aims are (1) to design codoN-optimized 
synthetic genes of relevant pharmaceutical molecules, (2) to optimize production and 
delivery modalities tailored to the specific needs, and (3) to screen and select transient and 
transgenic plant host lines for sustained production of therapeutic biologics in a Mars-like 
environment. 
Our initial therapeutic target is the gravity-associated bone anabolism of astronauts. We are 
developing a plant-based platform for expression of Parathyroid Hormone (N-terminal 
fragment) fused to the Fragment Crystallizable (Fc) antibody region. We are also in the 
process of developing a novel biologically-derived purification platform to reduce the 
complexity of biopharmaceutical production in the limited resource environment of deep 
space. The integrated strategic plan and initial experimental research will be presented, 
along with future research aimed at safeguarding the health of deep space explorers. 
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We have developed a novel orthogonal expression system (SES) for plants that offers broad 
range and highly constitutive expression levels of target genes. The expression system is 
based on a synthetic transcription factor (sTF) that regulates expression of the target gene 
via a sTF-dependent promoter. The sTF expression is driven by a universal core promoter, 
which was obtained by a specifically designed screening assay. The sTF is employed in the 
SES system as a potent transcription activator for the target gene. The sTF-dependent 
promoter regulating the expression of the target gene also contains a similar type of 
universal core promoter, making the whole expression system independent of the host’s 
native regulation and therefore functional in diverse species. The varying number of the sTF-
binding sites in combination with a choice of core promoters, and trans-activation domains 
in the sTF, enable adjustment of the target-gene expression levels over a wide range, from 
very low to very high. On the high end, the expression is substantially exceeding the levels 
achievable by the established double-enhancer CaMV35S promoter system. This 
expression system provides robust expression platform in a broad spectrum of host 
organisms with numerous applications in metabolic engineering and protein/enzyme 
production. 
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Tissue engineering aims to utilise biologic mediators to facilitate tissue regeneration. Several 
recombinant proteins have potential to mediate induction of bone production, however, the 
high production cost of mammalian cell expression impedes patient access to such 
treatments. The aim of this study is to produce recombinant human osteopontin (hOPN) in 
plants for inducing dental bone regeneration. The expression host was Nicotiana 
benthamiana using a geminiviral vector for transient expression. OPN expression was 
confirmed by Western blot and ELISA, and OPN was purified using Ni affinity 
chromatography. Structural analysis indicated that plant-produced hOPN had a structure 
similar to commercial HEK cell-produced hOPN. Biological function of the plant-produced 
hOPN was also examined. Human periodontal ligament stem cells were seeded on an OPN-
coated surface. The results indicated that cells could grow normally on plant-produced 
hOPN as compared to commercial HEK cell-produced hOPN determined by MTT assay. 
Interestingly, increased expression of osteogenic differentiatioN-related genes, including 
OSX, DMP1, and Wnt3a, was observed by realtime PCR. These results show the potential 
of plant-produced OPN to induce osteogenic differentiation of stem cells from periodontal 
ligament in vitro, and suggest a therapeutic strategy for bone regeneration in the future. 
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of compounds with skin rejuvenating activity 
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The use of plant tissue cultures as a source of safe, sustainable and effective skin care 
ingredients became not only a trend but also a valid alternative to the traditional plant extract 
preparations. Currently, a number of plant cell suspension culture derived ingredients with 
proven efficacy have been already available on the cosmetic market. Among the advantages 
of the plant cell suspension cultures as source of bioactive compounds is their versatility. 
This means that it is possible to induce the overproduction of specific compounds by simply 
modifying the growth conditions or inducing metabolic pathways by elicitor treatments. 
Moreover, by modulating growth regulator ratios or applying physical stresses, plant cell 
cultures can be further stimulated to produce differentiated tissues, which are more 
specialized and therefore able to synthesise compounds that are not produced in cell 
cultures at detectable levels (Barbuloba et al., 2014).  
One example is represented by the differentiation of the somatic embryos, bipolar structures, 
morphologically and physiologically identical to the zygotic embryos contained in the seeds. 
The somatic embryos pass through the same developmental stages as zygotic embryos, 
but without employing any gamete fecundation.  In these terms, somatic embryo cultures, 
and the process of somatic embryogenesis itself, represent the maximum expression of 
plant totipotency. It has been demonstrated that the somatic embryos express differentiation 
regulating genes and normally specific changes in the synthesis and mobilization of proteins, 
carbohydrates and lipids occur during their development (Horstman et al., 2017). Moreover, 
the somatic embryos are newly formed plant structures in constant mitotic activity, which 
makes them an interesting source of bioactive compounds promoting cell growth and 
differentiation in the skin. 
By employing molecular and analytical approaches, we investigated on the different 
composition of somatic embryo and cell culture derived ingredients, and demonstrated that 
extract preparations, obtained from somatic embryo-enriched cultures, were capable of 
attenuating senescence associated phenotypes in skin fibroblasts, by inducing important 
components of the extra cellular matrix and activating cell rejuvenation factors.   
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The RNA-guided DNA binding activity of CRISPR/Cas9 offers unprecedented possibilities 
in the fields of synthetic biology, molecular farming and metabolic engineering, among 
others. Modifications of the Cas9 protein or its guide RNA (gRNA) enable the expansion of 
the range of Cas9 activities, from its original nuclease activity to other DNA binding-related 
activities, like transcriptional activation/repression. This opens the possibility of modulating 
the expression of selected genes or sets of genes in plants through CRISPR/Cas9-based 
programmable transcription factors, thus directing metabolic fluxes towards the 
accumulation of certain products.  
The objective of this work is to design modular gRNA modifications that allow the attachment 
of regulatory domains to the CRISPR/Cas9 complex via its gRNA for plants. To achieve this, 
the CRISPR/gRNA-directed synergistic activation mediator or SAM strategy was adapted 
via Goldenbraid cloning system. SAM strategy consists of the adding of an RNA aptamer 
that binds the Ms2 phage coat protein, to free positions of the gRNA. This creates a structure 
comprising the chimeric RNA-guide and Cas9, which binds to Ms2 fused to a domain or 
protein of interest. In order to optimize the process, two chimeric RNA-guides were designed 
containing two copies of the Ms2 aptamer in two different positions. One of them adds the 
aptamer to the 3´end of the RNA-guide, whereas the second one incorporates it in a free 
loop of the RNA-guide hairpin. These structures were used for the attachment of several 
combinations of transcriptional activators to the gRNA/Cas9 complex fused to the Ms2 
protein. Taking advantage of the modular Goldenbraid cloning system, the construction of a 
combinatorial array of programmable transcriptional regulation with other proteins that bind 
aptamer sequences, like PP7 and COM, and several regulatory domains was facilitated.  
After test different strategies, the conclusion was that SAM/Ms2 strategy with the aptamer 
in the 3’ of the scaffold was the most efficient in N. benthamiana. Furthermore, the efficiency 
of using SAM/Ms2 strategy was compared with others where the activator domain was fused 
directly to the dCas9 testing different promoters, like Nopaline synthase promoter (pNos), 
MetallothioneiN-like protein type 2B promoter (pMTB) or dihydroflavonol 4-reductase 
promoter (pDFR), in transient and stable expression in N. benthamiana. The results 
obtained show the great potential of the Cas9/SAM system to modulate metabolic pathways 
and optimize the production of metabolites or proteins of interest. 
Session 3 
82 
 
 
References 
Nowak, C. M., Lawson, S., Zerez, M., Bleris, L. 2016. Guide RNA engineering for versatile Cas9 functionality. 
Nucleic Acids Research, 44: 9555-9564.  
Vazquez-Vilar, M., Bernabé-Orts, J. M., Fernandez-del-Carmen, A., Ziarsolo, P., Blanca, J., Granell, A., 
Orzaez, D. 2016. A modular toolbox for gRNA–Cas9 genome engineering in plants based on the GoldenBraid 
standard. Plant Methods, 12:1, 10.  
  
Session 3 
83 
 
Molecular Farming 6.0: Hexa-mutant Nicotiana 
benthamiana plants lacking plant plant-specific  
N-glycans for transient expression 
Jansing J1, Sack M1, Augustine SM1, Fischer R1, Bortesi L1 
1RWTH Aachen University, Aachen, Germany 
2Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany 
Corresponding author: Julia Jansing <julia.zischewski@molbiotech.rwth-aachen.de> 
 
The field of genome editing has been revolutionized by the recent emergence of the 
CRISPR/Cas9 technology, which makes the engineering of genomes simpler and cheaper 
than before. The RNA-guided nuclease Cas9 can easily be programmed to introduce a 
double strand break (DSB) in one or multiple sequences of choice simultaneously. In plants, 
DSBs are preferentially repaired by noN-homologous end-joining, which can result in 
frameshift mutations and thus the knock-out (KO) of targeted genes.  
Plants are a fast and flexible alternative for the production of pharmaceutical proteins, but 
differences between plant and mammalian N-glycosylation can affect the activity and 
immunogenic potential of a plant-produced protein. Thus it is desirable to modify the 
endogenous N-glycosylation machinery of Nicotiana benthamiana – by far the species of 
choice for protein production via transient expression – to make mammaliaN-like N-glycan 
structures. Previous efforts to eliminate the plant-specific α-1,3-fucose and β-1,2-xylose 
from N-glycans by RNAi (Strasser et al.), classical mutagenesis (Weterins & van Eldik) and 
TALEN (Li et al.) have only been partially successful, as the presence of α-1,3-fucose could 
be reduced but never eliminated. Here, we employed multiplexed CRISPR/Cas9 genome 
editing to generate plant lines completely deficient in α-1,3-fucosyltransferase and β-1,2-
xylosyltransferase activity. We generated constructs targeting either the xylosyl- (X) or the 
fucosyl-transferases (F) separately, and both sets of genes simultaneously. In the T2 
generation, F-KO and X-KO lines were identified and the functional gene knock-out was 
confirmed by mass spectrometric analysis of their N-glycans. FX-KO lines were then 
generated by crossing, and - thanks to the favorable appearance of new germinal mutations 
by ongoing Cas9 activity - homozygous knock-out lines were quickly identified. 
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Genome editing is a transformative technology with general applicability providing a very 
wide range of potential uses to tackle societal challenges. Worldwide, several genome-
edited plants and products thereof are already approved as noN-regulated articles and are 
reaching the market. In January 2017 the U.S. Department of Agriculture (USDA) and the 
U.S. Food and Drug Administration (FDA) have published four documents related to the pre-
market regulatory oversight of a variety of biology-based agricultural tools, including 
genetically engineered plants and plants and animals derived from certain newer precision 
breeding techniques, such as genome editing. EASAC, the European Academies Science 
Advisory Council, has published a Report on Genome Editing: scientific opportunities, public 
interests and policy options in the EU in March 2017. In this report, EASAC takes a broad 
perspective on the research advances, applications, policy implications and priorities for EU 
strategy for promoting innovation and managing regulation. EPSO, the European Plant 
Science Organization, has highlighted that in the implementation of the EU biotechnology 
regulatory framework there is a disproportionate focus on the genetic improvement 
technique used. This has led to the misinterpretation that GMOs are merely defined by the 
use of certain techniques. This is incorrect. Whether or not the resulting organism is a GMO 
depends on the fact if a novel combination of genetic material has been produced beyond 
the natural barriers of mating and recombination. This is not the case for several new plant 
traits obtained by genome editing. Based on the documents mentioned above future 
perspectives on biotechnology legislation will be discussed. 
In a first reaction on the Advocate General’s Opinion regarding mutagenesis and the 
Genetically Modified Organisms Directive the European Plant Science Organisation 
welcomes the Advocate General’s opinion in case C-528/16 published on 18 Jan 2018 as 
an important step in clarifying the European Directive 2001/18/EC concerning organisms 
modified by recent mutagenesis techniques that appeared after 2001. The opinion provides 
a general scheme to follow now by the European Court of Justice. 
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Looking over the edge of the European plate (Sprink et al., 2016), regulatory triggers, the 
regulatory status of genome edited crops, and biotechnology oversight efforts in Argentina, 
Australia, Canada, China, Japan, and the USA will also be discussed. 
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Development of the next generation influenza vaccine 
Marc-André D’Aoust 
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In the 2017-2018 influenza season, vaccination only provided a limited protection against 
the virus. It has even been calculated that, next year’s vaccine could provide only 20% 
protection against the dominant subtype H3N2 (Bonomo & Deem, 2018). Such suboptimal 
efficacy of the flu vaccines is the results of mutations resulting from egg-based vaccine 
production process, stressing the need for a new generation of influenza vaccines. 
Medicago has developed a recombinant seasonal influenza vaccine in the form of virus-like 
particles (VLPs). The plant-based production technology used allows for the production of 
vaccines that perfectly match the circulating strains and the VLP display of antigens results 
in strong humoral and cell mediated immune responses that have the potential to provide 
higher efficacy than the current vaccines. Today, our seasonal influenza vaccine is being 
evaluated in a human efficacy study involving 10 000 subjects. The presentation will detail 
the development of the next generation influenza vaccine, emphasising on the platform, the 
process and the analytical developments needed to bring this product to PIII clinical stage 
along with the most significant clinical results obtained to date. 
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Plants or plant cells can be used to produce pharmacological glycoproteins such as 
antibodies or vaccines. However these proteins carry N-glycans with plant-typical residues 
(β(1,2)-xylose and core α(1,3)-fucose), which can greatly impact the immunogenicity, 
allergenicity, or activity of the protein. Two enzymes are responsible for the addition of plant-
specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT). Our 
aim consisted of knocking-out two XylT genes and four FucT genes (12 alleles altogether) 
in Nicotiana tabacum BY-2 suspension cells using CRISPR/Cas9. Three XylT and six FucT 
sgRNAs were designed to target conserved regions. After transformation of N. tabacum BY-
2 cells, three lines showed a strong reduction of β(1,2)-xylose and α(1,3)-fucose, while two 
lines were completely devoid of them, indicating complete gene inactivation. The absence 
of these carbohydrates was confirmed by mass spectrometry analysis of the extracellular 
proteins. The KO lines did not show any particular morphology and grew as the wild-type. 
One KO line was transformed with genes encoding a human IgG2 antibody. The IgG2 
expression level was as high as in a control transformant which had not been 
glycoengineered. The IgG glycosylation profile determined by mass spectrometry confirmed 
that no β(1,2)-xylose or α(1,3)-fucose were present on the glycosylation moiety and that the 
dominant glycoform was the GnGn structure. These data represent an important step 
towards humanizing the glycosylation of pharmacological proteins expressed in N. tabacum 
BY-2 cells. 
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Anthocyanins are widely distributed, glycosylated, water-soluble plant pigments, which give 
many fruits and flowers red, purple or blue colouration. Their beneficial effects in a dietary 
context have encouraged increasing use of anthocyanins as natural colourants in the food 
and cosmetic industries. However, the limited commercial availability and diversity of 
anthocyanins have initiated searches for alternative sources of these natural colourants. In 
plants, high-level production of secondary metabolites, such as anthocyanins, can be 
achieved by engineering of regulatory genes as well as genes encoding biosynthetic 
enzymes. We have used tobacco lines which constitutively produce high levels of cyanidin 
3-O-rutinoside, delphinidin 3-O-rutinoside or a novel anthocyanin, acylated cyanidin 3-O-
(coumaroyl) rutinoside to generate cell suspension cultures. The cell lines are stable in their 
production rates and superior to conventional plant cell cultures. Scale-up of anthocyanin 
production in bioreactors has been demonstrated. The cell cultures also have proven to be 
a valuable production system for 13C-labelled anthocyanins. Our method for anthocyanin 
production is transferable to other plant species, such as Arabidopsis thaliana, 
demonstrating the potential of this approach for making a wide range of highly-decorated 
anthocyanins. The tobacco cell cultures represent a customisable and sustainable 
alternative to conventional anthocyanin production platforms and have considerable 
potential for use in industrial and medical applications of anthocyanins. 
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Partial neutralization of the Golgi lumen pH by ectopic expression of Influenza virus M2 
proton channel is a useful way to stabilize acid-labile recombinant proteins and peptides in 
the leaf cell secretory pathway (Jutras et al., 2015). Here we assessed the ‘off-target’ effects 
of M2 channel expression in agroinfiltrated Nicotiana benthamiana leaves. Transient co-
expression assays with fusion protein hybrids differentially susceptible to proteolytic 
breakdown first allowed to detect a significant alteration of host protease activities and 
recombinant protein processing in leaves upon M2 channel expression. An iTRAQ 
proteomics analysis then revealed a cell-wide impact for this protein on the leaf proteome. 
As expected given previously described effects of A. tumefaciens on the proteome (Goulet 
et al., 2012; Goulet et al., 2015), infiltrated leaves showed an altered soluble protein content 
compared to noN-infiltrated control leaves, associated with a strong decrease of 
photosynthesis-associated proteins (including Rubisco) and a concomitant increase of 
stress-related proteins. M2 co-expression partly compromised these effects on the proteome 
to restore original soluble protein and Rubisco contents in leaf tissue, associated with higher 
levels of translatioN-associated (ribosomal) proteins and reduced levels of stress-related 
proteins. Proteome alterations in M2-expressing leaves were determined both 
transcriptionally and post-transcriptionally, to alter the steady-state levels of proteins not only 
in the secretory pathway but also in other cellular compartments. These data suggest the 
potential of M2 channel-mediated proton export to modulate the stability of protease-
susceptible secreted proteins in planta via an indirect, pH-related effect on host resident 
proteases. They also reveal cell-wide effects for M2 on the leaf proteome, underlining the 
relevance of carefully considering the eventual ‘off-target’ effects of accessory proteins used 
to modulate specific cellular or metabolic functions in plant protein biofactories. 
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Natural products with their specific structural features deliver chemical starting points in drug 
discovery to develop innovative therapies for diseases for which no or only unsatisfactory 
treatments exist. The evolved function of natural products in regulating a plethora of diverse 
biological pathways in nature makes them to a biologically biased and complementary 
source of chemical probes to identify novel mechanisms of molecular interactions. As there 
is a high need for specific modulators of new targets, the identification of novel natural 
product chemotypes and the elucidation of their mechanism of action are gaining an 
increasing attraction in today’s drug research. Selected examples will illustrate how the 
investigation of new chemotypes from natural products and natural products-inspired 
synthetics in phenotypic assays can be shuttles to a new biological space of therapeutic 
relevance.  
The technological driving forces of Synthetic Biology, genome sequencing and DNA-
synthesis, are currently changing the face of natural products research. Whole genome data 
or the identification of cryptic natural products pathways iN-silico shed light on so far uN-
accessed genetically encoded small molecules and helping us to print and refactor active 
pathways of scientific interest.  
The human gut microbiome became a new research field in modern natural product 
discovery where big data analyses open the door to the discovery of beneficial commensals 
with essential roles in the homeostasis of the human body.  The fragmentation of natural 
products is a further scientifically exciting example how the broad chemical diversity of 
natural products can be leveraged in the science of drug discovery.  
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The new generation of anti-HIV broadly neutralising antibodies (bNAbs) have great potential 
to complement existing antiretroviral therapy (ARV) to control viremia and for use as pre-
exposure prophylaxis. The recent phase I clinical trial of VRC011 showed that although it 
can control viremia for up to two weeks longer than conventional ARV, it is not clinically 
significant. Apart from using combinations of bNAbs as an alternative method, we believe 
improving their serum half-life can also contribute to the efficacy of the bNAbs. To that end, 
we have generated different variants of the anti-HIV bNAbs VRC01 and 3BNC117 with either 
the YTE2 or LS3 mutation in their Fc region in ΔXF N. benthamiana plants. This was done 
using our iN-house Modular Idempotent DNA Assembly System (MIDAS). We found that the 
mutations in the Fc region improved biding to hFcRn, the receptor responsible for IgG 
recovery, while not compromising gp120 biding and HIV-1 neutralisation capabilities. Further 
experiments investigating the serum half-life of these bNAbs will be performed using 
transgenic mice expressing hFcRn. In lieu of recent research4, we also hypothesized that 
removal of the exposed light chain glycan could decrease binding to the hMR which clears 
proteins containing specific glycan from the bloodstream. However, we showed that VRC01 
with aglycosylated light chain produced in wild-type and ΔXF N. benthamiana did not bind 
to hMR in vitro. The removal of light chain glycan also affected HIV-1 neutralisation in 
3BNC117.  
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Production of secondary metabolites with plant cell 
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Plants have been considered as a source of natural substances for ages. Recently 
secondary metabolites gain interest as cosmetical ingredients and in the field of 
nutraceuticals, but most famous they are for medical applications. However, supply of 
compounds from natural harvest can be limited by numerous factors i.e. batch to batch 
variations, endangered species and low product content. In addition, CBD issues and the 
Nagoya protocol have to be considered. Often the complexity of secondary metabolites 
precludes chemical synthesis at least on a reasonable commercial basis. Extraction 
processes of intact plant material often require large amounts of hazardous and toxic 
solvents. In terms of sustainability the use of organic solvents should be minimized.  
With the successful production of the taxane paclitaxel at 75,000 L scale complying with 
GMP standards, Phyton demonstrates the power of plant cell fermentation (PCF®) as a tool 
for the production of complex secondary metabolites from plants. Reaching titers of 60 g/kg 
dry weight implies long history of process optimization.  
In addition also ingenanes produced by Euphorbiaceae are used in medical applications, 
i.e., in Picato® which is approved against actinic keratosis. In intact plants, however, the 
ingenanes are predominantly present in the milky latex at very low concentrations. The 
generation of cell lines expressing significant amounts of different ingenanes is another 
example underlining the strength of plant cell culture.  
A process optimization strategy for paclitaxel applying multivariate data analysis (MVDA) 
and the critical evaluation of a green chemistry survey are presented. Focus is on differences 
between natural harvest and Phyton’s PCF® route.  
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Immunoglobulin A (IgA) antibodies are useful therapeutics but production can be 
complicated by downstream product heterogeneity, often associated with degradation and 
aggregation of end products due to structural instability. Given the cost of producing these 
molecules, even small increases in stability, and resultant yield and product homogeneity, 
can translate to significant savings. An IgA-nanobody fusion is a modular type of molecule 
that comprises two highly ordered constant domains, collectively called the fragment 
crystallisable (Fc), fused to an antigen binding partner known as the variable heavy chain 
fragment (VHH) derived from camelids. Considering that the Fc is a key stability determinant 
when fused to a VHH partner, we hypothesized that improving the stability of the Fc could 
improve accumulation of the VHH-Fc fusion. Therefore, rational design of a bovine Fc was 
performed by bioinformatic analysis and molecular modeling to predict key amino acid 
substitutions that may induce either supercharging or disulfide bond formation to improve 
the stability of the fused molecule. The native bovine Fc was mutagenized to construct these 
candidates which were then transiently expressed in leaves of Nicotiana benthamiana and 
screened for protein accumulation, thermostability and solubility. We have identified and 
characterised five supercharging and one disulfide mutant that, in comparison to the native 
Fc, all improve accumulation and enhance thermostability. We also have found that 
pyramiding of these mutations results in a complementary increase of accumulation. Binding 
and neutralisation assays are currently being performed to verify that these mutations do 
not affect binding efficacy.  The goal of this project is to demonstrate as a proof of concept 
that a bovine Fc chain can be rationally designed for improved stability and be a viable 
strategy for improving accumulation of the therapeutic antibody without sacrificing efficacy. 
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From its biochemistry and the underlying genetic architecture that regulates it, the tobacco 
plant is highly complex and poorly understood. Traditional incremental improvements have 
in the past provided successes to adapting tobacco but these techniques alone may no 
longer be sufficient to sustain the crop for future applications and to meet regulatory 
requirements.  
Technological developments in areas such as sequencing and mass spectrometry, as well 
as data storage and analytical capabilities, have led to an era in which ‘big data’ plays a 
major role in biological research. This is pertinent to tobacco, where increasing amounts of 
genomic and transcriptomic data are becoming publicly available, including assemblies of 
the tobacco genome. This data is providing fresh insight into the workings of the tobacco 
plant, and the tens of thousands of genes that its genome contains. 
We have recently published (and continue to improve) an assembly of the tobacco genome 
(Edwards et al., 2017), which has facilitated much of our recent progress into understanding 
the plant’s complexities. The genome serves as a scaffold from which we are able to hang 
various ‘omics data sets. Because the tobacco genome is annotated to contain 69,500 
genes, generating and positioning this data is only the starting point, decoding it is where 
the real challenge lies.  
Using a combination of data and hypothesis-driven approaches, we have worked to mine 
and integrate transcriptomic and metabolomic datasets to lead us to long-lists of candidate 
genes. From these lists, we are able to apply association techniques, inserting these genes 
into co-expression networks. These networks have allowed us to short-list and prioritise 
candidate genes based on pockets of pre-existing knowledge and to also hypothesise their 
function.  
Reference 
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comparative analysis of yield, process costs and 
toxicity 
Gengenbach BB1, Keil LL2, Opdensteinen P1, Müschen CR2, Buyel JF1,2 
1Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany 
2RWTH Aachen University, Aachen, Germany 
Corresponding author:  
Benjamin Gengenbach <benjamin.gengenbach@ime.fraunhofer.de> 
 
Cancer is the leading cause of death in industrialized countries. Cancer therapy often 
involves monoclonal antibodies or small-molecule drugs, but carbohydrate-binding lectins 
such as mistletoe (Viscum album) viscumin offer a potential alternative treatment strategy 
(Zwierzina et al., 2011). Viscumin is toxic in mammalian cells, ruling them out as an efficient 
production system, and it forms inclusion bodies in Escherichia coli such that purification 
requires complex and lengthy refolding steps (Eiberle and Jungbauer, 2010). We therefore 
investigated the transient expression of viscumin in intact Nicotiana benthamiana plants and 
N. tabacum plant-cell packs (PCPs) (Rademacher et al., 2018), comparing a full-length 
viscumin gene construct to separate constructs for the A and B chains. The maximum yield 
of heterodimeric viscumin in PCPs was 5.0±1.2 mg kg-1 fresh biomass (arithmetic mean ± 
standard deviation, n=11) with the full-length construct, 10-fold higher than the separate A 
and B chains. In intact plants, the maximum yield was 3.0±1.3 mg kg-1 fresh biomass 
(arithmetic mean ± standard deviation, n=9) again with the full-length construct, which was 
1.5 fold lower than the yield of the equivalent product in PCPs. Using a lactosyl-Sepharose 
affinity resin, we increased the purity of viscumin by 150-fold compared to the clarified plant 
extract, to ~7%. The absence of refolding steps resulted in estimated cost savings of more 
than 35% when transient expression in tobacco was compared to E. coli. Toxicity of the 
plant derived viscumin product was increased more than 10-fold compared to the microbial 
counterpart. We conclude that plants offer a suitable alternative for the production of 
complex biopharmaceutical proteins that are toxic to mammalian cells, require authentic 
post translational modifications and that form inclusion bodies in bacteria. 
References 
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Foodborne diseases are a growing public health problem worldwide. They are the result of 
ingestion of foodstuffs contaminated with microorganisms or chemicals. The contamination 
of food may occur at any stage in the process from food production to consumption. 
Pathogenic Escherichia coli, Salmonella, Listeria, Clostridium and Campylobacter are most 
common foodborne bacterial infections. The prevention of microbial contamination mostly 
relies on such generic approaches as continuous cold chains, cooking, pasteurization, 
treatment with organic acids and oxidizing agents and proper animal farm and food 
processing plant hygiene. Use of traditional antibiotics for the treatment of food is 
inappropriate, particularly because of increased antibiotic resistance found in almost all 
foodborne pathogenic bacteria. 
Using antimicrobial proteins (bacteriocins and phage endolysins) as food additives or food 
processing aids is a promising new approach. It is especially attractive because of the 
magnitude of current food safety issues and because these product candidates can be 
approved relatively quickly using the so-called GRAS (Generally Recognized As Safe) 
regulatory approval path in USA. 
We showed that most bacteriocins and endolysins active against E. coli, Salmonella, Listeria 
can be manufactured efficiently in green plants using plant-virus-based production systems. 
Most antimicrobial proteins are expressed at high yields and are expected to command low 
commercially viable manufacturing costs. Nomad colicin (bacteriocins from E. coli) cocktails 
show very high activity against all major enterohemorrhagic E. coli serotypes defined by 
USDA/FDA. Salmocins (bacteriocins from Salmonella) are highly active against pathogenic 
Salmonella strains. Two salmocins, SalE1a and SalE1b, possess highest potency and broad 
antimicrobial activity against all 99 major Salmonella pathovars. Treatments with low (less 
than 10 mg bacteriocins per kg of treated food product) reduce the bacterial load of different 
pathogenic strains by >6 logs. In spike experiments using meats and vegetables and fruits 
spiked with pathogenic E. coli or Salmonella enterica, proposed cocktail-based antibacterial 
food additives and food processing aids efficiently reduce the titer of pathogenic bacteria.  
Nomad already has FDA’s GRAS status registration for its two first filings (GRN 593 and 
GRN676). We are preparing new GRAS applications which will deal with plant-made 
antimicrobial proteins for control of Salmonella and Clostridium perfringens.   
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Peptides as therapeutic agents have advantages over small molecule drugs in both 
specificity and potency, resulting in reduced side effects and improved user compliance. 
However, one disadvantage is that peptides are particularly prone to degradation, resulting 
in short in vivo half-lives and the requirement for injectable dosing. Thus, strategies to 
enhance the stability of peptide therapeutics are of prime importance. In certain plants, 
peptides termed cyclotides are known to accumulate as ultra-stable plant defense 
molecules. This stability is largely attributed to their cyclic backbone and unique disulfide 
bond arrangement. Together these structural features make cyclotides ideal scaffolds for 
peptide engineering where bioactive epitopes are inserted to stabilize bioactivity. One 
limitation to the commercial deployment of cyclotide-based peptide drugs is the lack of a 
cost-effective scalable production system. A plant-based approach is an appealing option, 
however early attempts at expressing cyclic peptides in biofactory host plants resulted in 
poor peptide cyclisation and low yields. Here we show that by co-expressing plant 
asparaginyl endopeptidases (AEPs) sourced from cyclotide producing plant species that 
cyclic peptide yields in planta can be dramatically improved, opening up opportunities for 
large scale production in plant hosts. Furthermore, we use molecular modelling, protein 
sequence space analysis and functional in planta testing of AEP variants to identify the 
structural features that differentiate AEPs that preference peptide cyclization over 
proteolysis. These structural features represent hot spots for further rational engineering of 
ligase type AEPs to broaden substrate specificity and kinetics.  
Session 5 
114 
  
Session 5 
115 
 
Understanding the regulation of the N-glycosylation 
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Few microalgae species, such as the green microalgae, Chlamydomonas reinhardtii and the 
diatom, Phaeodactylum tricornutum have been investigated as potential biofactories for the 
production of biopharmaceuticals including monoclonal antibodies (mAbs). Indeed in this 
context, microalgae are cheap, classified as Generally Recognized As Safe (GRAS) 
organisms and can be grown easily. However, problems remain to be solved before any 
industrial production of microalgae-made biopharmaceuticals. Among them, post-
translational modifications of the proteins need to be fully understand and control. 
Especially, N-glycosylation acquired by the secreted recombinant proteins is of major 
concern since most of the biopharmaceuticals are N-glycosylated and it is well recognized 
that glycosylation represent one of their critical quality attribute. Therefore, the evaluation of 
microalgae as alternative cell factory for biopharmaceutical productions thus requires to 
investigate their N-glycosylation capability in order to determine to what extend it differs from 
their human counterpart and to determine appropriate strategies for remodelling the 
microalgae glycosylation into humaN-compatible oligosaccharides. In this presentation, we 
will present the work done recently to characterize the N-glycosylation pathways of C. 
reinhardtii and P. tricornutum and comment the consequences on the glycan engineering 
strategies that may be necessary to render the future microalgae-made biopharmaceuticals 
compatible with human therapy. 
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As the global population reaches nine billion, aquaculture - the fastest growing food 
production sector, rather than stagnating capture fisheries, will play a key role in future food 
security. However, infectious diseases still represent one of the most significant threats to 
this food production (FAO 2016).  Nervous Necrosis Virus (NNV) is a nodavirus that infects 
over 40 marine fish species and is a significant threat for the fish industry as it causes mass 
mortality in many economically important fish species worldwide. It is a small, spherical, 
noN-enveloped virus carrying a bipartite positive-sense RNA genome. RNA-2 (1.4 kb) 
encodes the coat protein precursor alpha (43 kDa) which rapidly self-assembles into T = 3 
provirions when expressed in a number of different systems. Provirions mature by 
spontaneous autocatalytic cleavage of the coat protein alpha post assembly; producing 
proteins beta (38 kDa) and gamma (5 kDa) which remain part of the mature virion. 
We have used transient expression of the full-length coat protein of Atlantic cod NNV 
(ACNNV) to produce virus-like particles (VLPs) in N. benthamiana as a candidate vaccine 
for use in aquaculture. The expressed coat protein assembled efficiently into VLPs which 
could be readily purified. In these particles, the majority of the coat protein is unprocessed, 
suggesting that they are essentially provirions. Cryo-electron microscopy of the plant-
produced VLPs yielded a 3.7 Å resolution structure that was characteristic of a nodavirus. 
Administration of the purified VLPs to sea bass showed that they were able to confer a 
degree of protection (up to 86.5 relative percent survival) against subsequent challenge with 
NNV. 
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African horse sickness is a devastating, infectious, but noN-contagious disease that causes 
great suffering and many fatalities amongst the horse population in sub-Saharan Africa. It is 
caused by African horse sickness virus (AHSV), an orbivirus of the family Reoviridae, and 
is spread by midges. The disease has significant economic consequences for the equine 
industry both in southern Africa, and increasingly further afield as the geographic distribution 
of the midge vector broadens with global warming. Live attenuated vaccines have been in 
use with relative success for more than five decades, but there is a risk of reversion to 
virulence as well as re-assortment of the segmented genome between outbreak and vaccine 
strains. Furthermore, the vaccines lack DIVA capacity, the ability to distinguish between 
vaccine-induced immunity and that induced by natural infection.  Several studies have 
demonstrated the potential for the use of plant expression systems for the production of 
VLPs, which are excellent vaccine candidates as they do not contain the virus genetic 
material, there is no risk of reversion to virulence or re-assortment with wild virus strains and 
they are DIVA compliant. 
In this study we report on the immunogenicity of N. benthamiana-produced AHSV serotype 
5 VLPs in horses: this serotype is not included in the attenuated live vaccine mix because 
of safety problems. We previously showed that co-infiltration of constructs encoding the four 
AHSV structural proteins VP2, VP3, VP5 and VP7 resulted in the assembly of complete 
VLPs. Production of these VLPs was scaled up using density gradient ultracentrifugation, 
and immunogenicity and serum neutralisation was tested in guinea pigs. Serum from the 
guinea pigs was shown to be reactogenic with all four structural proteins in western blots, 
and able to neutralise live virus after one prime and a single boost inoculation. The ability of 
plant-produced VLPs to stimulate immunogenicity in horses - the main target animals - was 
subsequently tested. Serum from horses immunised with 2 doses of plant-produced VLPs 
was shown to be highly reactive with VLPs. The serum is currently being tested in 
neutralisation assays. These results show that there is great potential for the production of 
a novel and effective AHSV serotype 5 vaccine in plants. 
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TricoPharming, a plant molecular farming research line, was created nearly four years ago 
by Sequentia Biotech, a spiN-off which goal is to create the know-how and the technologies 
for a sustainable development for the improvement of agriculture and human health. 
Trichomes’ peculiarity is that they are able to synthesize, store and secrete large amounts 
of specialized metabolites which could have significant commercial value as 
pharmaceuticals. TricoPharming use trichomes as natural bio-factories to produce high-
quality medicines at low cost. Moreover, the isolated compartmentalization in trichomes 
allows the production of potentially detrimental compounds without affecting plant 
development. Therefore, TricoPharming represent an unprecedented opportunity with high 
social impact to manufacture affordable modern medicinal compounds and make these 
available at a global scale.  
Our first product, Artennua, is an optimized version of the Artemisia annua plant achieved 
using different plant molecular farming strategies in order to produce the valuable product 
artemisinin; the most efficient molecule to treat malaria as recommended by the WHO. 
However, over the past decade diverse clinical trials have been carried out to elucidate the 
enormous therapeutic potential of artemisinin to treat not just malaria and related-diseases, 
but many other very different diseases that include cancer, autoimmune & inflammatory 
diseases, bacterial, viral & parasitic diseases, dermatological disorders and even mental 
diseases. Due to its high market potential, Artennua extracts will be produce in a variety of 
formats in order to encompass market segments such as nutraceuticals, pharma, 
dermatology, natural cosmetics, herbal and animal health. 
Based on these successful research results, in 2017 we started the pilot production in the 
field of our optimized plant in the Canary Islands; while large-scale production of Artennua 
will begin in 2019. However in the meantime, diverse struggling situations have happened 
through to the development of the final products. This is the true story behind the step from 
“peaceful” research to the challenging business development world.  
 
 
Session 5 
122 
 
 
 
Posters 
123 
 
 
 
 
 
 
ABSTRACTS FOR  
POSTER  
PRESENTATIONS 
 
 
Posters 
124 
  
Posters 
125 
 
1. The development of a chimaeric Rift Valley Fever 
Virus-like Particle vaccine candidate made in 
Nicotiana benthamiana   
Mbewana S, Meyers A, Rybicki E 
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Rift Valley Fever (RVF) is a zoonotic disease endemic in parts of Africa and the Arabian 
Peninsula but is described as an emerging virus due to the wide range of mosquitoes that 
could spread the disease into noN-endemic areas. RVF is characterised by high rates of 
abortion in ruminants and haemorrhagic fever, encephalitis, or blindness in humans. RVF is 
caused by Rift Valley fever virus (RVFV) which is an enveloped negative-stranded RNA 
virus and belongs to the genus Phlebovirus in the family Bunyaviridae. The virus major 
structural proteins Gn and Gc are the main immunogenic determinants of the virus. The 
disease can be prevented by vaccination, but there is currently no commercially available 
vaccine that can be used outside of endemic areas. Virus-like Particles (VLPs) are more 
immunogenic than simple subunit vaccines because they resemble the virus in shape and 
morphology, and display multiple repeating epitopes. In the case of RVFV, chimaeric VLPs 
presenting the immunogenic antigens could be a safe and effective vaccine candidate.   
We describe the generation of chimaeric RVFV VLPs consisting of a truncated RVFV Gn 
envelope glycoprotein fused to the H5N1 influenza HA transmembrane domain and cytosolic 
tail (TMD/CT) to make budding VLPs. The RVFV GnGc polyprotein gene was initially plant 
codon optimised, synthesised and cloned into a plant expression vector. It was then modified 
by truncation and fusion to the HA TMD/CT-encoding sequence, and protein expression was 
achieved by transient expression in Nicotiana benthamiana via Agrobacterium tumefaciens-
mediated gene transfer. The modified Gn polyprotein (Gne-HA) was successfully expressed 
in N. benthamiana seven days post infiltration. Protein expression analysis was carried out 
by western blotting. Recombinant plant-produced Gne-HA was purified by differential 
centrifugation on a 20–50 % iodixanol step gradient and fractions were analysed by 
polyacrylamide gel electrophoresis. Purified protein yields were calculated to be ~57 mg/kg 
fresh weight. Transmission electron microscopy (TEM) of gradient fractions was used to 
confirm particle formation. TEM showed Gne-HA particles of ~49–60 nm in the 30% 
iodixanol fraction which were noN-uniform in shape. The immunogenicity of purified Gne-
HA particles was tested in BALB/c mice. The presence of anti-Gn specific antibodies was 
analysed by indirect ELISA using plant-produced Gn protein as coating antigen. Preliminary 
immunogenicity studies of chimaeric RVFV Gne-HA VLPs illustrated that the vaccine 
candidate was immunogenic in mice.   
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Cyanophycin (CGP) is a cyanobacterial polypeptide which can be used both as valuable N-
rich ingredient for the feed and as biopolymer substituting chemicals. We introduced CGP-
synthesis into leaf plastids of the commercial tobacco cultivars Burley and Virgin, yielding 
up to 9.4% CGP per dry weight (dw) when using the constitutive 35s CaMV promotor 
(Nausch et al., 2016). Since CGP is only soluble at pH < 2 and insoluble at neutral pH, it 
can be easily purified from leaf tissue. 
Here we investigated CGP expression in seeds of the high producing events and analyzed 
a potential correlation to the CGP levels in leaves. The protocol, used for the extraction of 
CGP from tobacco leaves, was optimized for the CGP-isolation from seeds. Now, a field trail 
with the elite events in Argentina, done by the company Bioceres, will be prepared. In order 
to optimize the expression in seeds, we will use tissue-specific promotors and a cultivar 
specifically bred for high seed yield by the company Sunchem/Idroedil for the next 
generation of CGP-producing transgenic plants. We are also combining the CGP-purification 
method with that for oil and protein of Sunchem for the large scale isolation of all three 
components at the same time. Tobacco oil is used as biofuel, while the protein serves as 
feed in livestock industry. 
Combined with the development of new CGP-derived products, an economic analysis and 
socioeconomic studies, CGP might be one of the first transgene-encoded biomaterials that 
reach the market. 
The international consortium is funded by the ERA CoBioTech Call 1 as part of the European 
Union’s Horizon 2020 research and innovation program. The partners of this project are: 
Bioceres SA, Argentina 
Idroedil SRL, Italy 
University of Rostock, Germany 
Wageningen Research Centre, Netherlands 
Wageningen University, Netherlands 
Leuphana University Lüneburg, Germany 
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Livestock diets can be supplemented with dipeptides in order to promote optimal growth and 
wellbeing. Due to the dual role of arginine as building block for proteins and regulator of 
physiological functions, pronounced effects were observed after addition of β-aspartate-
arginine (β-Asp-Arg) dipeptides to feed. Currently, β-Asp-Arg is generated in vitro from the 
cyanobacterial storage polymer cyanophycin (CGP) via incubation with the cyanophycinase 
enzyme (CGPase) which are both produced in E. coli. Because of the high costs and limited 
scalability, bioreactor-based production is commonly used for the synthesis of high-value 
but not for cost-sensitive products such as supplements for animal diets. 
Alternatively, recombinant low-value products can be produced in plants in an economic 
manner using existing agricultural infrastructure and farming practices. We already 
established the production of CGP in plastids of tobacco and potato, yielding up to 9.4% of 
the dry weight in stably transformed plants. We also demonstrated that CGPases can be 
transiently co-expressed in the cytosol of CGP-producing tobacco via the MagnICON 
system without affecting the CGP accumulation in intact chloroplasts. Amongst different 
CGPases, CphE showed the highest yield and was able to degrade CGP in homogenized 
leaf tissue when the spatial separation of cytosol and plastid stroma was destroyed. Oral 
administration of feed pellets which contained purified CGP and CGPase to mice showed 
that the released dipeptides were absorbed into the blood. 
Now we could demonstrate that CGP degradation is not only possible after transient 
expression of CphE in the cytosol of CGP-producing tobacco, but also when the CGPase is 
introduced into these plants via stable transformation. Constitutive expression of CphE in 
parallel to CGP synthesis does not affect the accumulation of CGP in leaf chloroplasts and 
degrades CGP completely after decomposition of cells. The transfer of this system to feed 
plants would therefore provide an easy and cheap system to directly release the β-Asp-Arg 
dipeptides in the intestine of animals in the digestive process.  
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The small genomes of plant viruses can be easily engineered to transform these pathogens 
into powerful biotechnological tools able to induce the production of large amounts of 
recombinant proteins in the host plant, which is converted in a biofactory. Plant virus 
biotechnology approaches have traditionally focused on viral species that induce the 
production of huge amounts of some of their proteins, such us Tobacco mosaic virus (TMV) 
or Cowpea mosaic virus (CPMV). However, the amazing wealth of genome architectures 
and expression strategies found in plant viruses open many other possibilities. One of them 
is the use of potyviruses as viral vectors. Potyviruses (genus Potyvirus) make one of the 
largest groups of plant viruses with around 200 different species known to date. Their 
genome is composed of an about 10,000-nt long plus-strand RNA molecule that is bound at 
the 5’ end to a genome-linked viral (VPg) protein and is polyadenylated at the 3’ end. This 
genomic RNA is encapsidated in elongated and flexuous virions. What makes potyviruses 
special is their gene expression strategy. Basically, potyviruses express a single polyprotein 
that is processed by three viral proteases. The highly specific NIa protease (NIaPro) 
performs most cleavages in the viral polyprotein based on a seven amino acid recognition 
motif. We set up a potyvirus-derived vector system in which the viral cistron encoding the 
RNA-dependent RNA polymerase (NIb) is replaced by a cassette to produce several 
proteins. The cDNAs encoding for these proteins are flanked with sequences corresponding 
to the NIaPro cleavage site. This way, the viral vector produces equimolar amounts of 
several proteins in plants that co-express the viral NIb. Insertion of the recombinant cDNA 
at the most amino terminal end of the viral polyprotein has allowed us to target heterologous 
proteins to specific organelles, such as chloroplasts and mitochondria. Using these potyvirus 
vectors we have produced antibodies, transcription factors and metabolic enzymes. 
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The cattle industry worldwide is ravaged by bovine respiratory disease (BRD), caused 
mainly by the bacterium Mannheimia haemolytica. We have designed a chimeric protein 
subunit vaccine against M. haemolytica based on recent evidence demonstrating the 
protective potential of antigens against a virulence factor, leukotoxin, in addition to a surface 
lipoprotein. Plant-based production of this protein vaccine provides a safe and inexpensive 
alternative to traditional production methods. Plant-base production also supports the use 
of an edible vaccine that will deliver antigens to the pharyngeal mucosa to provide local 
immunization against M. haemolytica to prior to its progression into the lungs. Chloroplasts 
can produce and accumulate bacterial proteins, such as those comprising the vaccine we 
have designed, due to their prokaryotic translational machinery and lack of mechanisms of 
glycosylation and gene-silencing. Transplastomic production of our vaccine is therefore an 
attractive option. Transient expression by A. tumefaciens-mediated transformation offers 
another avenue for production. Transient expression allows large amounts of foreign protein 
to be produced within a short time following agroinfiltration. In this project, we conducted 
chloroplast transformation procedures on lettuce and tobacco, and conducted 
agroinfiltration of Nicotiana benthamiana to produce a M. haemolytica vaccine. This 
endeavor necessitated the development and optimization of lettuce chloroplast 
transformation and regeneration techniques. While lettuce transformants have not been 
generated thus far, this candidate vaccine was successfully produced transplastomically in 
N. tabacum and through agroinfiltration of N. benthamiana. 
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We have developed a novel orthogonal expression system (SES) that functions in a wide 
spectrum of eukaryotic organisms, including fungi and plants. The expression system is 
based on a synthetic transcription factor (sTF) that regulates expression of the target gene 
via a sTF-dependent promoter. The sTF expression is driven by a universal core promoter, 
which was obtained by a specifically designed screening assay. The universal core promoter 
provides highly constitutive expression level of the sTF, which is employed in the SES 
system as a potent transcription activator for the target gene. The sTF-dependent promoter 
regulating the expression of the target gene also contains a similar type of universal core 
promoter, making the whole expression system independent of the host’s native regulation 
and therefore functional in diverse species. The varying number of the sTF-binding sites in 
combination with a choice of core promoters enable adjustment of the target gene 
expression levels over a wide range, from very low to very high, which is particularly difficult 
in plant hosts with current genetic tools. This expression system provides robust and stable 
expression levels of target genes in a broad spectrum of host organisms with numerous 
applications in metabolic engineering and protein/enzyme production. 
The method for selecting the universal core promoters, construction of the expression 
system, and demonstrating its performance in comparison with the established CMV 
promoter system will be presented. In addition, the utility of the expression system will be 
demonstrated for the production of diverse recombinant proteins in tobacco leaves. 
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Infectious Bursal Disease virus (IBDV) is the cause of an economically important highly 
contagious disease of poultry. The capsid constituent VP2 is considered as the major host-
protective antigen. Vaccines are regarded as the most beneficial interventions to prevent 
this infection but are still based on whole pathogens and do not permit a differentiation of 
infected from vaccinated animals (DIVA).  
The aim of this study is to use plants as biofactories for the production of a low cost 
innovative recombinant vaccine against IBDV allowing DIVA. The “vaccine” is composed of 
an immunogenic VP2 domain fused to the constant domain of an IgY antibody. The fusion 
may result in the enhancement of the vaccine efficacy through the interaction with receptors 
on antigen presenting cells in chicken. Furthermore, the Fc portion may work as stabilizing 
partner and may result in the simplification of the extraction and purification procedures.  
The secretory VP2-FcY gene construct was cloned into a plant expression vector. 
Transformed Agrobacterium tumefaciens,  was used to infiltrate Nicotiana benthamiana 
plants and leaf tissues were assayed for recombinant protein expression by Western Blot 
(WB) analysis showing maximum accumulation of a product corresponding to the 
assembled VP2-FcY dimer at 5 days post infiltration. The secretion of the protein in the leaf 
intercellular fluids was also demonstrated, while the correct conformation of the VP2 domain 
was verified by ELISA. To optimize the production in plants, an extraction protocol was set-
up that allowed to minimize contamination by unwanted compounds/proteins. Purification 
was performed using a chromatography column that specifically binds to the highly 
hydrophobic FcY portion. The characterization of the purified product by SDS-PAGE 
indicated also the presence of high molecular weight multimers. Additionally, Mass 
Spectrometry analysis revealed an Fc glycosylation pattern very similar to that of chicken 
serum IgY with the formation of high mannose sugar chains.  
In conclusion, the VP2-FcY fusion protein was successfully produced in plants, where it 
correctly assembles in a dimeric form with the Fc portion showing an IgY-like glycosylation 
profile. Overall these results indicate that the fusion protein may bind to Fc receptors 
involved in immune response activation in chickens. The developed fast and convenient 
extraction and purification protocol will allow to verify this hypothesis through in vivo 
functional studies.  
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The traditional diagnosis of allergies is based on a skin test system (called also “Prick test”), 
which has different drawbacks, mainly its difficult standardization. As a consequence, allergy 
diagnosis is moving towards a molecular approach, which, in turns, currently lacks of a cost-
effective diagnostic method tailored on the patient’s clinical history and a flexible technique 
that allows a multiplexed analysis (Giangrieco et al., 2012). 
The Enzyme-Linked Immunosorbent Assay (ELISA), is one of the most popular technique 
for the detection and quantification of specific biomarker proteins and, as a consequence it 
is widely used for diagnostic kits set-up.  
Given the need of costs saving for the production of a diagnostic system, the antigen 
production should be cost-effective. Plant Molecular Farming (PMF) may help in this, being 
a production platform able to produce complex recombinant proteins in short time-frames 
and at a low-price (Ma et al., 2003). 
We was exploited the production of Bet v 1, a major allergen associated with birch pollen 
allergy. The production of the protein was measured using two different transient expression 
systems in N. benthamiana plants, one based on a binary vector (Karimi et al., 2002) and 
one using a vector based on the Potato Virus X genome (Porta, & Lomonossoff, 1996) their 
purification from leaf material and their suitability in a new generation allergy diagnosis 
system, the Friendly Allergen nano-Bead Array (FABER) which allows, the simultaneous 
analysis of different allergens and their choice based on the patient’s clinical history is 
described. 
Giangrieco, I., Rafaiani, C., Liso, M., Palazzo, P., Pomponi, D., ... Ciardiello, M. A. 2012. Allergens in allergy 
diagnosis: a glimpse at emerging new concepts and methodologies. Translational Medicine@ UniSa 4: 27. 
Karimi, M., Inzé, D., Depicker, A. 2002. GATEWAY™ vectors for Agrobacterium-mediated plant 
transformation. Trends in Plant Science 7: 193-195. 
Ma, J. K., Drake, P. M., Christou, P. 2003. Genetic modification: the production of recombinant pharmaceutical 
proteins in plants. Nature Reviews Genetics 4: 794. 
Porta, C., Lomonossoff, G. P. 1996. Use of viral replicons for the expression of genes in plants. Molecular 
Biotechnology 5: 209. 
Sino Biological Inc. ELISA encyclopedia. 2018. http://www.elisa-antibody.com/ELISA-Introduction/ELISA-
types  
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Hemophilia B is a congenital bleeding disorder caused by a malfunction or deficiency of 
coagulation factor IX (FIX), a vitamin K-dependent (VKD) serine protease. Current treatment 
is restricted to a proteiN-replacement therapy. Approximately 1.6 billion units of FIX were 
consumed in 2016 (World Federation of Hemophilia). However, still about 70-80% of the 
patients, mainly in developing countries, receive inadequate or no treatment because of 
unavailable and/or unaffordable FIX concentrates. Our aim is to produce high levels of 
recombinant human FIX in Physcomitrella patens bioreactors. This moss is an important 
model organism for evolutionary and functional genomics approaches and also a promising 
biopharmaceutical production platform for complex recombinant glycoproteins, with the first 
product, moss-aGal, successfully completed phase I clinical trials (www.greenovation.com). 
The ease of gene targeting was employed for precise genome engineering resulting in the 
elimination of plant-specific protein N-glycan residues. Transgenic lines were generated for 
the stable production of FIX and its amount reached up to 0.32% of total soluble protein. 
Additionally, the moss-produced FIX amino acid sequence was confirmed by mass 
spectrometry. For the production of bioactive FIX, additional genes encoding gamma-
glutamyl carboxylase (GGCX) and paired basic amino acid cleaving enzyme (PACE), which 
are responsible for the processing of FIX, will be introduced into the moss genome as both 
enzymatic functions do not exist in plants. Recombinant bioactive FIX-producing moss lines 
will be generated and characterized for gamma-carboxyglutamic acid content and N-
glycosylation via mass spectrometry. Furthermore, the activity of the moss-produced FIX 
will be evaluated by activated partial thromboplastin time assays. 
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Complement Factor H (FH) is the major regulator of the alternative pathway of complement 
activation. The complement system is a part of the innate immunity and defends the human 
body against pathogen infections. FH protects host cells from complement attack by 
controlling the activation of the system. Deficiency or impaired FH-activity can lead to severe 
kidney diseases (aHUS, C3G) or to serious visual impairment (AMD). To date, therapeutic 
options to treat FH-related diseases are limited. Attempts to produce biologically active 
recombinant FH in mammalian, insect or yeast production systems have failed to 
demonstrate therapeutic value. We showed earlier that the moss Physcomitrella patens is 
able to produce this complex and highly glycosylated protein (Büttner-Mainik et al., 2011). 
Here, the production of an improved moss-derived recombinant human factor H (FHmoss) 
devoid of potentially immunogenic plant-specific sugar residues on protein N-glycans will be 
reported. We found a homogeneous and predominantly di-antennary complex-type GnGn 
glycan pattern on FHmoss. Further, FHmoss displayed full in vitro activity concerning its 
binding affinity to cell surfaces, which is important for the host cell protective function of FH, 
as well as inhibition of specific downstream processes of the complement activation. In 
addition, in vivo studies with FH-knockout mice (FH-/-) showed that a treatment with FHmoss 
is effective in reducing pathologic complement intermediates in the kidney, which makes 
FHmoss a promising biopharmaceutical for the treatment of complement dysregulations 
(Michelfelder et al., 2016).  
Büttner‐Mainik, A., Parsons, J., Jérôme, H., Hartmann, A., Lamer, S., ... Decker, E. L. 2011. Production of 
biologically active recombinant human factor H in Physcomitrella. Plant Biotechnology Journal 9: 373-383.  
Michelfelder, S., Parsons, J., Bohlender, L. L., Hoernstein, S. N., Niederkrüger, H., ... Frischmuth, T. 2016. 
Moss-produced, glycosylatioN-optimized human factor H for therapeutic application in complement disorders. 
Journal of the American Society of Nephrology ASN-2015070745. 
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Decades of careless utilisation and abuse of antibiotics have engendered a global public 
health crisis of antibiotic resistance. While multidrug and extensively drug-resistant 
pathogens are becoming more prevalent and a burden to our health systems worldwide, the 
development of new classes of antibiotics to combat this threat has not kept pace. 
In the continuous struggle for survival advantage, bacteria have developed an arsenal of 
molecular weaponry directed against competing bacteria. Bacteriocins are antimicrobial 
proteins produced by bacteria to kill closely related competing strains. Colicins are 
bacteriocins produced by Esherichia coli whose modes of action include nuclease activity, 
cell depolarisation by forming pores in the target membrane, or inhibiting peptidoglycan wall 
synthesis. Therefore, they have potential biotechnology applications as food additives to 
prevent spoilage and safeguard consumer health, and in the prevention or control of 
infectious diseases. 
Our collection of colicins has been engineered for high expression in the tobacco Nicotiana 
benthamiana. We have transiently expressed twelve colicins in tobacco plants with high 
yields (up to approximately 40% total soluble protein). Screening coliciN-containing plant 
extracts against a panel of 70 multidrug-resistant (MDR) and extensively drug-resistant 
(XDR) E. coli clinical isolates, revealed that these colicins exhibit varying bactericidal activity 
with the most potent in the picomolar range. Crucially, none of the bacterial isolates exhibited 
resistance to all colicins. We have therefore combined colicins based on potency, molecular 
and biochemical characteristics, resistance profile, and the mechanism of actions to 
enhance coverage. We have tested the efficacy of these colicin cocktails compared to the 
individual colicins using standardised in vitro kill assays against pathogenic E. coli. As 
predicted colicin cocktails significantly reduce the incidence of resistant bacteria. 
Concomitantly, a larger percent of the pathogens were susceptible to lower doses of the 
cocktails compared to constituent colicins. Our observations indicated that for the most part 
the potency of the cocktail reflects the effect of the most active component in that cocktail. 
However, we also observed synergy leading to enhanced potency against some isolates. 
The mechanism(s) for this synergy are currently unknown. 
Colicins are effective, evolutionarily honed antimicrobials. Rational combinations of colicins 
offers a way of subverting resistance. We believe the use of colicins and colicin cocktails in 
combination with antibiotics, could circumvent nosocomial infections, and stave 
development of resistance, respectively.  
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African horse sickness (AHS) is a debilitating viral disease affecting equines and has 
resulted in many disastrous epizootics. To date, no successful therapeutic treatment exists 
for AHS and the commercially used live-attenuated vaccines (LAVs) have various side 
effects. Insoluble particulates have been shown to increase immunogenicity when compared 
to soluble subunit vaccines and previous studies demonstrated protection of BALB/c mice 
immunised with AHSV VP7 against a lethal challenge of AHSV-7. This study investigates a 
safer alternative based on plant-produced crystalline-particles of the serogroup-specific 
AHSV structural protein, VP7. Crystalline-particles were produced in N. benthamiana by 
means of Agrobacterium-mediated infiltration, using a recombinant A. tumefaciens strain 
containing the expression vector pRIC3.0 encoding AHSV-5 VP7. Crystalline-particles were 
purified using a discontinuous iodixanol density gradient and ultracentrifugation. 
Subsequent analysis by SDS PAGE, Coomassie staining and western blotting with anti-
AHSV guinea-pig serum confirmed satisfactory levels of purified recombinant VP7 protein. 
Crystalline-particle assembly was confirmed by transmission electron microscopy and 
concentrations of approximately 163ug/ml were quantified by gel densitometry. In guinea-
pig immunogenicity studies the experimental (n=5) group was inoculated with prime- and 
boost-inoculations of between 10 and 50ug of purified AHSV VP7, and the control (n=5) 
group inoculated with plant sap lacking the VP7 candidate. Analysis of the humoral and 
cellular immune response is presently underway: Guinea pig serum will be assayed for the 
presence of anti-VP7 antibodies by western blotting and ELISA and its live virus 
neutralisation capability will be assessed by serum virus neutralisation assays. In addition, 
RNA-seq transcriptome profiling of guinea-pig spleen derived RNA will be used to 
investigate the cell-mediated immune response to AHSV VP7 crystals. To the best of our 
knowledge, this is the first time AHSV VP7 crystalline-particles have been produced in plants 
and, furthermore, the first time that their effects on the cellular immune response have been 
investigated. If AHSV VP7 crystals demonstrate higher levels of immunogenicity when 
compared to commercially used LAVs this may highlight a safer, easy to produce, 
inexpensive vaccine alternative. 
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Bacteriocins are natural, noN-antibiotic bacterial proteins with potent antimicrobial activity 
against bacteria of (mostly) related species. Colicins, bacteriocins from Escherichia coli, and 
salmocins, coliciN-like bacteriocins from Salmonella enterica, have been proposed for 
control of Shiga toxiN-producing E. coli and S. enterica ssp. enterica, respectively, on foods 
(Schulz, et al., 2015; Schneider et al., 2018) both pathogens being leading causes of food 
poisoning worldwide. In USA, colicins produced in edible plants such as spinach and leafy 
beets have already been accepted by the U. S. Food and Drug Administration (FDA) and U. 
S. Department of Agriculture (USDA) as food-processing antibacterials through the GRAS 
(generally recognized as safe) regulatory review process (NOMAD’s GRN 593 and GRN 
674), and GRAS application for N. benthamiana as a production host has also been 
submitted. Thaumatin proteins are natural sweet-tasting proteins originating from the 
Katemfe fruit of the African bush Thaumatococcus daniellii. Thaumatin extracted from its 
natural plant source as a mixture predominantly consisting of related proteins thaumatiN-I 
and thaumatiN-II, has been used as low-calorie sweetener and flavor modifier, is classified 
as GRAS and is permitted for general use in food (Codex Alimentarius 2016). Recently, 
NOMAD received GRAS approval for plant-made recombinant thaumatins as sweeteners 
(GRN 738). We describe here generation, selection and analysis of stable transgenic N. 
benthamiana plant lines for ethanol-inducible expression of colicins, salmocins and 
thaumatins. Employment of this simple and inexpensive production and purification methods 
based on N. bethamiana as the production host, provides scalable and economically viable 
process for colicins, salmocins and thaumatins as multiple use food additives (Stephan et 
al., 2018). 
Schneider, T., Hahn-Löbmann, S., Stephan, A., Schulz, S., Giritch, A., ... Gleba, Y. 2018. Plant-made 
Salmonella bacteriocins salmocins for control of Salmonella pathovars. Scientific Reports 8: 4078. 
Schulz, S., Stephan, A., Hahn, S., Bortesi, L., Jarczowski, F., ... Gleba, Y. 2015. Broad and efficient control of 
major foodborne pathogenic strains of Escherichia coli by mixtures of plant-produced colicins. Proceedings of 
the National Academy of Sciences USA 112: E5454-E5460. 
Stephan, A., Hahn-Löbmann, S., Rosche, F., Buchholz, M., Giritch, A., Gleba, Y. 2017. Simple purification of 
Nicotiana benthamiana-produced recombinant colicins: high-yield recovery of purified proteins with minimum 
alkaloid content supports the suitability of the host for manufacturing food additives. International Journal of 
Molecular Sciences 19:1, 95. 
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Pseudomonas aeruginosa is an ubiquitous gram-negative bacterium belonging to Gamma 
Proteobacteria class, which persists in the environment as well as inside human body. P. 
aeruginosa is one of the six pathogens causing hospital ESKAPE (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp.) infections, which readily develop resistance to 
antibiotics. Recently, the WHO published a list of bacteria for which new antibiotics are 
urgently needed, and carbapenem-resistant Pseudomonas aeruginosa was declared a 
problem of critical importance in such context, a new generation of antimicrobial substances 
is urgently needed.  
Bacteriocins are instruments of microbial warfare in competition for ecological niches.  P. 
aeruginosa strains rival with each other by secreting various activity spectrum antibacterial 
proteins called pyocins: deoxyribonucleases, ribonucleases, pore-forming proteins, 
peptidoglycan synthesis-blocking proteins, lectiN-like proteins, and bacteriophage tail-like 
protein complexes. We attempted to express pyocins of all known types in highly efficient 
protein synthesis platform – a plant transient gene expression system. Pyocins involved in 
cell wall synthesis, pore-forming pyocins and lectiN-like pyocins were expressed most 
efficiently reaching 10-50% of total soluble leaf protein. Pyocins S5, PaeM, three lectiN-like 
pyocins (L1, L2 and L3) and one new pyocin, PaeM4, were purified to homogeneity and their 
antibacterial activity was tested in several assays. Since pyocins tend to be strain specific, 
we evaluated the spectrum of their activity with a collection of one hundred clinical strains. 
By using only three pyocins (S5, PaeM and PaeM4), we were able to target as much as 
68% of all tested strains, including multidrug resistant isolates. Among the three tested 
pyocins, PaeM4 targeted the largest number (53%) of clinical isolates.  
Plant-produced pyocins reduced P. aeruginosa CFU counts in liquid culture assays by 
several orders of magnitude and efficiently reduced biofilm growth. We further demonstrated 
the ability of plant-produced pyocins to protect Galleria melonella larvae against lethal P. 
aeruginosa infection. Also, mutation rates by fluctuation analysis were determined for 
pyocins. We propose that plant-produced pyocins should be considered as a viable 
alternative to antibiotics for the control of pathogenic P. aeruginosa. 
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Rodents are the most important group of mammals in terms of the problems they create in 
agriculture, horticulture, forestry and public health. Fertility is a key factor that determines 
the population density. Zona pellucida (ZP) glycoproteins, that are located on the surface of 
the oocyte and mediate the gamete recognition, have been proposed as candidate 
immunogens for development of a contraceptive vaccine. Oral application of the ZP antigens 
could be a promising alternative to control rodent pests populations. Sterilization of noN-
target species might be prevented by limiting the vaccine to small, species specific peptides. 
We tried to establish the transient expression of putative mice-specific contraceptive small 
mZP3-peptide in Nicotiana benthamiana, via viral MagniCON expression system, as a rapid 
and high-level transient expression system in plants. Nevertheless, the expression of small 
peptides can be a challenge. We have examined the production of immunocontraceptive 
antigen that comprised of a ‘promiscuous’ T cell epitope of tetanus toxoid (TT: 15 amino 
acid (aa)) followed by putative contraceptive mZP3-peptide (15 aa), a (6x)His-tag and an 
ER-retention signal SEKDEL. Although no band representing a protein with the expected 
size of the mZP3 peptide was detected by Western blot of the crude extract, fusion of antigen 
to GFP protein revealed a dominant protein band of the expected size. Successful 
production of mZP3 antigen and improved recombinant protein stability in plant were also 
achieved by tripling of the antigenic mZP3 epitope that can increase antigeN-antigenicity as 
well. The fusion protein of Oleosin and triple-mZP3 was also successfully produced in N. 
benthamiana. With regards to already reported features of the oleosin fusion technology, 
this step could lead to the desired specific immunocontraceptive for oral application. 
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Plant expression systems has several advantages such a large-scale production of mAb 
and absence of pathogenic animal contaminants. However, oligomannose (OM) type 
glycans structure of mAbpK SO57 in ER have showed a faster clearance compared to 
antibodies produced in animal cells. The neonatal Fc receptor (FcRn) regulates the 
persistence of IgG by the FcRN-mediated recycling pathway, which salvages IgG from 
lysosomal degradation within cells. In this study, Fc-engineering of plant-derived mAb SO57 
with an ER-retention motif (KDEL) (mAbpK SO57) was conducted to enhance its binding 
activity to human FcRn (hFcRn), consequently improve its serum half-life. ELISA and SPR 
assay showed altered binding affinity between the Fc region of three different mAbpK SO57 
mutants [M281Y/S283T/T285E (MST), M457L/N463S (MN), H462K/N463F (HN)] and 
hFcRn compared to wild type of mAbpK SO57. N-glycan structure was also confirmed that 
all of mAbpK SO57 mutants had OM type glycans structure similar to the parental mAbpK 
SO57. In addition, after engineering of mAbpK SO57, the three variants were effective as 
mAbpK SO57 in neutralizing the activity of the rabies virus CVS-11. 
This research was supported by a grant (Code# PJ0134372018) from the Korean Rural 
Development Administration, National Research Foundation of Korea Grant funded by the 
Korean Government (NRF-2017R1A2A2A0569788). 
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In this study, prostatic acid phosphatase (PAP), which is overexpressed in human prostate 
cancer cells, was cloned to be fused to the IgM constant fragment (Fc) for enhancing 
immunogenicity and expressed in transgenic tobacco plants. Then, the transgenic plants 
were propagated by in vitro tissue subculture. Gene insertion and expression of the 
recombinant PAP-IgM Fc fusion protein were confirmed in each tested the first, second, and 
third subculture generations (SG1, SG2, and SG3, respectively). Transcription levels were 
constantly maintained in the SG1, SG2 and SG3 leaf section [top (T), middle (M), and base 
(BA)]. The presence of the PAP-IgM Fc gene was also confirmed in each leaf section in all 
tested subculture generations. RNA expression was confirmed in all subculture generations 
using real-time PCR and quantitative real-time PCR. PAP-IgM Fc protein expression was 
confirmed in all leaves of the SG1, SG2, and SG3 recombinant transgenic plants by using 
quantitative western blotting and chemiluminescence immunoassays. These results 
demonstrate that the recombinant protein was stably expressed for several generations of 
in vitro subculture. Therefore, transgenic plants can be propagated using in vitro tissue 
subculture for the production of recombinant proteins.  
This research was supported by a grant (Code# PJ0134372018) from the Korean Rural 
Development Administration, National Research Foundation of Korea Grant funded by the 
Korean Government (NRF-2017R1A2A2A0569788).  
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The effectiveness of antigen–antibody complex (AAC)-mediated immunomodulation has 
spurred the development of diverse quaternary protein structures for vaccination. The 
technique of producing AAC vaccines with large quaternary structures in plants was 
developed to enhance immune responses and to generate anticancer IgGs which recognize 
the corresponding antigens. Both antigen and antibody proteins were expressed in a F1 
plant obtained by crossing the plants expressing each protein. In the F1 plant, both the 
antigen and antibody assembled to form a large (~ 30 nm) quaternary circular structure. 
These large quaternary protein structures induced immune responses to generate 
anticancer immunoglobulin G (IgGs), which inhibited the growth of human colorectal cancer 
cells in the xenograft nude mouse model. Thus, antigens and antibodies can be assembled 
to form large, complex quaternary protein structures in plants. Plant crossing represents an 
alternative strategy for the formation of AAC vaccines that efficiently enhance immune 
responses.  
This research was supported by the National Research Foundation of Korea Grant funded 
by the Korean Government (MEST) (NRF-2017R1A2A2A0569788), and Basic Science 
Research Program through the National Research Foundation of Korea (NRF) funded by 
the Ministry of Education (NRF-2016R1A6A3A11930180). 
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Currently, most plant-made recombinant proteins are produced using transient expression 
systems, i.e. the genetic information for producing the protein is not stably integrated into 
the plant genome but is introduced using the agrobacterial DNA transfer machinery. High 
yields are usually achieved by inserting the gene-of-interest into a viral replicon resulting in 
amplification of the genetic information and thus in high-level protein production. Transient 
expression has many advantages including flexibility and speed of the process. However, 
production at a large scale requires large quantities of agrobacteria, special equipment and, 
in case of an injectable drug, bacterial endotoxin has to be removed during the purification 
process.  
In contrast, transgenic plants expressing gene under transcriptional promoter can be grown 
in large numbers but usually suffer from low expression levels. We have developed a system 
that overcomes this limitation by stably introducing viral replicons into the genome of 
Nicotiana benthamiana plants which are activated by a simple treatment with a dilute ethanol 
solution. We show that two noN-competing viral replicons (TVCV and PVX) can be 
introduced into the same plant giving high expression of a full-size antibody upon ethanol 
induction. Antibody yield is comparable to transient expression from agroinfiltration as 
demonstrated for the therapeutic antibodies Rituximab and Trastuzumab. 
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Thuenemann E, Lomonossoff G 
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Bluetongue Virus-like particles (VLPs) are just one of the many types of VLP that can be 
efficiently produced in plants using the transient HyperTrans (HT) expression system. These 
heteromultimeric particles have previously been shown to be efficacious as a vaccine 
against Bluetongue disease in sheep (Sainsbury & Lomonossoff, 2008; Sainsbury, 
Thuenemann & Lomonossoff, 2009; Thuenemann et al., 2017).  
The large internal space within bluetongue virus (BTV)-like particles also makes them ideally 
suited to nanotechnology applications. A thin shell of approx. 40 nm internal diameter is 
formed by only 120 copies of the innermost structural protein, VP3. Fusion of green 
fluorescent protein (GFP) to VP3 results in assembly of BTV-like particles with functional 
GFP on the inside, which still resemble wild-type particles on the outside (with co-expression 
of the other structural proteins) (Brillault et al., 2017). Similarly, fusion of a kinase enzyme 
to VP3 still allows assembly of BTV-like particles which have the potential to act as a nano-
scale reaction vessel allowing diffusion of substrate into and out of the particles through 
pores. Such internally modified particles could find application in bioimaging and medicine, 
for instance. 
To aid in development and scale-up of production of these particles, we are developing 
protocols which allow us to purify BTV-like particles using conventional floor-standing 
centrifuges. 
References 
Sainsbury, F., Lomonossoff, G. P. 2008. Extremely high-level and rapid transient protein production in plants 
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Human deep space exploration and the setting of Martian outposts is though to be possible 
especially in connection to the development of plant-based life support systems. This work 
deals with the design of novel plant systems directed towards the production of valuable 
bioactive compounds to tackle both health and food supply issues related to long-term 
manned space missions.  
Subject of our experimental design for space-tailored approaches is tomato (Solanum 
lycopersicum L.), excellent source of bioactive molecules like carotenoids, ascorbic acid and 
other vitamins, but generally poor in anthocyanins. Anthocyanins are colored molecules 
involved in many plant physio-pathological mechanisms including cell oxidative stress. 
Through the optimization of the production of these natural anti-oxidants, we wanted to 
explore tomato plant-based systems as natural ‘bioreactors’ of anthocyanins improving, at 
the same time, the resilience of these systems to the harsh environmental conditions 
encountered in deep space flights or outposts. We started with “hairy root”cultures (HRCs), 
as a good test bed system for resilience to adverse aerospace conditions. Subsequently, 
we engineered whole tomato plants (cv. MicroTom). We introduced In both systems a 
permanent genetic switch of the anthocyanins pathway by the ectopic expression of a MYB-
like transcription factor (PhAN4) of Petunia hybrida.  
HRCs and plants harboring this additional gene showed a purple phenotype and an 
increased total polyphenol content as compared to controls. Anthocyanin content profiling 
was performed by liquid chromatography coupled to high resolution mass spectrometry and 
revealed 5 major derivatives of delphinidin and petunidin. Transcript profiling is currently 
under investigation.  
The increased flavonoid content in these plant systems results in enhanced scavenging 
ability towards free radicals. In fact, Electron Spin Resonance Spectroscopy (ESR) 
experiments show that dried tissues are able to counteract reactive oxygen species 
generated upon gamma irradiation. 
In conclusion, novel plant “ideotypes” were devised for space applications by a single gene 
engineering. These plants/organs could become natural bioreactors of molecules designed 
to counteract oxidative stress encountered in plant growing in non natural conditions and as 
nutraceutical and dietary supplement for the crew.   
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Natural, safe and healthy are the megatrends in global cosmetic industry. Many cosmetic 
ingredients are synthetic, especially the preservatives, which are associated with many 
negative or even toxic effects by the consumer. Plant based natural compounds and extracts 
have raised a lot of positive interest and they are screened at the moment by many cosmetic 
companies for their preservative characteristics and other positive activities.  
The role of skin microbiome in skin health is one of the hot topics in cosmetic research. Skin 
is the largest organ of human body, harboring one billion microbes/cm2, and cosmetic 
companies are just now starting to understand the importance of a healthy skin microbial 
community to the general health and wellbeing of the skin. New product category is just 
entering the market focusing on supporting and stabilizing healthy skin microbiota by limiting 
the growth of harmful and pathogenic microbes and supporting the growth of beneficial ones. 
VTT has a long experience on berry research, especially on antimicrobially active phenolic 
compounds. The focus has been on the industrial berry side streams and the utilization of 
the whole berry raw material. We have developed berry and fruit based natural antimicrobial 
ingredients for the cosmetics originating from the berry and fruit side streams by novel 
technologies. Three technologies have been patented and they are based on 1) dry 
fractionation technologies using seed sanding, 2) mild and gently milling, and 3) novel 
extraction technologies. 
In addition to antimicrobial activity the fractions provide several important technological 
advantages as cosmetic ingredients: totally water soluble, free of toxic solvents or reagents, 
good storage life.  
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Leaf Expression Systems is a manufacturing and contract development business 
specialising in the expression and production of proteins, metabolites and complex natural 
products for research and bio-medical applications using a proprietary, transient expression 
technology, Hypertrans®. Leaf Expression Systems is based in a purpose-built, state of the 
art facility on the Norwich Research Park that was opened in January 2017. It provides 
services to companies and research organisations by producing sufficient quantities of these 
valuable proteins and other natural products to enable research and product development. 
Hypertrans®, is efficient, safe and simple to use to quickly produce proteins in plants such 
as vaccines, antibodies or enzymes. Other potential uses include producing many proteins 
at the same time and so creating new biochemical pathways for producing complex 
‘bioactive’ molecules such as novel anti-cancer drugs and anti-infectives. We are exploring 
the potential of the Hypertrans® to express therapeutic and diagnostic proteins. In addition, 
we are working on a number of grant funded projects to develop virus-like particle based 
vaccines against emerging diseases.  
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In view of dengue disease which estimates to haunt 50% of the world population, several 
preventive and control measures have been employed in research which include Aedes 
vector suppression, antiviral drug discovery and vaccine development. As the existence of 
four antigenically distinct dengue serotypes can complicate the disease condition via 
antibody-dependent enhancement, the research on producing a safe and effective vaccine 
is prioritised. Virus-like Particles (VLPs) have always been known to confer stronger 
immunogenicity in vivo and hence represent a very appealing platform for vaccine 
development. In this context, the chimeric VLPs were designed by displaying dengue 
envelope protein domain III (cEDIII) on the hepatitis B core antigen (HBcAg) which served 
as the epitope carrier for expression using pEAQ-HT vector. These cEDIII VLPs were 
produced in Nicotiana benthamiana. The successful assembly of chimeric VLPs presenting 
the cEDIII antigen was verified by transmission electron microscopy and immunogold 
labelling. Moreover, specific antibody responses against cEDIII were also detected following 
the immunogenicity testing of the purified chimeric VLPs in BALB/c mice. Despite of the 
modest immune responses, current study has solidly shown that the insertion of a small 
protein (cEDIII) into the major immunodominant region of HBcAg would not disrupt the VLPs 
assembly. This potentiates further investigations towards the development of a VLP-based 
vaccine for dengue in near future.  
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Dengue outbreaks have spurred intriguing concerns in recent years, primarily affecting 
nations in the tropical and subtropical regions. As dengue virus co-circulates in the form of 
four antigenically distinct serotypes, the chance of acquiring secondary infection is relatively 
high, by which this can cause severe dengue and leads to life-threatening conditions. In 
order to prevent the risk of disease exacerbation by antibody-dependent enhancement, a 
dengue vaccine should provide a robust protection against the four serotypes 
simultaneously. In this study, a consensus sequence of the dengue virus envelope protein 
domain III (named as cEDIII) was expressed in Nicotiana benthamiana as the vaccine 
antigen of interest. A fusion with cholera toxin B subunit was strategised to boost the 
immunogenicity of the recombinant protein. Following the vector construction using pEAQ-
HT, transient expression was achieved via agroinfiltration in host plants. The recombinant 
protein was purified and then subjected to BALB/c mice immunisation. Serum analyses 
showed that a successful stimulation of anti-cEDIII response was obtained along with its 
neutralisation activities against the four dengue serotypes. Furthermore, a mixed Th1/Th2 
response was detected following the antigenic stimulation of mouse splenocytes. These 
findings have thereby provided an evidence that the development of a plant-based dengue 
vaccine is feasible and will be anticipated to make a significant impact in dengue control in 
the future. 
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The expression of heterologous membrane proteins in E. coli might be challenging, some 
costly proteins (e.g. GDNF), are hardly expressed in this system. Although, most of the 
processes leading to expressing cloned proteins, are clarified already, in some specific 
cases, the explanations of reasons leading to low expression level of certain proteins are 
not trivial, e.g., the intramembrane serine protease cleavage (Erez & Bibi, 2009). It is known, 
that in proteins with low expression levels DNA codon usage in membrane-binding domains 
(MBD) is crucial (Claassens et al., 2017). Manipulation with the genetic code may lead to 
higher production of functionally active membrane proteins, but may lead to misfolded and 
unstable products as well (Nørholm et al., 2012). However, at the native expression level, it 
is a common practice to consider that co-expression of several proteins in one host does 
not affect the expression levels of each of the proteins and that the change in MBD affects 
only the protein they are attaching to. To get better understanding of the effect of MBD on 
protein expression, we examined simultaneously the effect of MBD on the expression of the 
attached protein and co-expressed protein in the same cell. The influence of the MBD 
attached to the C-terminal of a fluorescent protein (EGFP) on its expression level and on the 
co-expression of another fluorescent protein (mCherry) was investigated. We have found 
that MBD fusion dramatically decreases the expression level of EGFP. Moreover, MBD 
decreased the expression not only of its cis-fusion protein, but of the totally different trans-
protein as well. Thus, we have elaborated a working model, which allows investigation of 
the influence of a membrane protein expression on the expression level of another noN-
membranal protein.  
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The skin is a complex and fragile ecosystem at the interface with the outside environment.  
The overall of microorganisms, which colonize the skin, is called the cutaneous microbiota. 
Numerous endogenous and exogenous disturbances can cause a change in the 
composition of this flora and affect the host–microorganism relationship. Indeed, the healthy 
skin microbiome functions as guardian of host defense, while an imbalance between 
bacteria (called dysbiosis) leads to skin inflammation and disease such as psoriasis, eczema 
and acne. 
Consequently, we developed innovative experimental approach putting forward a way to 
regulate skin microbiome using plant and cell culture extracts. First, the inhibition capacity 
of several hydrothermal extracts prepared from plant and cell culture, separately and 
together, was screened on isolated strains by an optimized agar diffusion method. Then, in 
order to quantify the inhibition of bacteria growth, measurement was performed in liquid 
culture as a more accurate assay. Results show that extracts, by acting in a synergistic way, 
control growth of specific bacteria involved in microbial skin balance. This model highlights 
the capacity of plant and cell culture extracts to affect bacterial functions in order to regulate 
the balance of skin microbiome.  
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Ruiz T, López-Moya JJ, Coca M 
Centre for Research in Agricultural Genomics Barcelona, Spain 
Corresponding author: Tarik Ruiz <tarik.ruiz@cragenomica.es> 
As the global recombinant protein market grows, and the platforms for protein production 
develops, biotechnological tools for protein purification are more necessary. Among them 
are included proteases required for processing of fusion proteins. Potyviruses are a rich 
source of proteases with potent activity and high specificity. These viruses are the largest 
family of RNA plant viruses (Wylie et al., 2017). Their genome expression strategy relies in 
the proteolytic cleavage of a large polyprotein mediated by specific viral proteases. A well-
known and broadly exploited potyvirus-derived protease is the NIa-Pro from Tobacco etch 
virus (TEV).  
In this work, we decided to design a simple system for screening other NIa-Pro proteases 
by combining in vivo visualization and molecular analysis. We started with the 
characterisation of NIa-Pro protease from the potyvirus Sweet potato feathery mottle virus 
(SPFMV). The viral gene product was cloned in a vector adequate for transient expression 
in leaves of N. benthamiana plants via agroinfiltration. Also, we generated a reporter 
construct containing the specific Nla-Pro cleavage sequence placed between an oleosin 
protein and the green fluorescent protein (GFP). Plant oleosins are known to target proteins 
to oil bodies as fusion proteins (Van Rooijen & Moloney, 1995; Montesinos et al., 2016). 
When agroinfiltrated alone, this reporter construct produced fluorescently labelled oil bodies, 
but when co-agroinfiltrated in the presence of the NIa-Pro construct, the cleavage of the 
reporter resulted in cytoplasmatic localization of the GFP fluorescence. This change was 
easily monitored using confocal laser microscopy. These observations were validated by 
WesterN-blot analysis of the produced intact or processed fusion proteins, confirming the 
visually detected activity of the NIa-Pro. Finally, the interest of this in vivo screening system, 
and the potential uses of the SPFMV NIa-Pro protease as a biotechnological tool in 
molecular farming will be discussed. 
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Polyketide derivatives are important secondary metabolites in plants with various bio-
activities. Their biosynthesis is initiated by type III polyketide synthases (PKSs) catalyzing 
iterative decarboxylation condensation reactions, and then undergo a series of enzymatic 
reduction, cyclisation and aromatization reactions (Stewart Jr et al., 2013). In gerbera 
(Gerbera hybrida), the polyketide derivatives gerberin, parasorboside and 4-hydroxy-5-
methylcoumarin (HMC) are highly produced in all tissues. Three gerbera specific PKSs have 
been identified accounting for synthesis of these compounds. Gerbera 2-pyrone synthase 1 
(G2PS1) is responsible for the biosynthesis of gerberin and parasorboside (Eckermann et 
al., 1998) and G2PS2 and G2PS3 are involved in HMC biosynthesis (Pietiäinen et al., 2016). 
Two ancient anther-specific chalcone synthase like genes, GASCL1 and GASCL2, were 
also identified in gerbera. They encode the key PKSs in the biossyntheis of sporopollenin, 
the main component of the exine layer of mature pollen grains (Kontturi et al., 2017. 
Polyketide reductases are supposed to catalyze the reduction of intermediates in all of these 
polyketide biosynthetic pathways.  
Coexpression analysis was conducted with transcriptomic data collected from a number of 
gerbera tissues and a tetraketide α-pyrone reductase 2 (TKPR2) like gene GRED1 was 
found highly co-expressed with G2PS1. Besides GRED1, there is one other gene, GRED2, 
belonging to the TKPR2 gene family in gerbera. TKPR2 (and TKPR1) are anther-specific 
genes involved in sporopollenin synthesis. However, the gerbera GRED1 and GRED2 are 
expressed almost everywhere. Gerbera GRED1 and GRED2 RNAi lines showed aborted 
pollen and significant reduction of HMC and parasorboside content was detected in GRED2 
RNAi leaves and petals. Based on these observations, we speculate that GRED1 and 
GRED2 may be not only involved in sporopollenin biosynthesis but also catalyze the 
reduction steps in parasorboside and HMC biosynthesis in gerbera. In the near future, in 
vitro experiments will be done to provide more information. 
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In nature, cellulose is degraded by a combination of synergistically acting enzymes, which 
can be secreted or anchored in the cellulosomes of anaerobic microorganisms. Recently 
this multi-enzyme structure has served as a model for designer cellulosomes, mimicking the 
natural spatial organization of synergistically acting enzymes for technological purposes. In 
this respect, positional control is necessary for effective biomass degradation and can be 
achieved by immobilizing enzymes onto reusable artificial scaffolds to improve their stability 
and activity (Artzi et al., 2017). However, recombinant scaffolds are usually expressed from 
long open reading frames, providing multiple possibilities for the selective attachment of 
matching enzymes, and this can result in low expression levels and unstable mRNA (Feng 
& Niu, 2007). This disadvantage can be circumvented by using molecular farming to produce 
high yields of identical coat protein (CP) subunits assembled into plant virus nanoparticles 
(VNPs). Plant viruses feature a precisely ordered 3D structure, but examples of catalyst-
decorated nanoparticles are rare. The functionality of VNPs can be tailored by chemical 
conjugation to exposed amino acid residues, genetic engineering or a combination of both 
(Le & Hu, 2017). However, these strategies suffer from limitations, most notably the genomic 
instability of large inserts, the need for certain amino acids as conjugation sites, and the 
usually poor overall coupling efficiency or fusion protein yield. A convincing solution would 
be a protein tag on the virus surface that can be generally applied for the attachment of 
different target proteins. 
Because covalent binding strategies usually achieve more efficient functionalization than 
noN-covalent protein interactions, we used the Streptococcus pyogenes 
SpyTag/SpyCatcher (ST/SC) system. Using this system, we achieved the stable and rapid 
immobilization of whole enzymes onto Potato virus X (PVX) and Tobacco mosaic virus 
(TMV) scaffolds without increasing the genetic load, as demonstrated by the attachment of 
Trichoderma reesei endoglucanase Cel12A. PVX and TMV not only differ in their flexibility, 
but also in the helical arrangement of their CPs, which influences the catalytic activity of the 
displayed enzymes. The activity of Cel12A increased ~2.5-fold when it was immobilized on 
PVX rather than TMV particles, whereas more endoglucanase molecules were concentrated 
on the shorter TMV scaffold. PVX-ST and, when other functions are desired, also TMV-ST 
nanoparticles are universally applicable platforms allowing the dense and stable 
presentation of target peptides that usually require post-translational modifications. 
Artzi, L., Bayer, E. A., Moraïs, S. 2017. Cellulosomes: bacterial nanomachines for dismantling plant 
polysaccharides. Nature Reviews Microbiology 15: 83. 
Feng, L., Niu, D. K. 2007. Relationship between mRNA stability and length: an old question with a new twist. 
Biochemical Genetics 45: 131-137. 
Le, D. H., Hu, H., Commandeur, U., Steinmetz, N. F. 2017. Chemical addressability of potato virus X for its 
applications in bio/nanotechnology. Journal of Structural Biology 200: 360-368.  
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32. Future pharma: A Phase I dose escalation trial to 
evaluate the safety of single IV administration of 
P2G12 in healthy volunteers 
Bartolf A, Cosgrove C, Ma JKC  
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Corresponding author: Angela Bartolf <abartolf@sgul.ac.uk> 
 
Despite progress in the development of quality of care and treatments to prolong life for 
those infected, HIV continues to be pandemic It is likely that a range of new strategies will 
be needed simultaneously to bring the epidemic under control and a HIV neutralising 
antibody could play an important role in post exposure including  mothers in labour.  
P2G12 is a human IgG1 class monoclonal antibody (MAb) which has been expressed in 
tobacco plants. The parent molecule is one of a handful of MAbs with potent neutralising 
activity against HIV-1 and a variant has demonstrated protection against SHIV challenge in 
macaques. It was also safe in repeated intravenous infusions (IVIs) in HIV-infected humans. 
The P2G12 has not raised any safety concerns in completed rat and human studies. Phase 
I, dose escalation in 3 ascending dose cohorts of 18 healthy subjects aged 18-45 years. 
This will be the first formal Phase I study in Europe, of a GMP compliant plant-derived MAb 
delivered by IVI.  
The aim of this study was to establish the safety of P2G12 administered as IVI by assessing 
> grade 3 reactions. Secondary objectives will look at the concentration of P2G12 in the 
serum and any grade events post-IV. P2G12 in saline will be infused IV. Following no 
observed effects after 10 minutes at slow rate, this will be increased to complete the infusion 
in 30 minutes. There will be a delay of >4 hours between volunteer doses and escalation to 
the higher dose will not occur until 2 week safety data of the last volunteer. 
Participants will undergo a health screening to assess eligibility to the inclusion/exclusion 
criteria prior to drug administration. Frequent medical monitoring (new medical concerns, 
routine laboratory parameters, ECG and vital signs) will continue up to 12 weeks post-IV. 
Serum immunogenicity and the associated plant-glycans will be measured at 11 time points 
using a specific ELISA and pharmacokinetic (PK) analysis will be completed. PK results will 
be compared with those from rats to determine if the rat model can be used to predict PK of 
plant antibodies. Favourable safety and immunogenicity results will be needed prior to a trial 
of P2G12 infusion in people who live with HIV infection.  
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33. Expression and characterization of milk-clotting 
cyprosin B from Cynara cardunculus and function 
of its plant specific insert in Nicotiana 
benthamiana 
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1Swedish University of Agricultural Sciences, Alnarp, Sweden  
2Linnaeus University, Kalmar, Sweden 
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The aqueous flower extracts of Cynara cardunculus are traditionally used for cheese-making 
in Mediterranean countries. The lack of availability of cardoon flowers in the region limits its 
production at industrial level. Hence, a study was undertaken to heterologously produce milk 
clotting enzyme, cyprosin (CYPB), a major component in the flowers of C. cardunculus and 
to confirm the role of their plant-specific insert (PSI) in the activity and localization of CYPB 
in N. benthamiana. In our study, CYPB and PSI deleted CYPB (CYPBΔPSI) genes were 
transiently expressed in N. benthamiana. Heterologously produced proteins were extracted 
from 9 days post infiltration and purified, which produced the yield of 80 mg kg-1 (CYPB) 
and 60 mg kg-1 (CYPBΔPSI) fresh weight of leaves, thus making it possible for large-scale 
industrial endeavors. The proteolytic activity of purified recombinant CYPBΔPSI was 
determined as 18.7 U, which was almost three times higher than the activity of CYPB (6.4 
U). This suggests that deletion of PSI is not directly related to the activity of CYPB. Milk-
clotting assay of purified CYPB and CYPBΔPSI showed that the time required to clot the 
milk was almost similar to that of wild type protein extracted from flowers of cardoon. To 
determine the significance of PSI in localization of CYPB, cDNAs of CYPB, CYPBΔPSI and 
PSI were fused with enhanced green florescent protein and transiently expressed in N. 
benthamiana. Subcellular localization analyses indicated that CYPB destined to vacuole, 
while CYPBΔPSI was trafficked in endoplasmic reticulum (ER) and vacuolar membrane i.e. 
tonoplast and PSI was observed in both ER and vacuole which suggests that CYPB with or 
without PSI was targeted into vacuoles. This indicated that the major function of PSI is 
vacuolar membrane permeabilization and absence of PSI (CYPBΔPSI) ended in tonoplast 
exemplifies existence of some vacuolar targeting signals in the regions of CYPB as well as 
PSI to target the vacuole. 
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34. Carnivorous plants as a potential new drug-
producing system 
Bonitz T, Kolano R, Fester K 
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Corresponding author: Tobias Bonitz <tobias.bonitz@uni-leipzig.de> 
 
The digestive fluid of carnivorous plants contains a wide variety of well-defined hydrolytic 
enzymes. This ability to produce, secrete and transport substances into special 
compartments of the plant could be used to produce pharmaceutical relevant substances, 
e.g. recombinant proteins. Furthermore, by interfering signal transduction pathways we can 
gather information about the regulation of enzyme secretion in carnivorous plants. Here we 
present the transformation (Hirsikorpii et al., 2002) of several genera of carnivorous plants 
with the marker protein GFP (green fluorescent protein) using different transformational 
methods. 
Reference 
Hirsikorpi, M., Kämäräinen, T., Teeri, T., Hohtola, A. 2002. Agrobacterium-mediated transformation of round 
leaved sundew (Drosera rotundifolia L.). Plant Science 162: 537-542. 
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35. N-glycosylation pattern of secretomes of 
Chlorella species 
Kim S-R1, Choi J1, Jeon JM1, An HJ2, Oh MJ2  
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Chlorella, unicellular green algae, has been spotlighted not only as a model organism to 
help study biological questions but also as a cell factory for various metabolites, biofuels 
and biopharmaceuticals. For using Chlorella as a biopharmaceutical source, it is required to 
understand N-glycosylation pattern of proteins. To this end, we have analyzed the N-
glycosylation of secretomes from C. vulgaris UTEX395 and an arctic Chlorella species 
Arm0029B. By using ultra-high resolution 15T FT-ICR mass spectrometry, we found 427 
and 53 proteins from the culture of UTEX395 and Arm0029B, respectively. Among the 427, 
128 were predicted as secreted proteins. MS analysis of the secretome showed that a major 
form of N-glycan in UTEX395 was Man8, whereas that in Arm0029B was 
Man4_GluNAc2_Fucose1_Xylose1. The N-glycosylation pattern in both UTEX 395 and 
Arm0029B showed plant specific methylation. We believe that the findings in this study can 
extend our knowledge about the signaling and defense systems in Chlorella. Furthermore, 
it would contribute to the development of future biopharmaceutical production 
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Chicory (Cichorium intybus L.) produces bitter sesquiterpene lactones (STLs). STLs form a 
class of compounds that predominantly occur in Asteraceae species. STLs have a variety 
of bioactivities, ranging from allelopathic activity to protective activity towards herbivorous 
insects in roots and flowers. In chicory, STLs provide bitterness, which gives the typical 
flavour to the belgian endive, and their presence in roots has been deployed to convert 
chicory root into a coffee substitute. STLs have a number of health associated properties, 
such as antimicrobial activity, and are used as chemotherapeutic agents. The initial 
dedicated enzymes in the biosynthetic pathway leading to costunolide have been 
characterized. However, the genetic organization and tissue specificity of their biosynthesis 
is largely unknown. Concentration of two sesquiterpene lactones in different chicory tissues 
was correlated to expression of genes involved in the first dedicated biosynthetic steps. BAC 
clones encoding different paralogs of the germacrene A synthase and germacrene A 
oxidase were sequenced, and revealed several tightly linked copies of these paralogs. 
Promoters of two germacrene A synthases and a germacrene A oxidase were fused to GFP 
and expressed in plants regenerated from chicory hairy root cultures. Highest gene 
expression was observed in epidermal tissues of leaf and root. This work opens the 
possibility to select for chicory germplasm diversified in STL content, and to study their role 
in chicory in defence and physiology.      
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carbohydrate profiling for proteins transiently 
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Proteins which require mammaliaN-type glycosylation for proper folding or efficacy present 
additional hurdles for plant production systems. This is largely due to the potential for 
incomplete and/or immunogenic oligosaccharide structures (noN-mammalian or noN-
human residues and configurations) to be added to proteins of pharmaceutical interest by 
expression host plants. Assessment of oligosaccharides attached to proteins is normally 
performed with chromatographic or chromatography-hyphenated spectroscopic methods 
(e.g. LC-MS) which are time consuming, expensive and often specialist in nature. In this 
work, we have explored the use of a lectin microarray approach, coupled with carbohydrate-
specific enzymatic treatment, to rapidly assess the structures attached to proteins 
ectopically-expressed within the leaves of Nicotiana benthamiana. A proprietary lectin 
microarray consisting of fifty lectins sourced from plant, fungal and bacterial sources was 
used to analyse transiently expressed proteins after fluorescent labeling. Signatures for 
untreated recombinants were compared to signatures for proteins treated with glyco-active 
enzymes. Evidence of the contribution of typical plant substituents was observed through 
the selective release of structures. This approach is relatively inexpensive and provides a 
means of rapidly validating the glycosylation profiles of transiently expressed, high value 
proteins for end-line human biomedical and health applications. 
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39. Tobacco BY-2 - a highly economic production 
host for recombinant proteins  
Häkkinen ST, Reuter L, Nuorti N, Joensuu JJ, Rischer H, Ritala A 
VTT Technical Research Centre of Finland Ltd., Espoo, Finland 
Corresponding author: Suvi Häkkinen <suvi.hakkinen@vtt.fi> 
Plant cell culture technology is a fascinating tool for various biotechnological applications 
offering possibilities for optimizing production, independently of climatic or environmental 
effects. However, often encountered hindrance in using plant cells in biotechnological 
platforms is the economic burden, i.e. the contained cultivation of plant cells is expensive 
mainly due to the specialized medium requirements and low multiplication rate of the cells. 
Tobacco BY-2 (Nicotiana tabacum cv. ‘Bright Yellow’) cell line is highly synchronisable and 
thus desirable for investigation of various aspects of plant cell biology and metabolism. 
Rapid accumulation of biomass and easy transformation has made the BY-2 cells the most 
frequently used plant cell line for protein production. However, when it comes to industrial 
production two factors must be specifically ensured: stability of the production host and the 
cost efficiency of the production process. The aim of this work was to identify most cost-
relevant nutrients in the culture medium and to determine culture medium compositions 
resulting in cheaper production of either biomass and/or recombinant protein.   
A cost estimation was performed to identify the most expensive nutrients in the culture 
medium. This involved the evaluation of costs of macro- and microsalts, vitamins and plant 
hormones. Price evaluation of the culture medium was performed based on the list prices of 
the nutrients provided by SigmaAldrich. No other factors such as production costs were 
included in the evaluation. Evaluation resulted in altogether 7 compounds, which were 
selected as studied factors based on their final cost and relevance. The screening of the 
factors was performed with BY-2 clone ‘Hulk’ against biomass production and GFP-HFBI 
accumulation using DoE1.  
The most promising medium composition in respect of biomass production was subjected 
to more detailed examination, i.e. the cost of the selected media were compared and for the 
most cost-efficient media, components were reduced from 100 % to 50 % levels in 10 % 
intervals. With the optimized culture medium, 43-55 % cost reduction in regards to biomass 
and up to 69 % reduction in regards to recombinant protein production was achieved. In 
order to determine the whole cost structure of the production of plant-based protein, TEA or 
LCA should be conducted with actual desired recombinant protein of commercial interest. 
However, this study shows that significant cost savings can be achieved with reducing the 
consumption of most expensive components in the culture medium. 
Häkkinen, S. T., Reuter, L., Nuorti, N., Joensuu, J. J., Rischer, H., Ritala, A. M. 2018. Tobacco BY-2 media 
component optimization for a cost-efficient recombinant protein production. Frontiers in Plant Science 9: 45.  
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Monoclonal antibodies (mAbs) are currently the dominating type of proteinaceous 
biopharmaceuticals on the market and well-established production routines are available for 
their manufacture. In most cases the purification of mAbs starts with, or at least incorporates 
at some point, a Protein A affinity step, which has resulted in substantial improvements of 
the ligand. However, resin prices are still high and can be a major cost factor during 
production. Several alternative ligands have therefore been developed but often lack the 
selectivity/specificity of Protein A. Here we report the development of a fusioN-protein affinity 
ligand consisting of a base scaffold fused to the linear epitope of a target mAb. This will 
facilitate a rapid adaptation of the method to other mAbs with linear epitopes in the future. 
We cost-effectively produced the ligand in plants, one-step purified it and used a design of 
experiments approach to optimize the coupling to a sepharose base-resin. The resulting 
affinity resin was used to capture the epitope-specific mAb from another crude plant extract 
in a column format. We screened and optimized the elution conditions and evaluated the 
dynamic binding capacity as well as ligand stability for comparison with Protein A. 
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Molecular farming is a useful option for the production of valuable recombinant proteins. As 
a major prerequisite, highly efficient and cost effective expression systems are required. The 
cereal grain is an attractive vehicle for producing recombinant proteins, because its evolution 
as a protein storage organ assures an environment in which proteins accumulate to high 
abundance and remain stable over long periods without any need for refrigeration or aseptic 
conditions. To establish efficient recombinant protein accumulation in the barley endosperm, 
the reporter gene Gfp was expressed under control of the oat GLOBULIN1 promoter. 
Transgenic barley grain accumulated up to 1.2 g/kg dry weight of recombinant protein 
(GFP), deposited in small roundish compartments assumed to be ER-derived protein 
bodies. The molecular farming potential of the system was tested by generating doubled 
haploid transgenic lines engineered to synthesize the anti-Human Immunodeficiency Virus 
antibody 2G12, which is a well-studied model and had been used in many different 
expression systems including plants. The 2G12 antibody was produced in a functional and 
soluble form and its level of accumulation exceeded those achieved in transgenic tobacco, 
maize and rice. 
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Human papillomavirus (HPV) infects mucosal and cutaneous basal epithelial cells after 
tissue microtrauma. Most infections are cleared by the immune system; however, some 
benign cervical lesions progress to invasive cervical cancer, caused predominantly by high-
risk HPVs. There are currently 3 licensed vaccines on the market, but these vaccines have 
limitations due to their type-restricted prophylactic efficacy, a lack of therapeutic efficacy and 
the high costs associated with production. Plant-based expression has significant potential 
to facilitate reduction in vaccine costs due to lower cost of goods, and its rapid scalability in 
comparison to other systems. The HPV E6 and E7 early gene products are ideal targets for 
use as therapeutic vaccines due to their role in disruption of the cell cycle and their 
constitutive expression in premalignant and malignant tissues.  
To address the lack of therapeutic efficacy of current vaccines, we aimed to develop a novel 
E7-based DNA vaccine delivered by plant-made HPV pseudovirions (PsVs). A geminivirus-
derived self-replicating plasmid encoding a shuffled E7 (E7SH) sequence that has no 
transformation ability but contains natural cytotoxic T-lymphocyte epitopes, was constructed 
using GoldenBraid technology and co-expressed in plants with HPV-16 or HPV-35 L1- and 
L2- encoding expression vectors. GoldenBraid assembly was successful and the 
pseudogenome was encapsidated into HPV-16 and -35 plant-made PsVs. HEK 293TT cells 
were transfected with the PsVs to examine potential E7SH expression. The PsVs were 
capable of infecting mammalian cells resulting in E7SH expression. This shows the promise 
for use of plant-made HPV PsVs to encapsidate and deliver candidate therapeutic DNA 
vaccines for HPV infections and HPV-associated lesions as well as for other applications. 
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Glycosylations have a major impact on the physicochemical properties of bioactive natural 
products. They increase the stability of labile small molecules; decrease the toxicity of 
potential hazardous compounds, and influence the bioactivity of pharmaceuticals. Hence, 
targeted glycosylation of acceptor molecules is of high scientific significance. However, 
regio- and stereoselective chemical synthesis is challenging and expensive. A promising 
approach is the enzymatic glycosylation via glycosyltransferases (GTs). They catalyze the 
transfer of a sugar moiety from an activated donor, usually UDP-glucose, to a broad range 
of acceptor molecules. Thus, GTs are a powerful tool for the biotechnological glycosylation 
of bioactive natural products. Investigations on novel GTs from new plant sources will enable 
the modification of a diverse range of value chemicals currently applied in the food and 
cosmetics industry.  
Therefore, we identified and functionally characterized GTs from tobacco (Nicotiana 
benthamiana). A substrate screening and kinetic analysis were performed, and the enzyme 
specificities determined. In doing so, we uncovered novel enzymatic activities towards 
ionols. Overexpression of the GTs in tobacco plants verified the in vivo activity. Furthermore, 
we employed whole cell biotransformation to produce these interesting glucosides on a large 
scale to test them in various technical applications.  
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Human Cytomegalovirus (HMCV) represents a major cause of congenital disease when 
infecting the fetus. Glycoprotein B (gB), which is a crucial viral membrane protein involved 
in host cell fusion, contains 18 potential N-glycosylation sites. The ability to characterize and 
control the glycosylation pattern of recombinant gB represents a major goal before its use 
as a vaccine. The aim of our study consisted of obtaining plant cell lines that express gB 
and of evaluating its glycosylation profile. We expressed the large soluble ectodomain of 
HCMV gB in Nicotiana tabacum BY-2 cells. gB was secreted in the culture medium at a 
concentration of 60 mg/L. The protein was purified directly from the culture medium by 
ammonium sulfate precipitation and size exclusion chromatography. We analyzed the 
glycosylation status of the gB protein produced in three independent transgenic BY-2 lines. 
First, the occupancy rate of each N-site was determined. We then identified and quantified 
the N-glycans present on 17 out of the 18 N-sites by multienzymatic proteolysis and mass 
spectrometry (LC-MS/MS). Interestingly, the glycosylation profile differed on each site, some 
sites being occupied exclusively by oligomannose type N-glycans and others by complex bi-
antennary N-glycans processed in some cases with additional Lewis-a structures. These 
data were compared to those obtained in parallel for the same HCMV gB variant produced 
in CHO cells. Apart from the typical plant-specific N-glycans, the profiles were strikingly 
similar between BY-2 and CHO-produced gB, indicating that, overall, the gB conformational 
structure is conserved when expressed in plant cells and that this structure influences the 
glycosylation profile at each site. However, the processed N-sites displayed much more 
heterogeneity in CHO cells with the presence of bi-, tri- and tetra-antennary structures that 
can be further elongated with sialic acids 
This work was supported by a grant from the Service Public de Wallonie in Belgium 
(WBHealth 1318062). 
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Two main approaches are available to produce recombinant proteins in plants: stable 
transformation and transient expression. In recent years the transient expression technology 
has made rapid and impressive progress. High level of target protein expression, speed and 
scalability, reduced environmental concerns due to the production in contained facilities are 
major advantages of this method (Lomonossoff & D'Aoust, 2016). Transient expression is a 
two-component system consisting of expression vector and host plant. Therefore, both 
factors - expression vector used and host genome modification - might have a positive 
impact on quality and quantity of plant-produced recombinant proteins. Nicotiana 
benthamiana is a favourite host for transient expression because of its high susceptibility to 
viral and agrobacterial infection and fast growth rate under indoor conditions.  
This study was aimed at developing N. benthamiana lines with increased biomass 
production, with a view to reduce the operation costs for plant host manufacturing at a large 
scale. To this end we generated transgenic N. benthamiana plants harbouring the CycD2 
gene from Arabidopsis thaliana. The CycD2 gene is a positive regulator of the cell cycle and 
is known to influence the transmission from G1 phase to S phase (Cockcroft et al., 2000). 
The T1 progeny of CycD2 transgenic plants was evaluated in the greenhouse for above-
ground biomass accumulation. We could select several lines with boosted biomass 
production that were morphologically indistinguishable from wild type plants. To check their 
suitability for foreign protein expression we agroinfiltrated these lines with a TMV-based 
vector carrying a gfp gene. The accumulation level of GFP protein in CycD2 transgenic 
plants was comparable to that in noN-transformed plants suggesting suitability of these lines 
for breeding new N. benthamiana genotypes with increased biomass production for 
molecular farming.  
References 
Cockcroft, C.E., den Boer, B.G.W., Healy, J.M.S., Murray, J.A.H. 2000. Cyclin D control of growth rate in plants. 
Nature 405: 575-579. 
Lomonossoff, G.P., D'Aoust, M.A. 2016. Plant-produced biopharmaceuticals: A case of technical 
developments driving clinical deployment. Science 353: 1237-1240.  
  
Posters 
170 
46. Production and characterization of glyco-
engineered anti-CD20 tumour-targeting scFv-Fc 
antibodies and interleukiN-2 conjugates in whole 
plants and hairy root cultures of N. benthamiana 
Donini M, Marusic C, Lonoce C, Pioli C, Novelli F, Benvenuto E  
ENEA Research Center, Rome, Italy 
Corresponding author: Marcello Donini <marcello.donini@enea.it>  
Anti-CD20 recombinant antibodies are successfully used for the treatment of B-cell 
malignancies such as noN-Hodgkin lymphomas. We demonstrated that recombinant anti-
CD20 scFv-Fc antibodies derived from C2B8 mAb (rituximab), can be efficiently produced 
in Nicotiana benthamiana leaves by agroinfiltration and that an immunocytokine (IC) 
obtained by fusing the scFv-Fc to the human interleukin 2 (hIL-2) showed a CD20 binding 
activity comparable to that of rituximab and was efficient in eliciting antibody-dependent cell-
mediated cytotoxicity (ADCC). Moreover, the IC devoid of the typical xylose/fucose N-
glycosylation plant signature(IC-XF) and the corresponding scFv-Fc-XF antibody not 
fused to the cytokine, were obtained in a glyco-engineered XylT/FucT N. benthamiana line. 
Purification yields from agroinfiltrated plants amounted to 20-35 mg/Kg of leaf fresh weight. 
When assayed for interaction with FcRI and FcRIIIa, IC-XF exhibited significantly 
enhanced binding affinities if compared to the counterpart bearing the typical plant protein 
N-glycosylation profile and to rituximab. The glyco-engineered recombinant molecules also 
exhibited a strongly improved ADCC and complement-dependent cytotoxicity (CDC). 
Notably, our results demonstrate a reduced C1q binding of xylose/fucose carrying antibodies 
compared to versions that lack these sugar moieties.  
In the attempt to find an alternative production system for the anti-CD20 antibodies, we 
expressed these molecules in hairy root cultures (HR). HR cultures represent an attractive 
platform for the production of heterologous proteins due to the possibility of secreting the 
molecule of interest into the medium. The aim of our study was to enhance the accumulation 
of the scFv-Fc with humaN-compatible glycosylation profile in HR culture medium. To this 
purpose we engineered N. benthamiana HR cultures expressing the red fluorescent protein 
(RFP) as a model for an easy screening of different auxins able to induce heterologous 
protein secretion into the medium. The 2,4-dichlorophenoxyacetic acid (2,4-D) was found to 
induce remarkable accumulation levels of RFP in the medium. The same protocol was 
applied for the tumor-targeting antibody from glyco-engineered XTFT N. benthamiana HR 
cultures. Addition of 2,4-D determined an increased antibody accumulation up to 16 mg/L 
while N-glycosylation profile revealed GnGn structures devoid of xylose and fucose 
residues. To our knowledge, this is the first example of the expression at high levels in HR 
of an engineered anti-CD20 antibody in a scFv-Fc format, paving the way towards organ 
cultures as contained production platform of recombinant biopharmaceuticals with a suitable 
glycosylation profile.  
Marusic, C., Novelli, F., Salzano, A. M., Scaloni, A., Benvenuto, E., Pioli, C., Donini, M. 2016. Production of 
an active anti‐CD20‐hIL‐2 immunocytokine in Nicotiana benthamiana. Plant Biotechnology Journal 14: 
240-251.  
Marusic, C., Pioli, C., Stelter, S., Novelli, F., Lonoce, C., ...Donini, M. 2018. N‐glycan engineering of a plant‐
produced anti‐CD20‐hIL‐2 immunocytokine significantly enhances its effector functions. Biotechnology 
and Bioengineering 115: 565-576.  
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Corresponding author: Rosemary Meggersee <rosemary.meggersee@gmail.com> 
 
Human papillomaviruses (HPV) are known to infect the genital epithelium and can produce 
lesions which can progress to invasive cervical cancer. More than 200 HPV types have been 
characterised based on their genome sequences, at least 12 of which cause cervical cancer. 
Cervical cancers are the 4th most common cancer in women and in 2012, an estimated 
527,624 cases of HPV induced cervical cancer arose annually, of which 50.3% were fatal. 
In current diagnostic settings HPV serology is used to identify current and past-exposed 
individuals; however the balance between sensitivity and specificity of these assays are a 
problem. Many monoclonal antibodies have been developed against different HPV types to 
identify and characterize papillomavirus neutralizing epitopes, however these antibodies are 
often not commercially available, require the use of mice for production and are tedious and 
very expensive to make. Phage display represents an alternative approach to monoclonal 
antibody isolation. In this study anti-HPV L1 antibodies were generated from a mouse phage 
display library and bio-panned against HPV-16 L1 protein. The highest affinity binders were 
sequenced and cloned into a plant expression vector. The proteins were expressed in 
Nicotiana benthamiana plants and purified using nickel affinity chromatography. These 
single chain variable region antibody fragments showed specificity in binding and were able 
to detect HPV L1 in ELISA and western blot tests.  
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fucosyltransferases for glyco-engineering of 
‘native’ helminth N-glycan structures in planta 
van Noort K1 Nguyen DL2, Hokke CH2, Schots A1, Wilbers R1 
1Wageningen University & Research, Wageningen, The Netherlands 
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Corresponding author: Kim van Noort <kim.vannoort@wur.nl> 
Clinical trials with live parasites and mouse model studies have shown the potential of 
helminths and their excretory/secretory (ES) proteins to dampen allergic reactions and 
autoimmune disorders. Moreover, glycaN-dependent mechanisms have been shown to be 
involved in several cases. To further develop helminth-derived ES glycoproteins as 
biopharmaceuticals, a large-scale expression system is required for the production of 
recombinant glycoproteins with defined and tailored glycosylation. The trematode 
Schistosoma mansoni produces highly fucosylated N-glycan structures on its glycoproteins, 
which cannot be synthesized in current production systems. Thereto, co-expression of 
specific fucosyltransferases in the expression host are required to introduce helminth-like N-
glycan modifications. In the GeneDB database 20 different S. mansoni fucosyltransferase 
(SmFucTs) genes for N-glycosylation can be found. To date one α1,3 fucosyltransferase is 
characterised in vitro using glycan acceptors and shows to synthesise Lewis X. Thereto, we 
examined the function of ten selected SmFucTs by transient co-expression with model 
proteins in Nicotiana benthamiana plants. With this method we have identified SmFucTs 
that fucosylate LDN (forming LDN-F, F-LDN and F-LDN-F), synthesise Lewis X or are 
involved in α1,3 or α1,6 core fucosylation. These functionally characterised 
fucosyltransferases can immediately be applied to synthesise desired helminth-like N-
glycan structures on recombinant glycoproteins in plants. Therefore, characterisation of 
SmFucTs, other glycosyltransferases and combinations of different glycosyltransferases 
expands our glyco-engineering toolbox and offers perspectives for large scale production of 
glycoproteins with functional helminth N-glycan structures in plants. 
 
 
 
 
 
 
The authors kindly acknowledge the collaboration with Herta Steinkellner, Richard Strasser 
and Andreas Faissner.  
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49. Working towards a plant-produced Bovine 
papillomavirus vaccine: Expression of BPV1 
virus-like particles and pseudovirions in plants 
Hitzeroth II, Pietersen I, van Zyl AR, Rybicki EP 
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Corresponding author: Inga Hitzeroth <inga.hitzeroth@uct.ac.za> 
 
Bovine papillomaviruses (BPV) are small DNA viruses implicated in several diseases and 
cancers of considerable veterinary and agricultural importance in cattle, horses and several 
wild animal species, leading to their economic depreciation and deterioration of their function 
and appearance. As BPV is widespread, easily transmissible, and infection often occurs 
asymptomatically, it is imperative that routine vaccinations are carried out to mitigate the 
threat of outbreaks occurring in livestock. There is a demand for prophylactic vaccines to 
immunise animals routinely and from a young age so as to prevent infection from occurring, 
as there is currently no fully effective treatment against established disease. Prophylactic 
VLP-based vaccines against BPV types 1, 2, and 4 have previously been produced in 
cultured animal cells. However, these are largely type-specific, expensive, and not widely 
available in developing countries, where food security and the use of cattle for meat, dairy, 
leather products, as well as draft animals, is often essential for survival.  
Bovine papillomavirus has often been used as a model for the study of human (HPV) and 
other papillomaviruses (PV), and the use of a plant-produced BPV vaccine may set a 
platform for the development and testing of an HPV vaccine in an animal model. To address 
the lack of a cheap and readily-available prophylactic vaccine, we aimed to develop a plant-
made VLP-based vaccine using the L1 and L2 capsid proteins of BPV1, the most prevalent, 
and one of the most virulent BPV types. We successfully expressed relatively high yields of 
both L1 and L1/L2 VLPs in N. benthamiana. Furthermore, we managed to encapsidate self-
replicating plant geminivirus-derived reporter-gene plasmids into the L1/L2 capsids, 
demonstrating the first successful production of BPV pseudovirions (PsVs) in plants. These 
particles were also shown to infect and express the reporter gene in mammalian HEK293TT 
cell cultures. Particles of different sizes, probably corresponding to T=1 VLPs (~20-30nm) 
and T=7 PsVs (~50-60nm), were obtained in the production of PsVs. We were able to 
concentrate particles of different sizes by use of density gradient centrifugation, which is 
useful for separating the particles to study their functions, and in their use for different 
applications.   
These findings highlight the potential use of BPV PsVs for a diverse range of functions, 
including their use as dual prophylactic-therapeutic vaccines capable of delivering 
therapeutics or DNA vaccines to specific tissues.  
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Naturally occurring peptides offer great potential as leads for drug design. This presentation 
will focus on a class of cyclic peptides from plants known as cyclotides. Cyclotides are 
topologically unique in that they have a head-to-tail cyclised peptide backbone and a cystine 
knotted arrangement of disulfide bonds. This makes them exceptionally stable to chemical, 
thermal or enzymatic treatments and, indeed, they are amongst nature’s most stable 
proteins. Because of their exceptional stability and well-defined structures cyclotides make 
excellent templates for drug design applications. This presentation will give an overview of 
the discovery, distribution and evolution of cyclotides and will describe recent applications 
of cyclotides and related peptides in the design of drugs for cancer (Huang et al., 2015), 
pain (Castro et al., 2018) and thrombosis (Swedberg et al., 2016). Natural cyclotide-
producer plants make cyclotides in high yield (~1g/kg fresh plant weight). Having designed 
therapeutically active cyclotides, we are now using crop plants to produce them. We 
describe the use of tobacco, Arabidopsis and petunia for the biopharming of designer 
cyclotides. We have established the Clive and Vera Ramaciotti Facility for the Production of 
Therapeutic Drugs in Plants to do this work. Cyclotides fill a gap in the pharmaceutical 
industry between ‘small molecule’ drugs and ‘biologics’ (antibodies and growth factors). 
Because they are naturally produced by plants cyclotides are ideal biopharming scaffolds. 
References 
Castro, J., Grundy, L., Deiteren, A., Harrington, A., O’Donnell, T., … Brierley, S. 2018. Cyclic analogues of α-
conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain. 
British Journal of Pharmacology (n press). 
Huang, Y.-H., Henriques, S. T., Wang, C. K., Thorstholm, L., Daly, N. L., Kaas, Q., Craik, D. J. 2015. Design 
of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Scientific Reports 5: 12974. 
Swedberg, J. E., Mahatmanto, T., Ghani, H. A., de Veer, S. J., Schroeder, C. I., Harris, J. M., Craik, D. J. 2016. 
Substrate guided design of potent FXIIa inhibitors based on the plant-derived Momordica cochinchinensis 
trypsin inhibitor-II (MCoTI-II) scaffold. Journal of Medicinal Chemistry 59: 7287-7292. 
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51. Nucleus specific degradation of GFP-tagged 
proteins in plants 
Sorge E, Lermontova I, Helmold C, Conrad U 
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Corresponding author: Eberhard Sorge <sorge@ipk-gatersleben.de> 
 
Previous studies showed specific degradation of GFP-tagged proteins by alteration of 26S-
proteasome pathway subunits. To recruit the cell´s own proteolytic machinery, the Fbox 
subunit of an E3-Ligase was fused to a nanobody with high specificity for GFP. With this 
chimeric construct, it was possible to rise experimental evidence for in vivo degradation of 
target proteins in insect and human cells (Caussinus et al., 2011). We have been able to 
replicate these results in tobacco plants, by addressing Full length EGFP as target protein 
(Baudisch et al., 2018). 
Our latest experiments focus on specific subcellular protein degradation. Based on recent 
literature, we used a human BTB – anti-GFP nanobody fusion protein (Ju Shin et al., 2015) 
to channel the proteolytic activity to the nucleus of plant cells. This enabled us to observe 
strong reduction of GFP-fluorescence of target fusion proteins in nuclei.   
References  
Baudisch, B., Pfort, I., Sorge, E., Conrad, U. 2018. Nanobody-directed specific degradation of proteins by the 
26S-Proteasome in Plants. Frontiers in Plant Science 9: 130. 
Caussinus, E., Kanca, O., Affolter, M. 2011. Fluorescent fusion protein knockout mediated by anti-GFP 
nanobody. Nature Structural & Molecular Biology 19: 117-121. 
Shin, Y. J., Park, S. K., Jung, Y. J., Kim, Y. N., Kim, K. S., ... Kee, Y. 2015. Nanobody-targeted E3-ubiquitin 
ligase complex degrades nuclear proteins. Scientific Reports 5: 14269.   
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Transient expression systems can enable large-scale production of novel recombinant 
proteins in shorter timeframes than stable transgenic systems. We are developing a 
transient plant cell culture expression platform that uses genetically engineered 
Agrobacterium tumefaciens for gene delivery. Since different proteins could be produced 
simply by using different Agrobacterium constructs in conventional bioreactor systems, this 
system is well suited for rapid response applications. To demonstrate the potential for 
production of human therapeutic proteins using this platform, glycoengineered, β(1,2)-
xylosyltransferase and α(1,3)-fucosyltransferase knockdown Nicotiana benthamiana cell 
suspension cultures were used. An anthrax toxin receptor-Fc fusion protein (CMG2-Fc) was 
transiently produced by adding Agrobacterium to the glycoengineered N. benthamiana cell 
suspension cultures in shake flasks. Compared to CMG2-Fc produced through 
agroinfiltration of wild type N. benthamiana, CMG2-Fc produced in the glycoengineered 
transient cell culture system had dramatically reduced levels of β(1,2)-xylose and core 
α(1,3)-fucose. The impact of various process parameters (including the mass ratio of 
Agrobacterium added to plant biomass, plant cell growth stage, and co-culture media 
volume) on CMG2-Fc production will also be discussed.  
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and re-tooling a plant genome to increase circular 
peptide production 
Gilding EK, Jackson MA, Craik DJ 
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Cyclotides are head-to-tail cyclized disulfide-rich peptides of roughly 30aa that have been 
implicated in plant defense. Their characteristic knotted and circular structure imbues these 
peptides with increased stability when challenged with temperature extremes and proteolytic 
environments. Because of these qualities they are actively being investigated as a scaffold 
for peptide based pharmaceuticals and agrichemicals. Five angiosperm families are known 
to produce cyclotides, however their distribution amongst taxa is inconsistent with 
phylogenetic relationships, suggesting the structure and machinery to synthesize these 
peptides are products of convergent evolution. Fortuitously, Solanaceae contains several 
taxa known to make cyclotides and, in addition it is a family with important plant expression 
systems (ex. Nicotiana). Key biosynthetic enzymes are asparaginyl endopeptidase (AEPs) 
isoforms that function as transpeptidases to create these circular peptides. NoN-cyclotide 
producing plants without transpeptidase-type AEPs and induced to transiently express 
cyclotide precursors produce mostly misprocessed linear products, thus illustrating the 
importance of the biosynthetic machinery and precursor structure as being factors in efficient 
cyclotide production in planta. Here we aim to create a plant platform optimized for plug-
and-play cyclotide production. The strategy is to trace the genetic origins of cyclotide 
precursor and biosynthetic genes to identify the best homologs in Nicotiana benthamiana to 
be replaced with cyclotide-attuned isoforms from various plants using CRISPR. Data is 
presented on the evolution of the gene families involved in producing these fascinating 
molecules and on efforts to create a strain of N. benthamiana competent as a plug-and-play 
circular peptide production platform. 
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structure to enable expression of promising 
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A plant-based production system for therapeutic peptides can offer a cheaper, greener 
alternative to traditional chemical synthesis. This work focuses on the production of a class 
of cyclic peptides called cyclotides, and overcoming one particular obstacle in their 
biosynthesis in plants – the cyclisation step. Cyclotides are ribosomally-synthesised 
peptides that are naturally occurring in plants. Head-to-tail cyclisation of these peptides 
render their C- and N- terminal residues inaccessible to enzymatic degradation, while the 
presence of three disulfide bonds strengthens the structure further. This ultra-stable 
cyclotide structure is adopted as a scaffold to stabilise smaller therapeutic peptide epitopes 
that would be otherwise unstable. Where in vitro synthesis of cyclotides has allowed 
laboratory scale studies to be carried out, it is not the most suitable method for producing 
cyclotides in large quantities for commercial production due to prohibitive costs and the use 
of harsh chemicals. This is where plant molecular farming comes in. However, the concepts 
used for in vitro synthesis of modified cyclotides cannot be applied to plant-based 
production. In fact, during chemical synthesis the cyclotide backbone can be cyclised at 
almost any position, but plant-produced cyclotides are cyclised enzymatically at a precise 
position. Incidentally, almost 75% of modified cyclotides interrupt the cyclisation point in the 
cyclotide sequence, meaning that recombinant expression of the mature cyclic product is 
not possible. A new cyclisation site needs to be engineered into the recombinant peptide in 
order to keep any new bioactive epitope in its optimal place within the backbone, and at the 
same time allow production of the stable, cyclic, product in planta. Through semi-rational 
design, and some trial and error, an alternative point of cyclisation was introduced into the 
cyclotide backbone, which was successfully processed into the mature cyclic product by the 
same enzymes found in cyclotide-producing plants. This breakthrough in cyclotide 
production should enable the most effective and promising cyclotide-based therapeutics to 
progress from small scale laboratory testing to large scale biosynthesis in plants. 
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Plant-produced cyclic peptides range from 14~37 amino acids in length and are 
characterised by a head--to--tail cyclised backbone that is further strengthened by 
intramolecular disulfide bonds. They exhibit various bioactivities, including uterotonic, 
antimicrobial and anti--HIV activities, which are potentially exploitable for therapeutic uses. 
Moreover, due to their unique stable topological structure and tolerance to residue 
substitution, cyclic peptides have become promising molecular scaffolds for pharmaceutical 
protein-engineering applications. Currently, chemical synthesis is a common strategy for 
producing native and modified cyclic peptides, as well as recombinant synthesis and natural 
extraction. However, these strategies are limited for large-scale production by the high 
production cost, complexity of separation and deficient knowledge of the biosynthesis 
pathway. To address these issues, this project is aiming to investigate a non-native cyclic 
peptide producing species, rice, as a plant bioreactor to express cyclic peptides of interest. 
Rice represents a promising recombinant peptide production platform based on its proven 
stable accumulation of proteins, low bio-safety risk and cost-effectiveness. So far, no native 
cyclic peptides have been identified in any monocot species, however, several peptide 
precursor genes with homology to cyclic peptide genes have been identified, differing only 
in the absence of residues known to be important for in planta cyclisation. In this study, we 
aim to test the capacity of rice to produce cyclic peptides through transformation of a variety 
of precursor peptide genes together with or without Asparaginyl endopeptidase (AEP), a 
gene to aid cyclisation in planta. Native linear cyclic peptide-like precursor genes of rice 
were engineered with cyclisation-competent C-termini to further explore the mechanism of 
cyclisation in planta and the flexibility of cyclic peptide grafting in a monocot system. 
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of West Nile Virus in planta as a viable, low-cost 
method for vaccine and diagnostic reagent 
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West Nile virus (WNV) is widely disseminated, with a geographic range that now includes 
Africa, North America, Europe, the Middle East and West Asia. The virus is maintained in a 
bird-mosquito transmission cycle and mammals are considered accidental-dead-end hosts. 
WNV is a member of the Japanese encephalitis virus serocomplex, and in humans WNV 
infections can develop into febrile illness and severe meningoencephalitis. To date there is 
no human vaccine available. 
Diagnostic reagents and vaccines are made by recombinant protein expression in a variety 
of systems, including bacteria, fungi and yeasts, and mammalian or insect cells. Transient 
plant-based expression systems are possibly the cheapest means of making complex 
proteins; have the ability to process proteins very similarly to mammalian cells, and do not 
require sterile incubation. Therefore, it is proposed that this system could be a viable means 
of making feasible, low cost reagents for West Nile virus for use as diagnostics, as well 
possibly being used to produce virus-like particles (VLPs) for use as vaccines in South Africa 
and elsewhere. 
We aim to use the envelope (E) and membrane (prM/M) proteins of WNV to make noN-
infectious empty VLPs as a candidate vaccine, and to use the noN-structural protein 1 (NS1) 
to make a diagnostic reagent for viral detection, in planta. The E, prM/M and NS1 genes 
were cloned into the plant expression vectors pTRAkc-ERH and pEAQ-HT, and infiltration 
time trials of the assembled constructs were conducted to determine the optimal OD600 for 
infiltration and the optimal sampling point for maximum protein yield. We investigated the 
results of co-expression of human derived chaperone proteins on viral protein expression. 
We report data on the yield of viral proteins and on the optimisation of their expression. 
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Cyclotides are small, head-to-tail cyclised peptides with a knotted topology. They are of 
interest to many because they can be used as ultrastable scaffolds for grafting peptide-
based therapeutics. To date, there are five angiosperm plant families that are known to 
produce them: Violaceae, Rubiaceae, Solanaceae, Cucurbitaceae and Fabaceae. This work 
focuses on butterfly pea (Clitoria ternatea), the only species in the Fabaceae family that is 
currently known to produce cyclotides. Combined with genome walking and fourth 
generation sequencing, the cis-regulatory elements upstream of butterfly pea cyclotides 
were scrutinised to determine the key factors that can enhance cyclotide production. 
Induction experiments on wild type butterfly pea seedlings showed significant increase in 
cyclotide production when exposed to numerous stress factors such as salicylic acid and 
ethylene biosynthetic precursor, among others. Being a native cyclotide producer equipped 
with the pre- and post-translational enzyme machinery to produce cyclotides, the study 
further looks into developing butterfly pea as a production platform for cyclotide-based 
therapeutics. A big step towards this endeavour is the establishment and optimisation of the 
hairy root transformation protocol in butterfly pea.  With the knowledge gained from studying 
the cyclotide CREs in butterfly pea that can contribute to significant increase in cyclotide 
production, and the development of hairy root transformation protocol, butterfly pea can be 
an excellent biofactory for the production of cyclotide-based therapeutics.  
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applications for veterinary purposes 
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The H5N1 avian influenza A virus is a highly contagious, deadly pathogen in poultry, 
transmitted from poultry to humans causing high mortality (ca 60%) and able to pose a 
pandemic threat. Vaccination is the most effective approach to reduce illness and death 
from pandemic influenza. Influenza vaccines generally in use today are derived from viruses 
grown in hens’ eggs. However, this approach exposes several obstacles such as complex 
processes, long preparation time and limited capacity. To address these points, the subunit 
vaccines are an alternative approach to meet the global demand for the influenza vaccines. 
However, the subunit vaccines generally induce low immunogenicity against influenza. To 
overcome this effect, we present new and innovative ways to generate highly immunogenic 
H5 oligomers from avian flu hemagglutinin in planta. H5 oligomers in the plant crude extract 
were highly active in hemagglutination resulting in high titers. Immunization of mice with two 
doses of plant crude extracts containing H5 oligomers caused strong immune responses 
and induced neutralizing specific humoral immune responses in mice. These results allow 
for the development of cheap influenza vaccines for veterinary application in future. 
  
  
Posters 
183 
 
59. Tackling emerging viruses – Plant made Virus- 
like Particles as candidate vaccine against 
Dengue virus 
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Dengue virus (Denv) is an enveloped virus, belonging to the family of flaviviridae, and 
emerged as a global threat in the last decades. It is transmitted by mosquitoes such as 
Aedes albopictus and Aedes aegypti and is currently present in Asia, Africa and the 
Americas and caused over 3 Mio infections in 2015 (WHO, 2016). Infection can be 
accompanied with fever and, in severe cases, neurological disorders, haemorrhagic fever 
and dengue shock syndrome (WHO, 2016). Prevention of infection can be achieved by 
vector control and vaccination. Dengvaxia®, a live attenuated recombinant vaccine, is 
currently the only approved vaccine against Denv in some Asian and South American 
nations, but raised concerns regarding to low vaccine efficiency and antibody depending 
enhancement of infection (WHO, 2016; Aguiar et al., 2016). Hence, a better and more 
immunogenic vaccine against Denv is of interest and might be achieved using virus like 
particles (VLPs). VLPs are self-assembled structures derived from viral components and 
antigens that mimic the native architecture of a virus, but lack the viral genome. 
Consequently, they are no N-pathogenic, but show a similar immunogenicity as the native 
virus, their size and repetitive structure contributing to their immunological efficacy (Chen & 
Lai, 2013). VLPs can be produced in yeast, bacteria, mammalian and insect cells and plants. 
Plants show several advantages compared to other expression systems regarding to safety, 
scalability and cost efficiency and have consequently become an attractive alternative 
expression system (Chen & Lai, 2013). 
We present the successful production of Denv VLPs using the pEAQ-hyper trans expression 
system (Sainsbury, et al., 2009) in Nicotiana benthamiana by the co-expression of structural 
and noN-structural proteins of Denv and address the challenges we faced relating to the 
purification of enveloped VLPs from plants. 
Aguiar, M., Stollenwerk, N., Halstead, S. B. 2016. The impact of the newly licensed dengue vaccine in endemic 
countries. PLoS Neglected Tropical Diseases 10:12, e0005179.  
Chen, Q., Lai, H. 2013. Plant-derived virus-like particles as vaccines. Human Vaccines & Immunotherapeutics 
9: 26-49. 
Sainsbury, F., Thuenemann, E. C., Lomonossoff, G. P. 2009. pEAQ: versatile expression vectors for easy and 
quick transient expression of heterologous proteins in plants. Plant Biotechnology Journal 7: 682-693.  
World Health Organization. 2016. Dengue vaccine: WHO position paper—July 2016. Weekly Epidemiology 
Record, 91:30, 349-364.  
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The variable domains of Heavy chain only antibodies (VHH) have many applications as 
injectable therapeutics but a limitation is the rapid elimination from circulation by renal 
filtration (De Meyer et al., 2014). A solution is the genetic fusion of VHH to the Fc part of a 
conventional antibody ensuring recycling to the bloodstream by the neonatal receptor FcRn. 
Here, we report the production by transient expression in infiltrated Nicotiana benthamiana 
leaves of VHH fusions to an Fc fragment derived from mouse IgG (VHH-IgG) and from 
mouse IgA (VHH-IgA) (Hultberg et al., 2011). This allowed us to demonstrate virus 
neutralizing activity of plant extracts with both IgG and IgA-based VHH fusions. Quality and 
functionality of these fusions were analyzed by western blot and ELISA, respectively. While 
being functional, VHH-IgA Fc fusions display only a weak band of the expected length 
(42kDa) and a pronounced band of about 25kDa, suggesting extensive proteolytic cleavage 
of the IgA-Fc part. The unavailability of commercial affinity ligands for purifying mouse IgAs 
currently presents a problem for the comparison of the protective activity in vivo of full-length 
VHH-IgA versus VHH-IgG antibodies. To circumvent this, the glycosylation site of the CH2-
CH3 interface in mouse IgA-Fc was mutated to contain the paratope of the commercially 
available SSL7 resin (Wines et al., 2011). This novel adapted mouse IgA fusion could be 
purified by SSL7 affinity chromatography and was found to be functional in ELISA and 
neutralization assays. However, the copurification of the proteolytic fragment prevented us 
from comparing the VHH-IgG versus VHH-IgA efficacy in animal experiments. 
References 
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Fungi that infect plants, animals or humans pose a serious threat to human and animal 
health, food security and ecosystem resilience. Only a few classes of antifungals are 
currently available, which are questionable due to resistance, host toxicity and undesirable 
side effects. There is thus an urgent need for novel antifungals with improved properties and 
action mechanisms different from existing ones. Antifungal proteins (AFPs) secreted by 
filamentous fungi are promising biomolecules for the development of new antifungal 
therapies in medicine and agriculture (Meyer, 2008). They are small proteins, usually 
cationic, rich in cysteine, and folded in compact structures supported with disulfide bridges, 
which make them highly stable and resistant to heat, proteases and extreme pH. They 
exhibit specifically potent antifungal activity at very low concentrations against important 
human and plant fungal pathogens, and do not show toxic effects on plant or mammalian 
cells. The exploitation of AFPs, however, requires efficient, safe and economic production 
systems. Plants represent a good option for the production of these cysteine-rich proteins 
that require formation of disulphide bridges and proper folding. 
Here, we report the development of an easy-to-manipulate viral vector for the production of 
large amounts of these small AFPs in Nicotiana benthamiana plants. The viral vector derives 
from a tobacco mosaic virus (TMV) infectious clone in which part of the sequences coding 
for the coat protein are replaced by the gene of interest. The engineered viral replicons are 
introduced into the biofactory host via agroinfiltration. Using this simple viral vector, we 
efficiently produced the Aspergillus giganteous AFP (Vila et al., 2001) and the Penicillium 
digitatum AfpB (Garrigues et al., 2017). High accumulation levels were reached when these 
bioactive small proteins were targeted to the apoplast, although low accumulation and toxic 
effects in the host plants were observed when targeted to intracellular compartments. 
Moreover, AFPs were easily purified from the apoplastic fluids by one-single step 
chromatography. We also demonstrate that this production system renders AFPs fully active 
against target pathogens, thus supporting the idea that plants are suitable biofactories to 
bring these antifungal proteins to the market. 
Garrigues, S., Gandía, M., Popa, C., Borics, A., Marx, F., ... Manzanares, P. 2017. Efficient production and 
characterization of the novel and highly active antifungal protein AfpB from Penicillium digitatum. Scientific 
Reports 7: 14663. 
Meyer, V. 2008. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological 
value. Applied Microbiology and Biotechnology 78: 17-28. 
Vila, L., Lacadena, V., Fontanet, P., del Pozo, A. M., Segundo, B. S. 2001. A protein from the mold Aspergillus 
giganteus is a potent inhibitor of fungal plant pathogens. Molecular Plant-Microbe Interactions 1411: 1327-
1331.  
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Modelling recombinant protein yields in higher plants used as production hosts for 
biopharmaceuticals requires a careful monitoring of protein rates as a function of leaf age, 
while the plant is growing and developing (Robert et al., 2013). We here characterized the 
accumulation patterns of different cytosol- and cell secretory pathway-targeted proteins in 
agroinfiltrated leaves of the transient expression host Nicotiana benthamiana. Accumulation 
rates were determined seven days post-infiltration in young, mature and older leaves to 
establish the relative importance of each leaf age group on protein yield at the whole plant 
level. Our data highlight the importance of young and mature leaves on overall yield, in 
contrast with older leaves representing almost 30% of the whole biomass but contributing 
less than 5% of total protein yield. Our data also highlight the relative importance of axillary 
stem leaves, which account for 35 to 50% of total recombinant protein yield depending on 
cultural conditions before agroinfiltration. These findings underline the importance of 
considering the relative importance of axillary stem and main stem leaves in protein map 
models for the N. benthamiana expression host. A general trend to come out of this work is 
the relation between recombinant protein yield per plant and the ‘main stem leaf to axillary 
stem leaf’ ratio, and hence the relevance of defining cultural conditions, physical treatments 
(e.g. pruning) or chemical (e.g. hormonal) treatments that promote axillary stem growth 
towards an optimal plant architecture for maximal productivity (Michaus et al, 2017). 
Examples along this line will here be discussed in terms of impact on leaf biomass 
production, recombinant protein yield and metabolic impact at the leaf cell proteome scale. 
Reference 
Michaud, D., Pepin, S., Ethier, G., Goulet, M. C., Gaudreau, L., ... Gosselin, A. 2017. U.S. Patent Application 
No. 15/324,926. 
Robert, S., Khalf, M., Goulet, M. C., D’Aoust, M. A., Sainsbury, F., Michaud, D. 2013. Protection of recombinant 
mammalian antibodies from development-dependent proteolysis in leaves of Nicotiana benthamiana. PLoS 
One 8: e70203.  
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35 years after the human immunodeficiency virus (HIV) was identified as the cause of 
Acquired Immune Deficiency Syndrome (AIDS), there is still no cure, only drugs to control 
it. Life-long antiretroviral therapy is costly, which limits availability to many patients, and its 
effectiveness may be compromised by viral escape. Broadly neutralising antibodies (bNAbs) 
offer a different perspective to pre-exposure prophylaxis (PrEP) and early post-exposure 
therapy. Promising results could be achieved by a combination of the bNAbs 10-1074 and 
3BNC117, which was able to induce long-lasting virus control in macaques (Nishimura et 
al., 2017) and is currently undergoing a phase 1b clinical trial in HIV-1 infected and noN-
infected individuals (NCT02825797).  
To improve the efficacy of the bNAb 10-1074, we introduced a YTE mutation into the Fc 
region. This mutation has been shown to improve the half-life of monoclonal antibodies by 
increasing the affinity to the neonatal receptor (FcRn) (Dall’Acqua et al., 2002), which is 
responsible for IgG recycling. We used ∆XF N. benthamiana as an expression platform to 
improve binding to FcγRIIIa (Ferrera et al., 2011), thus possibly enhancing antibody-
dependent cell-mediated toxicity (ADCC). We showed that the introduction of the YTE 
mutation into bNAb 10-1074 had a significant impact on yield, but no effect on affinity to 
gp120 nor its ability to potently neutralise HIV-1. As expected, 10-1074 carrying the YTE 
mutation exhibited a significantly higher affinity to FcRn than the noN-mutated 10-1074, 
suggesting an enhancement in its in vivo half-life. Our data also confirmed that removal of 
the core α1,3-fucose may lead to an improvement in ADCC.  
References 
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Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. The Journal of 
Immunology 169: 5171-5180.  
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., ... Umaña, P. 2011. Unique carbohydrate–
carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core 
fucose. Proceedings of the National Academy of Sciences USA 108: 12669-12674.  
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therapy can induce long-lasting immunity to SHIV. Nature 543: 559. 
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More than three decades passed from production of first vaccine candidate proteins in 
plants. Transgenic plant produced Hepatitis B surface antigen showed to have a suitable 
conformation for induction of antigenicity and immunity in experimented animals. However, 
low expression level and time needed for growth of transgenic plant enhanced the 
improvement of the system such as applying transient expression.  
Each year, Influenza virus results in five million cases of severe illness and about 250,000 
to 500,000 deaths (WHO 2014). It has been shown that Influenza vaccines could protect 
human against sickness, hospitalizations and deaths caused by these viruses. Because of 
the rapid change of virus, new version of the vaccine is developed twice a year and highly 
needed by at risk people such as pregnant women, the elderly, children between six months 
and five years of age. The intrinsic characteristic of some viral proteins to  self-assemble as 
a Virus like Particle (VLP)  in plant  has made it a good system for expression of VLPs as in 
Influenza virus (Medicago, 2016). The repetitive nature of antigen in Virus like particle while 
there is no infectious genome has made VLP a good candidate to substitute the present 
inactivated influenza virus vaccines. One of the major concerns in production of VLP in plant 
is its assembly and stability during purification. Byrd-Leotis et al (2015) have shown that 
different mutations affect the resistance of virus to environmental factors. Their results 
showed that HA mutation in Lysin 58 to Isoleusin which is located at the membrane distal 
tip of the short helix of the hairpin loop structure, improved the stability and  conferred the 
acid-stable phenotype for nearly all HAs examined. Considering the success, these two 
characteristics of K58I are interesting for potential use of the mutation in the development 
of stable Influenza vaccine candidates.   
We have prepared original, plant codon optimized and mutated forms of Influenza A virus 
(A/Indonesia/5/2005(H5N1)) hemagglutinin (HA) gene. To produce the mutated form of HA, 
its coding sequence was subjected to site directed mutagenesis by PCR using two sets of 
primers carrying the K58I mutation. The overlap PCR was done to assemble the HA gene. 
The genes were cloned in EcoR1 and BamH1 site of pTRAKc-ERH to remove KDEL 
fragment and introduced into Agrobacterium. Co-agroinfiltration of the above agrobcteria 
with agrobacteria carrying p19( silencing suppressor) gene cloned in pcambia into Nicotiana 
benthamiana plant were done. The VLP Purification and mouse immunogenicity 
experiments  will be further investigated. 
Byrd-Leotis, L., Galloway, S. E., Agbogu, E., Steinhauer, D. A. 2015. Influenza hemagglutinin (HA) stem region 
mutations that stabilize or destabilize the structure of multiple HA subtypes. Journal of Virology 89: 4504-4516.  
Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine, MEDICAGO Sep 26, 2017, at: 
https://www.prnewswire.com/news-releases/medicago-announces-phase-3-study-of-vlp-quadrivalent- 
influenza-vaccine-647905263.html 
WHO. 2014. Influenza (Seasonal) Fact sheet No. 211. Archived from the original on 30 November 2014.   
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Plant cell culture (PCC) technology is an interesting new approach for production of plant 
based food. Even though plant cells have been considered for food production previously, 
studies and applications have concentrated on extracts and high value compounds instead 
of the plant cell mass itself.  It has been proven that lingonberry (Vaccinium vitis-idaea) cell 
suspension cultures have great potential for food purposes based on both the visual 
appearance and from nutritional point of view. (Nordlund et al., 2018) 
To achieve deeper understanding about the crucial factors affecting the biomass formation, 
lingonberry cell cultures have been studied under laboratory and pilot scale conditions. At 
small-scale experiments in 250mL flasks, the induced variation in starting pH of the media 
have shown a positive effect on fresh biomass increment. To optimize the physical growth 
conditions of lingonberry cell cultures, stirred tank cultivations (2 L wv) were carried out. 
Based on collected data the importance of lighting conditions and dissolved oxygen for 
example, were analysed in relation to biomass production and visual appearance of cell 
mass.  
Due to its facility in use and appealing look, lingonberry cells are a good source of creativity. 
These cells have already been used for making jams, jellies and other sorts of prototype 
gastronomic "berry-experiences", where they are applied as the main ingredient.  
Reference 
Nordlund, E., Lille, M., Silventoinen, P., Nygren, H., Seppänen-Laakso, T., ... Rischer, H. 2018. Plant cells as 
food – A concept taking shape. Food Research International 107: 297-305. 
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The production of agricultural products from cell cultures of bacteria, yeasts, fungi, animals 
and plants, collectively coined Cellular Agriculture, has received a lot of public attention for 
its potential to tackle some of the grand challenges in sustainable food production. 
Particularly in vitro meat is hyped because it could make animal husbandry obsolete. 
However, a plant-based diet is generally considered healthier than animal-based food and 
therefore the potential of plant cell cultures (PCCs) is extremely promising, too. A major 
advantage is that the technical processes for the production of phytochemicals for 
pharmaceuticals, pigments, cosmetics and additives by PCCs are already established, even 
at large scale. However, the value of the whole biomass as food has been neglected. First 
investigations confirm that PCCs contain nutritionally relevant combinations of proteins, 
carbohydrates and lipids, enriched with vitamins and health-promoting compounds. 
Additionally, they exhibit technological processability that influences digestibility and 
sensory attributes  
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The b-NGF (Beta Nerve Growth Factor) gene encode pre-pro-NGF consists of the signal 
peptide, pro domain and mature NGF protein. NGF is secreted mainly in its mature form. 
The pro domains of the neurotrophins have an important role in intracellular processing and 
the proper folding of NGF (Rattenholl et al., 2001). Also, the pro domain of neurotrophins is 
essential for intracellular trafficking and secretion, therefore it can significantly affect 
neurotrophins's function (Lu, 2003). The pro-domain of NGF is most likely removed by the 
serine protease furin in the trans-Golgi network and mature NGF with biologically active form 
is secreted. Active b-NGF is a dimeric protein of ~15 kDa in which three disulfide bridges 
connect the two monomers (Seidah et al., 1996). In this study, we have investigated the 
possibility of Processing of transiently expressed human pre-pro-NGF in Nicotiana 
benthamiana. Human pre-pro- NGF gene sequence was optimized according to N. 
benthamiana codon usage and  cloned in PVX viral vector. To express the hNGF in N. 
benthamiana leaves, recombinant PVX-hNGF plasmids were electroporated to 
Agrobacterium tumefaciens strain GV3101. Leaves of infiltrated plants were vacuum-
infiltrated to isolate apoplastic fluids.. Detection of rhNGF was done by western blot analysis, 
hNGF protein concentration were determined by reverse phase-high performance liquid 
chromatography (RP-HPLC). By Western blot analysis on crude extracts, Pro-NGF migrated 
at the expected size about 27 kDa. As predictable, the mature rhNGF was detected at ~15 
kDa in the isolated apoplastic fluids. The rhNGF protein concentration was calculated about 
70 μg/g fresh leaves by RP-HPLC analysis. Here, we show that expression of biologically 
active NGF protein without the requirement of chemical refolding is feasible in plants. Using 
N. benthamiana for producing recombinant proteins, as a plant-based expression system, 
has advantages over other organisms.   
Lu, B. 2003. BDNF and activity-dependent synaptic modulation. Learning & Memory 10: 86-98. 
Rattenholl, A., Ruoppolo, M., Flagiello, A., Monti, M., Vinci, F., ... Rudolph, R. 2001. Pro-sequence assisted 
folding and disulfide bond formation of human nerve growth factor 2. Journal of Molecular Biology 305: 523-
533. 
Seidah, N. G., Benjannet, S., Pareek, S., Savaria, D., Hamelin, J., ... Murphy, R. A. 1996. Cellular processing 
of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochemical Journal 314:Pt 
3, 951.  
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The increasing demand for recombinant proteins used as therapeutic agents has influenced 
the development of different production platforms. Plant systems are attractive for 
recombinant protein production as they offer safety (no risk of human-threatening viral 
contamination), low upstream costs, complex glycosylation, and high scalability. Among the 
plant-based systems, hairy root cultures present several advantages such as rapid 
propagation, genotypic and phenotypic stability, and among others, possible extracellular 
secretion of expressed proteins in a well-defined medium. The optimization of the hairy root 
cultures to produce sufficient yields of secreted and easy-to-purify recombinant proteins is 
an on-going endeavor as it usually depends on the protein of interest. As part of the H2020 
PharmaFactory project, several strategies are being assessed to maximize the productivity 
of “hard-to-produce” recombinant proteins in hairy root cultures. In this regard, we are 
evaluating the impact of selected culture medium agents on productivity. The aim is to 
identify, from a range of culture medium additives, those that when used in combination or 
alone, increase the productivity of recalcitrant recombinant proteins. The potential of such 
agents has been evaluated based on statistical experimental design. Subsequently, with the 
biomass values and recombinant protein yields retrieved, a model is created to predict 
culture media conditions giving rise to the best recombinant protein yield. Currently, sucrose 
and calcium chloride have demonstrated to be important for the biomass production. More 
research is still required in order to create models with a higher prediction power.   
 
  
Posters 
195 
 
71.  In-solution antibody capture with plant-made 
hydrofobin-Protein A fusions  
Kurppa K1, Reuter L1, Ritala A1, Linder MB1,2, Joensuu JJ1 
1VTT Technical Research Centre of Finland Ltd. Espoo, Finland 
2 Aalto University, Espoo, Finland 
Corresponding author: Jussi Joensuu <Jussi.joensuu@vtt.fi> 
 
There is urgent need to reduce production and processing costs for monoclonal antibodies 
(MAbs). The current industrial standard for MAb purification involves use of initial affinity 
chromatography step with a column that consists Staphylococcus aureus Protein A / G that 
has been chemically immobilized to solid support beads. Aqueous two-phase systems are 
an interesting and scalable alternative to column chromatography for protein purification. 
We have previously shown that hydrophobins (HFBs), surface-active fungal proteins can be 
utilized as purification tags, enabling efficient capture of target proteins using a surfactant-
based aqueous two-phase system (ATPS).  
Here, antibody binding domains of Protein A were genetically fused with fungal 
hydrophobins and expressed transiently in Nicotiana benthamiana and in transgenic 
tobacco BY-2 cell suspension cultures. Protein A-HFB fusion expression was scaled up and 
the target protein was purified from plant extracts. The binding of these proteins to human 
antibodies was confirmed. Furthermore, the functionality of Protein A-HFB fusions was 
tested for in-solution capture of a MAb from hybridoma culture supernatant. The 
demonstrated ATPS process offers alternative to Protein A column chromatography and 
creates an exciting alternative for MAb purification. 
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Antimicrobial peptides (AMPs) are an important mechanism for combatting microbes and 
are produced by animals, plants, fungi and bacteria. AMPs are considered promising 
alternatives for current antibiotics (Fjell et al., 2012). Tobacco chloroplasts might be a useful 
platform for the production of these peptides due to their capacity for high protein 
accumulation (Bock 2015). Also expression of these peptides could provide a strategy for 
protecting plants against bacteria and fungi. In order to protect short single AMPs from 
potential degradation by the Presequence Protease (Kmiec et al., 2013) and in order to 
create multi-functional molecules, several AMPs were fused by flexible linkers. The 
presented research shows that it is possible to accumulate antimicrobial peptides that are 
fused to each other in sets of 3 different peptids. Strongly constitutive production of fusion 
peptides leads to pale or white plants. A next generation of plants producing these peptides 
under the chloroplast encoded inducible RAmpER system (Emadpour et al., 2015) strongly 
reduced these plant phenotypes. Ongoing work is focused on the characterisation of plant 
resistance, peptide purification and characterising antimicrobial activity, optimization of 
induction and tighter control of expression through inducible nuclear encoded switches.  
 
References 
Bock, R. 2015. Engineering plastid genomes: methods, tools, and applications in basic research and 
biotechnology. Annual Review of Plant Biology, 66, 211-241. 
Emadpour, M., Karcher, D., Bock, R. 2015. Boosting riboswitch efficiency by RNA amplification. Nucleic acids 
research, 43(10), e66-e66. 
Fjell, C. D., Hiss, J. A., Hancock, R. E., Schneider, G. 2012. Designing antimicrobial peptides: form follows 
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2013. Organellar oligopeptidase (OOP) provides a complementary pathway for targeting peptide degradation 
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Aquaculture is the fastest growing food-production sector worldwide, recently overtaking wild-
capture as the major provider of fish for human consumption and contributing over US$160bn 
to the global economy. Like many agricultural systems, a key concern for the sustainability of 
aquaculture is the effect of virus-borne diseases on livestock. With relatively low profit margins 
and the price sensitivity of the aquaculture market, fish farmers require low-cost interventions to 
protect against viral diseases.   
Plant-based expression systems have a proven track record in producing vaccine candidates 
for use against human and animal diseases. The simple growing conditions and ease of 
candidate screening position plant-based vaccine production as a low-cost alternative to existing 
technologies, and an attractive avenue of research for the aquaculture industry. 
To date there have been few reports of plant-produced vaccine candidates targeted at 
enveloped viruses. Enveloped viruses are typically more complex than their non-enveloped 
counterparts, requiring multiple post-translational modifications such as glycosylation during 
maturation. We have used Salmonid alphavirus (SAV), the causal agent of salmon pancreas 
disease, to explore the use of multiple plant-based expression systems to produce vaccine 
candidates against this enveloped virus.  
Using both whole-plant expression in Nicotiana benthamiana and tobacco BY-2 cell culture we 
have produced vaccine candidates based on the major glycoprotein E2 of SAV. These include 
previously characterised immunogenic regions that are known to elicit antibody responses. We 
have developed methods that allow scalable purification of the antigens, and show that the plant-
derived proteins cross-reacts with neutralising antibodies regardless of expression system used. 
The glycosylation state of purified proteins has been explored, allowing us to investigate 
differences in post-translational modification between whole-plant and cell culture systems. 
We have demonstrated the ability of these two systems to produce vaccine candidates in a 
scalable manner suitable for industry. However, the key determinant of whether such 
approaches will benefit aquaculture will be the ability of the plant-produce material to stimulate 
protect immunity. Thus, although we can determine the yield of the vaccine candidates produced 
by each expression system, further investigations into vaccine efficacy in situ are required for a 
full economic analysis. 
Posters 
198 
  
List of participants 
199 
List of participants 
Fabio Apone  
Arterra Bioscience srl., Italy  
fapone@arterrabio.it 
 
Ingo Appelhagen  
John Innes Centre, UK  
ingo.appelhagen@jic.ac.uk 
 
Shruti Bakshi 
VIB - University of Gent, Belgium 
shruti.bakshi@ugent.vib.be 
 
Ani Barbulova 
Arterra Bioscience srl., Italy 
ani@arterrabio.it 
 
Muriel Bardor  
University of Rouen Normandie, France 
muriel.bardor@univ-rouen.fr 
 
Angela Bartolf  
St. George's University of London, UK 
abartolf@sgul.ac.uk 
 
Eugenio Benvenuto  
ENEA, Italy  
eugenio.benvenuto@enea.it 
 
Sheeba Bloodsworth 
St. George's University of London, UK  
sbloodsw@sgul.ac.uk 
 
Lennard Bohlender 
University of Freiburg, Germany  
lennard.bohlender@biologie.uni-freiburg.de 
 
Tobias Bonitz  
University of Leipzig, Germany  
tobias.bonitz@uni-leipzig.de 
 
Luisa Bortesi  
Maastricht University, The Netherlands  
luisa.bortesi@maastrichtuniversity.nl 
 
Dirk Bosch  
Wageningen UR, The Netherlands  
dirk.bosch@wur.nl 
 
 
 
 
 
 
 
Frederic Bourgaud  
Plant Advanced Technologies, France  
frb@plantadvanced.com 
 
David Brault  
INNO-3B inc., Canada  
dbrault@inno-3b.com 
 
Inge Broer  
University of Rostock, Germany  
Inge.Broer@uni-rostock.de 
 
Jennifer Bromley  
British American Tobacco, UK  
jennifer_bromley@bat.com 
 
Johannes Felix Buyel  
Fraunhofer IME, Germany  
johannes.buyel@ime.fraunhofer.de 
 
Katarina Cankar  
Wageningen University, The Netherlands  
katarina.cankar@wur.nl 
 
Maria Teresa Capell 
Universitat de Lleida, Spain 
teresa.capell@pvcf.udl.cat 
 
Aleyo Chabeda 
University of Cape Town, South Africa  
aleyo.chabeda@gmail.com 
 
Qiang Chen  
Arizona State University, USA 
qiang.chen.4@asu.edu 
 
Paul Christou  
Universitat de Lleida, Spain 
christou@pvcf.udl.cat 
 
María Coca 
CRAG, Spain 
maria.coca@cragenomica.es 
 
Udo Conrad  
IPK Gatersleben, Germany  
conradu@IPK-gatersleben.de 
 
List of participants 
200 
David Craik 
The University of Queensland, Australia 
d.craik@imb.uq.edu.au 
 
Marc-Andre D´Aoust  
Medicago Inc., Canada  
daoustma@medicago.com 
 
Philippe Dehottay  
GSK, Belgium  
philippe.dehottay@gsk.com 
 
Christina Dickmeis  
RWTH Aachen University, Germany  
Christina.Dickmeis@molbiotech.rwth-aachen.de 
 
Marcello Donini  
ENEA, Italy  
marcello.donini@enea.it 
 
Parastoo Ehsani  
Pasteur Institute of Iran, Iran  
p_ehsani@yahoo.com 
 
Arto Forsberg  
VTT, Finland  
arto.forsberg@vtt.fi 
 
Noriho Fukuzawa  
A.I.S.T, Japan  
noriho-fukuzawa@aist.go.jp 
 
Benjamin Bruno Gengenbach  
Fraunhofer IME, Germany  
benjamin.gengenbach@ime.fraunhofer.de 
 
Jared Gerlach  
National University of Ireland, Ireland  
jared.gerlach@nuigalway.ie 
 
Khadijeh Ghasemian  
Rostock University, Germany 
khadijeh.ghasemian@uni-rostock.de 
 
Edward Gilding 
The University of Queensland, Australia  
e.gilding@imb.uq.edu.au 
 
Anatoli Giritch  
Nomad Bioscience GmbH, Germany  
giritch@nomadbioscience.com 
 
Marie-Claire Goulet  
Université Laval, Canada  
marie-claire.goulet@fsaa.ulaval.ca 
Melanie Grandits  
St George's University of London, UK 
p1607569@sgul.ac.uk 
 
Cornelius Gunter  
University of Cape Town, South Africa 
corriegunter@gmail.com 
 
Noemi Gutierrez Valdes  
VTT, Finland 
ext-noemi.gutierrezvaldes@vtt.fi 
 
Simone Hahn-Löbmann  
Nomad Bioscience GmbH, Germany  
hahn@nomadbioscience.com 
 
Céline Hanani 
VTT, Finland  
celine.hanani@vtt.fi 
 
Inga Hitzeroth  
University of Cape Town, South Africa  
inga.hitzeroth@uct.ac.za 
 
Matthijs Hoelscher  
MPIMP, Germany  
hoelscher@mpimp-golm.mpg.de 
 
Tanja Holland  
Inofficial ISPMF Fanclub, Germany  
Tanja-Holland@web.de 
 
Nicholas Holton  
Leaf Expression Systems, UK  
holtonn@leafexpressionsystems.com 
 
Hannu Hotti  
VTT, Finland  
ext-hannu.hotti@vtt.fi 
 
Sandy Hwei-Sanloh  
The University of Nottingham, Malaysia  
sandy.loh@nottingham.edu.my 
 
Suvi Häkkinen 
VTT, Finland 
suvi.hakkinen@vtt.fi 
 
Katja Härtl 
Technical University of Munich, Germany  
katja.haertl@tum.de 
 
Mark Jackson  
The University of Queensland, Australia  
m.jackson1@uq.edu.au 
List of participants 
201 
Julia Jansing 
RWTH Aachen University, Germany  
julia.zischewski@molbiotech.rwth-aachen.de 
 
Jussi Joensuu  
VTT, Finland  
jussi.joensuu@vtt.fi 
 
Selvaraju Kanagarajan  
SLU, Sweden  
selvaraju.kanagarajan@slu.se 
 
YangJoo Kang  
Chung-Ang University, South Korea  
yangjoo33@naver.com 
 
Franziska Kellner  
Leaf Expression Systems, UK 
kellnerf@leafexpressionsystems.com 
 
Mi-Young Kim 
Chonbuk National University, South Korea 
mkim@jbnu.ac.kr 
 
Seong-Ryong Kim  
Sogang University Korea  
sungkim@sogang.ac.kr 
 
Deuk-Su Kim  
Chung-Ang University, South Korea  
verymana@naver.com 
 
Kisung Ko 
Chung-Ang University, South Korea  
ksko@cau.ac.kr 
 
Lilya Kopertekh  
Julius Kühn-Institut (JKI), Germany  
lilya.kopertekh@julius-kuehn.de 
 
Elviira Kärkkäinen  
VTT, Finland  
elviira.karkkainen@vtt.fi 
 
Eija Lehmuskallio  
NatureGate Promotions Finland 
eija@naturegate.net 
 
Jouko Lehmuskallio  
NatureGate Promotions Finland  
jouko@naturegate.net 
 
Camille Lemasson  
Root Lines Technology, France  
camille.lemasson@rootlines-tech.com 
Efraim Lewinsohn  
The Volcani Center, Israel 
twefraim@agri.gov.il 
 
George Lomonossoff  
John Innes Centre, UK  
george.lomonossoff@jic.ac.uk 
 
Julian Ma  
St. George’s University of London, UK  
jma@sgul.ac.uk 
 
Maricarmen Martí  
Universidad Politécnica de Valencia, Spain  
mcmarti@ibmcp.upv.es 
 
Coby Martin 
The University of Western Ontario, Canada  
cmart245@uwo.ca 
 
Silvia Massa  
ENEA, Italy  
silvia.massa@enea.it 
 
Luis Matias  
Sequentia Biotech, Spain  
lmatias@sequentiabiotech.com 
 
Siv Matomaa  
VTT, Finland  
siv.matomaa@vtt.fi 
 
Takeshi Matsumura  
A.I.S.T. Japan  
matsumura-t@aist.go.jp 
 
Kouki Matsuo  
A.I.S.T Japan  
matsuo-kouki@aist.go.jp 
 
Andrew Matthews  
INNO-3B inc., Canada  
amatthews@inno-3b.com 
 
Sandiswa Mbewana  
University of Cape Town, South Africa  
sandiswa.mbewana@uct.ac.za 
 
Rosemary Meggersee  
University of Cape Town, South Africa  
rosemary.meggersee@gmail.com 
 
Rima Menassa  
Agriculture and Agr-Food Canada, Canada  
rima.menassa@agr.gc.ca 
List of participants 
202 
Sébastien Mercx  
Université Catholique de Louvain (UCL), Belgium  
sebastien.mercx@uclouvain.be 
 
Ann Meyers  
University of Cape Town, South Africa  
ann.meyers@uct.ac.za 
 
Dominique Michaud  
Universite Laval, Canada  
dominique.michaud@fsaa.ulaval.ca 
 
Sissi Miguel  
Plant Advanced Technologies, France  
contact@plantadvanced.com 
 
Dominik Mojzita  
VTT, Finland  
dominik.mojzita@vtt.fi 
 
Cathy Moore  
St. George's University of London, UK  
cmoore@sgul.ac.uk 
 
Kristiina Mäkinen  
University of Helsinki, Finland  
kristiina.makinen@helsinki.fi 
 
Somen Nandi  
University of California, USA  
snandi@ucdavis.edu 
 
Henrik Nausch  
University of Rostock, Germany  
henrik.nausch@uni-rostock.de 
 
Catherine Navarre  
Universite Catholique de Louvain, Belgium  
catherine.navarre@uclouvain.be 
 
Greta Nölke  
Fraunhofer IME, Germany  
greta.noelke@ime.fraunhofer.de 
 
Hamideh Ofoghi 
IROST, Iran 
ofoghi@irost.ir 
 
Georgianna Kae Oguis  
The University of Queensland, Australia  
g.oguis@imb.uq.edu.au 
 
Kirsi-Marja Oksman-Caldentey  
VTT, Finland  
kirsi-marja.oksman@vtt.fi 
Diego Orzaez  
IBM CP-CSIC, Spain  
dorzaez@ibmcp.upv.es 
 
Sarunas Paskevicius  
UAB Nomads, Lithuania  
paskevicius.sarunas@gmail.com 
 
Frank Petersen  
Novartis Pharma AG, Switzerland  
frank.petersen@novartis.com 
 
Hadrien Peyret 
John Innes Centre, UK 
hadrien.peyret@jic.ac.uk 
 
Trong Hoang Phan  
IPK Gatersleben, Germany  
hoang@ipk-gatersleben.de 
 
Elizabeth Pinneh  
St. George's University of London, UK  
epinneh@sgul.ac.uk 
 
Daniel Ponndorf 
John Innes Centre, UK 
daniel.ponndorf@jic.ac.uk 
 
Riitta Puupponen-Pimiä  
VTT, Finland  
riitta.puupponen-pimia@vtt.fi 
 
Haiou Qu  
Institute for Molecular Bioscience, Australia  
h.qu@imb.uq.edu.au 
 
Emile Rage 
ENEA, Italy  
emile.rage@gmail.com 
 
Kaewta Rattanapisit  
Chulalongkorn University, Thailand  
som_kaewza@hotmail.com 
 
Nicole Raven  
Fraunhofer IME, Germany  
nicole.raven@ime.fraunhofer.de 
 
Lauri Reuter  
VTT, Finland  
lauri.reuter@vtt.fi 
 
Jaana Rikkinen 
VTT, Finland  
jaana.rikkinen@vtt.fi 
List of participants 
203 
Heiko Rischer 
VTT, Finland  
heiko.rischer@vtt.fi 
 
Anneli Ritala  
VTT, Finland  
anneli.ritala@vtt.fi 
 
Tarik Ruiz  
CRAG, Spain  
tarik.ruiz@cragenomica.es 
 
Juliane Röder  
RWTH Aachen University, Germany  
Juliane.Roeder@molbiotech.rwth-aachen.de 
 
Markus Sack 
Pro-SPR GmbH, Germany  
markus.sack@pro-spr.com 
 
Kazuki Saito  
Chiba University & RIKEN, Japan  
ksaito@faculty.chiba-u.jp 
 
Mattia Santoni  
University of Verona, Italy  
mattia.santoni@univr.it 
 
Andreas Schaaf  
Greenovation, Germany  
aschaaf@greenovation.com 
 
Joachim Schiemann  
Julius Kühn Institut, Germany  
joachim.schiemann@julius-kuehn.de 
 
Stefan Schillberg  
Fraunhofer IME, Germany  
stefan.schillberg@ime.fraunhofer.de 
 
Sara Selma García 
IBMCP, Spain 
saselgar@doctor.upv.es 
 
Jun-Hye Shin  
Université de Toulouse, France  
junhyeshin@gmail.com 
 
Yoram Shotland  
SCE Shamoon College of Engineering, Israel  
yshotlan@sce.ac.il 
 
Samuel Smith  
St. George's University of London, UK  
sasmith@sgul.ac.uk 
Bronwyn Smithies 
Institute for Molecular Bioscience, Australia  
b.smithies@imb.uq.edu.au 
 
Eberhard Sorge  
IPK Gatersleben, Germany  
sorge@ipk-gatersleben.de 
 
John Steele  
John Innes Centre, UK  
john.steele@jic.ac.uk 
 
Åke Strid   
University of Örebro, Sweden  
ake.strid@oru.se 
 
Sara Sukenik  
University of California, USA 
scsukenik@ucdavis.edu 
 
Solomia Sumyk  
VTT, Finland  
ext-solomia.sumykmaletych@vtt.fi 
 
Guangxin Sun  
Technical University of Munich, Germany  
guangxin.sun@tum.de 
 
Tim Szeto  
St. George's University of London, UK  
tszeto@sgul.ac.uk 
 
Teemu Teeri  
University of Helsinki, Finland  
teemu.teeri@helsinki.fi 
 
Audrey Teh  
St. George's University of London, UK  
ateh@sgul.ac.uk 
 
Tuuli Teikari  
VTT, Finland  
tuuli.teikari@vtt.fi 
 
Arja Tervahauta  
University of Eastern Finland, Finland  
arja.tervahauta@uef.fi 
 
Eva Thuenemann  
John Innes Centre, UK  
eva.thuenemann@jic.ac.uk 
 
Oguz Top  
University of Freiburg, Germany  
oguz.top@sgbm.uni-freiburg.de 
List of participants 
204 
David Ullisch  
Phyton Biotech GmbH, Germany  
david.ullisch@phytonbiotech.com 
 
Sophie van Gorkom  
Janssen Vaccines and Prevention B.V.,  
The Netherlands  
sophie.vangorkom@gmail.com 
 
Kim van Noort  
Wageningen University, The Netherlands  
kim.vannoort@wur.nl 
 
Philippe Varennes-Jutras  
University of Oxford, UK 
philippe.varennes-jutras@plants.ox.ac.uk 
 
Heribert Warzecha  
Technische Universität Darmstadt, Germany  
warzecha@bio.tu-darmstadt.de 
 
Jennifer Wayland  
University of Cape Town, South Africa  
jennifer-wayland@hotmail.com 
 
Stefan Werner  
Nambawan Biotech GmbH Germany  
werner@nambawanbiotech.com 
 
Moonsik Yang  
Chonbuk National University,  
Republic of Korea 
mskyang@jbnu.ac.kr 
 
Lingping Zhu  
University of Helsinki, Finland  
lingping.zhu@helsinki.fi 
 
 
 
 
 
Author Index 
205 
Author index 
A 
Abdulheem S ............................................. 77 
Afonso A .................................................. 115 
Ajenjo Bauzá M .......................................... 81 
Alikhani A ................................................. 189 
Alonso AD ................................................ 183 
Amini-Bayat Z .......................................... 192 
An HJ ......................... 95, 103, 141, 159, 176 
Anderson MA ........................................... 113 
Apone F ............................................... 79, 80 
Appelhagen I .............................................. 93 
Arash-Kaps L ............................................. 55 
Augustine SM ............................................ 83 
Avesani L ................................................. 132 
 
B 
Baccaro S ................................................ 146 
Bakshi S .................................................. 184 
Bar E .................................................... 47, 99 
Barbulova A ......................................... 79, 80 
Bardor M .................................................. 115 
Bartolf A ................................................... 156 
Baschieri S............................................... 131 
Beekwilder J ............................................ 160 
Bennici E ................................................. 146 
Benvenuto E .................................... 146, 170 
Bernabé Orts J ........................................... 81 
Berthold T ................................................ 197 
Blanco J ..................................................... 45 
Bock R ..................................................... 196 
Bogdanovic M .......................................... 160 
Bohlender LL ........................................... 134 
Boitel-Conti M .......................................... 194 
Bonitz T ................................................... 158 
Bortesi L ............................................ 83, 138 
Bosch D ................................................... 160 
Boutry M ............................................ 91, 168 
Bouwmeester H ....................................... 160 
Brodelius P .............................................. 157 
Broer I ...................................... 126, 127, 140 
Bromley J ......................................... 105, 107 
Burel C ..................................................... 115 
Busch A ............................................. 55, 134 
Buyel JF ........................................... 109, 164 
C 
Canela-Xandri ............................................ 45 
Cankar K .................................................. 160 
Capell Capell, T ........................................  45 
Cardon F .................................................. 194 
Carrillo J..................................................... 45 
Cater, P.............................................. 43, 148 
Cemmi A .................................................. 146 
Chabeda A ............................................... 166 
Chaikeawkaew D ....................................... 77 
Chan LY ................................................... 113 
Charlton, S. ................................................ 43 
Chaumont F ....................................... 91, 168 
Chen Q .................................................... 183 
Chin-Fatt A ............................................... 103 
Choi J ...................................................... 159 
Christou P ................... 45, 46, 67, 69, 70, 132 
Ciardiello MA ........................................... 132 
Clotet B ...................................................... 45 
Coca M ............................................ 153, 185 
Colucci MG .......................................... 79, 80 
Commandeur U .................................. 63, 155 
Conrad U ................................. 165, 175, 182 
Cordero T ................................................. 185 
Cosgrove C .............................................. 156 
Craik DJ ............ 113, 174, 177, 178, 179, 181 
Cunningham s .......................................... 161 
D 
D’Aoust MA .................................. 89, 95, 187 
Dapkutė V ................................................ 139 
Daròs JA .......................................... 128, 185 
Davidovich-Rikanati R ................................ 47 
De Pauw E ......................................... 91, 168 
De Rossi P ............................................... 146 
Decker EL ........................................ 133, 134 
Del Fiore A ............................................... 146 
Demurtas OC ........................................... 146 
Dennis SJ ................................................ 119 
Author Index 
206 
Depicker A ....................................... 132, 184 
Di Sarcina I .............................................. 146 
Dickmeis C ................................................. 63 
Diego Martin B ........................................... 81 
Diretto G .................................................. 146 
Donini ...................................................... 131 
Donini M .................................................. 170 
Dowall ........................................................ 43 
Dragicevic M ............................................ 160 
Dudareva N ................................................ 47 
Dumontier R ............................................. 115 
Durek T .................................................... 113 
E 
Ehnert TM ................................................ 144 
Ehsani P .......................................... 189, 192 
Ele Ekouna JP ......................................... 194 
Ellert C ..................................................... 101 
Engler C ................................................... 144 
F 
Facchini PJ ................................................ 47 
Fang CM .......................................... 149, 150 
Farahmand B ........................................... 189 
Farré G ................................................ 45, 69 
Fearon SH ............................................... 137 
Fekete G .................................................... 55 
Fester K ................................................... 158 
Fischer R ........................................... 83, 109 
Floss DM ................................................. 165 
Fode B ..................................................... 134 
Forner J ............................................. 10, 196 
Fotouhi F ................................................. 189 
Frischmuth T ...................................... 55, 134 
G 
Gagné M .................................................. 187 
Gagneul D................................................ 160 
Geissler M.................................................. 71 
Gengenbach BB ...................................... 109 
Gerlach J ................................................. 161 
Ghasemian K ........................................... 140 
Gilding EK ......... 113, 174, 177, 178, 179, 181 
Giritch A ................................... 111, 136, 138 
 
Gleba Y ............................. 111, 136, 138, 139 
Gochera T ................................................ 136 
Gorr G ...................................................... 101 
Goulet M-C .................................. 95, 96, 187 
Grandits M ............................................... 188 
Granell A .............................................. 81, 82 
Gresch U .................................................. 182 
Grinishin I ................................................. 151 
Guarino R ................................................ 113 
Gunter CJ .................................................. 57 
Gutierrez Valdes N ................................... 194 
H 
Hagel JM .................................................... 47 
Hahn S ............................................. 111, 138 
Hahn-Löbmann S ..................................... 138 
Hamel L ..................................................... 95 
Han D ...................................................... 141 
Hanani C .................................................. 152 
Harris KS ......................................... 113, 174 
Hassan SS ....................................... 149, 150 
Havranek K .............................................. 144 
Helmold C ................................................ 175 
Hendriks T ............................................... 160 
Hendrikse M ............................................. 166 
Hennermann JB ......................................... 55 
Hensel G .................................................. 165 
Hitzeroth II .......... 57, 119, 137, 166, 171, 173 
Ho TT ....................................................... 182 
Hoelscher M ............................................. 196 
Hoernstein SNW ...................................... 134 
Hokke CH ................................................ 172 
Holton, N. ........................................... 43, 148 
Honkapää K ............................................. 147 
Huang YH ........................................ 174, 178 
Huckauf J ................................................. 140 
Hurdiss DL ............................................... 117 
Hvoslef-Eide AK ......................................... 93 
Häffner K .................................................. 134 
Häkkinen TS .................................... 163, 194 
Härtl K ................................................ 65, 167 
J 
Jackson MA……113, 174, 177, 178, 179, 181 
Jansing J .................................................... 83 
Jeon JM ................................................... 159 
Jia H ........................................................ 113 
Joensuu JJ ............................... 130, 163, 195 
Joshi l ...................................................... 161 
Juarez P................................................... 184 
Jutras PV ..................................... 95, 96, 145 
Author Index 
207 
K 
Kaas Q ............................................. 113, 174 
Kaldis A ................................................... 129 
Kanagarajan S ......................................... 157 
Kang JK ................................................... 142 
Karuppanan K .................................... 73, 176 
Kayser O .................................................... 71 
Kazanavičiūtė V ....................................... 111 
Keil LL ...................................................... 109 
Kellner, F ........................................... 43, 148 
Khorsandi S ............................................. 189 
Kiefer-Meyer MC ...................................... 115 
Kim D-S ............ 143, 157, 159, 172, 175, 186 
Knödler M ................................................ 164 
Ko K .................................. 141, 142, 143, 186 
Koch J ................................................ 98, 134 
Koes R ..................................................... 146 
Kolano R .................................................. 158 
Kolotilin I .................................................. 129 
Kopertekh L ............................................. 169 
Krieghoff N ............................................... 134 
Kubera A .................................................... 77 
Kumlehn J ................................................ 165 
Kurppa K .................................................. 195 
Kärkkäinen E ........................................... 190 
L 
Lai KS ...................................... 149, 150, 183 
Lavoie P-O ........................................... 83, 95 
Lebrilla CB ............................................... 176 
Lee HK ................................ 98, 141, 143, 186 
Lehmuskallio, E. ........................................ 35 
Leibold T .................................................. 101 
Lemasson C ............................................. 194 
Lermontova I ............................................ 175 
Lerouge P ................................................ 115 
Lewinsohn E .............................................. 47 
Lico C ...................................................... 131 
Linder MB ................................................ 195 
Loh SHS .......................................... 149, 150 
Lomonossoff GP .................. 43, 61, 117, 132,  
145, 149, 150, 161, 169, 183, 197 
Lonoce C ................................................. 170 
López-Moya JJ ........................................ 153 
Louaizil M ................................................ 152 
Loutelier-Bourhis C .................................. 115 
Lucas P-L ................................................ 115 
Lundgren A .............................................. 157 
M 
Ma JKC ..... .12, 31, 33, 77, 99, 132, 136, 156, 
188 
Maltais AM ............................................... 187 
Mareck A .................................................. 115 
Mari A .............................................. 128, 132 
Marsian J ................................................. 117 
Martens S .................................................. 93 
Martí M .................................................... 128 
Martin C ............................................. 93, 129 
Marusic C ......................................... 131, 170 
Mason HS .................................................. 77 
Massa S ................................................... 146 
Matías-Hernández L ................................ 121 
Mati-Baouche N ....................................... 115 
Matros A .................................................... 93 
Mbewana S .............................................. 125 
McDonald KA ..................................... 73, 176 
McNulty M .................................................. 73 
Meggersee RL ......................................... 171 
Menassa R ....................................... 103, 129 
Mercx S.............................................. 91, 168 
Meshcheriakova Y ................................... 183 
Meyers AE……..119, 125, 137, 145, 171, 180 
Michaud D .................................... 95, 96, 187 
Michelfelder S .......................................... 134 
Misiūnas A ............................................... 139 
Mock H-P ................................................... 93 
Mojzita D ...................................... 67, 75, 130 
Molinos-Albert LM ...................................... 45 
Moravec P ................................................ 166 
Myeung SC ...................................... 143, 186 
Müschen CR ............................................ 109 
 
N 
Nandi S .............................................. 73, 176 
Nausch H ......................................... 126, 127 
Navarre C .......................................... 91, 168 
Nguyen DL ............................................... 172 
Niederkrüger H......................................... 134 
Nohynek L ........................................ 147, 152 
Novelli F ................................................... 170 
Nuorti N.................................................... 163 
O 
O’Keefe BR .......................................... 45, 46 
Oertel A...................................................... 93 
Ofoghi H................................................... 192 
Author Index 
208 
Oguis GK ......................................... 174, 181 
Oh MJ ...................................................... 159 
Oksman-Caldentey, K-M……39, 41, 147, 194 
Opdensteinen P ....................................... 109 
Ordóñez RA ............................................... 45 
Orzaez D ....................................... 31, 81, 82 
P 
Paley R .................................................... 117 
Pang EL ........................................... 149, 150 
Park S ............................... 141, 148, 161, 175 
Parsons J ................................................. 134 
Paškevičius Š .......................................... 139 
Pavasant P ................................................ 77 
Petersen F ........................................... 87, 97 
Peyret H ...................... 61, 149, 150, 161, 183 
Phan HT .................................................. 182 
Phoolcharoen W ........................................ 77 
Pietersen I................................................ 173 
Pioli C ...................................................... 170 
Plasson C ................................................ 115 
Poh IN ...................................................... 134 
Polinder E ................................................ 197 
Pong LY ........................................... 149, 150 
Ponnorf D ................................................ 183 
Poon S ..................................................... 113 
Popov M .................................................. 151 
Popov S ................................................... 151 
Pump M ................................................... 101 
Puupponen-Pimiä R ................. 147, 152, 190 
Q 
Qiao L .............................................. 143, 186 
Qu H ................................................ 174, 179 
Quattrocchio F ......................................... 146 
Quillet MC ................................................ 160 
R 
Rage E ..................................................... 131 
Ranson NA .............................................. 117 
Rantasalo A ............................................. 130 
Rattanapisit K ............................................ 77 
Ražanskienė A ................................. 111, 139 
Regnard GL ............................................... 57 
Reski R ............................................ 133, 134 
Reuter L .............................. 49, 163, 190, 195 
Rischer H…………….130, 152, 163, 190, 191 
Ritala A ............................. 163, 194, 195, 197 
Rojas M ................................................... 197 
Ruiz T ...................................................... 153 
Russell J .................................................... 93 
Rutten T ................................................... 165 
Rybicki EP ......... 57, 119, 125, 137, 145, 166,  
171, 173, 180 
Rühl C ...................................................... 164 
Röder J .............................................. 63, 155 
S 
Sack M ............................................... 83, 109 
Saelens X ................................................ 184 
Sainsbury F ....... 43, 61, 95, 96, 145, 183, 187 
Saito K ................................................. 51, 59 
Sankar-Thomas YD ................................. 101 
Sanseverino C ......................................... 121 
Santoni M ................................................. 132 
Scaloni A .......................................... 131, 170 
Schaaf A ............................................ 55, 134 
Schepens B ............................................. 184 
Schiemann J .......................... 67, 85, 86, 169 
Schijlen E ................................................. 160 
Schillberg S .......................................... 51, 53 
Schinkoethe A .......................................... 182 
Schipper B ............................................... 160 
Schneider T ..................................... 111, 138 
Schots A .................................................. 172 
Schulz S........................................... 111, 138 
Schwab W .......................................... 65, 167 
Schütte K ................................................. 101 
Selge T .................................................... 101 
Selma García S .......................................... 81 
Sena LM .................................................... 79 
Shafee T .................................................. 113 
Shattock R ........................................... 45, 46 
Shaversky A ............................................. 111 
Shi X ........................................................ 185 
Shotland Y ......................................... 47, 151 
Simonovic A ............................................. 160 
Smargiasso N .................................... 91, 168 
Smithies B ........................................ 174, 178 
Song I ...................................................... 141 
Sorge E .................................................... 175 
Spelt C ..................................................... 146 
Starkevič U .............................................. 139 
Steele J ............................................ 161, 197 
Stehle F ..................................................... 71 
Stelter S ............................................. 99, 170 
Stephan A ................................ 111, 136, 138 
Stocks M .................................................. 183 
Sukenik SC .............................................. 176 
Author Index 
209 
Sumyk MS ............................................... 190 
Sun G ...................................................... 167 
Szeto T .................................................... 136 
T 
Tardif R ...................................................... 95 
Teeri TH ........................................... 154, 158 
Teh AYH ...................................... 46, 99, 188 
Thuenemann E .......................... 61, 145, 183 
Todorovic S .............................................. 160 
Top O ....................................................... 133 
Twyman RM ......................................... 45, 46 
U 
Ullish DA .................................................. 101 
V, W 
Vamvaka E .......................................... 45, 46 
van Dolleweerd C....................................... 99 
van Gorkom S .................................... 10, 197 
van Houwelingen A .................................. 160 
van Noort K .............................................. 172 
van Zyl AR ....................................... 166, 173 
Warzecha H ............................................... 71 
Wayland J ................................................ 180 
Vazquez Vilar M ......................................... 81 
Werner S .................................................. 144 
Wilbers R ................................................. 172 
Virdi V ...................................................... 184 
Vitkauskienė A ......................................... 139 
Volk J ......................................................... 71 
Wulff-Vester AK ......................................... 93 
Y 
Yap K ....................................................... 113 
Z 
Zampieri R ............................................... 132 
Zangi M .................................................... 192 
Zeyner A .................................................. 127 
Zhu C ................................... 69, 70, 154, 157 
Zipfel PF .................................................. 134 
Ö 
Öhlschläger P .......................................... 166 
 
 
 210 
 
